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Abstract 
Background 
Pertussis is estimated to cause 2% of childhood deaths globally and is a 
growing public health problem. Infants are at greatest risk of morbidity and mor-
tality. Maternal vaccination during pregnancy may be effective to prevent pertus-
sis in young infants but population-based estimates of disease burden in infants, 
an understanding of maternal and infant pertussis antibody levels, and of effi-
ciency of maternal to infant antibody transfer in a low-income South Asian setting 
are lacking. This dissertation provides a population-based estimate of the inci-
dence of infant pertussis and associated clinical symptoms in Nepal. The timing 
of infant pertussis vaccination and risk factors for delay in Nepal are examined. 
The prevalence of maternal and infant pertussis toxin antibody and the efficiency 
of transfer were estimated.  
Methods 
 The pertussis study was nested within a prospective, community-based, 
randomized controlled trial of maternal influenza vaccination during pregnancy. In 
Sarlahi District, Nepal, over a two-year period between April 2011 and April 2013, 
approximately 3,700 women were enrolled. From birth to 6 months infants were 
visited in their homes weekly to ascertain if they had experienced any respiratory 
symptoms or received any vaccinations in the prior week. If any respiratory 
symptoms had occurred, a nasal swab was collected and tested with a multi-
target pertussis PCR assay. A subset of paired blood samples from mothers and 
infants were collected at delivery and tested for pertussis toxin (PT) antibodies by 
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ELISA. Infant, maternal, and household characteristics were captured at enroll-
ment, birth and at 6 months follow-up.  
The incidence of pertussis from age 0 to 6 months was estimated. Pertus-
sis vaccination coverage and time to vaccination were estimated. Multivariate re-
gression models were used to determine risks associated with vaccination de-
lays. PT antibody levels and the maternal to infant transfer efficiency were esti-
mated. Infant, maternal, and household characteristics associated with non-
presence and low levels of PT antibody were calculated through multivariate re-
gression models. 
Results 
 Only 7% of infants had received all three recommended pertussis vaccina-
tions by age 6 months. The incidence of PCR-confirmed Bordetella pertussis was 
5.2 cases per 1000 infant-years (95% CI, 2.1 – 10.7) and cases were generally 
mild. The PT infant to mother ratio was 1.1 (95% CI: 1.0 – 1.2). Mother and infant 
pairs with detectable PT antibody were correlated but the majority of mothers and 
infants had antibody levels below the level of quantification. 
Conclusion 
  Population-based active home surveillance for respiratory illness identi-
fied a low incidence of pertussis among infants in rural Nepal. Nepal's immuniza-
tion program, which includes 3 childhood whole cell pertussis vaccine doses, ap-
pears to be controlling pertussis in infants despite substantial delays in time to 
vaccination. Maternal and infant PT antibody levels were low. Overall transport 
was active for mothers with antibody titers above detectable levels and there was 
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an association between these mothers and their infant PT antibody levels. Ma-
ternal immunization could be an important intervention to support infant pertussis 
immunity before infants are fully vaccinated. 
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Chapter 1  
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Section 1 - History 
Guillaume de Baillou first described a 1578 French pertussis epidemic in a 
manuscript published in 16401. Baillou wrote, “The symptoms of [pertussis] are 
severe. The lung is so irritated that in its struggle to drive out by utmost effort the 
cause of irritation, it can neither inspire, nor with any ease expire. The patient 
seems to swell up, and as if on the verge of suffocation with his breathing ob-
structed in midthroat.”  Other descriptions and names of a pertussis-like illness 
are found dating to Hippocrates in 400 B.C. However, since modern diagnostic 
techniques were unavailable, we cannot know for certain that these accounts are 
related to the pertussis we understand today2. Recent genetic analysis indicates 
pertussis likely emerged in humans approximately 500 years ago3. In 1679 
Thomas Sydenham coined the name “pertussis” to the previously described dis-
ease4.  Bordetella pertussis, the causative agent of pertussis, was not isolated 
until Jules Bordet and Octave Gengou cultured the bacterium in 19065. 
Previously pertussis was a near universal childhood disease peaking in a 
cyclical pattern every 2-4 years in developed countries6.  During the 20th century 
the United States (U.S.) and Europe experienced a steady decline in pertussis 
mortality7,8. The introduction of the whole-cell pertussis (wP) vaccine in the 1930s 
accelerated the reduction in childhood pertussis infection and deaths. In the 
1990s the U.S. and other developed countries replaced the wP vaccine with the 
acellular pertussis (aP) vaccine. In recent decades, there has been a pertussis 
resurgence in high-income countries9. 
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Section 2 – Pertussis Burden 
Millennium Development Goal (MDG) 4 is to reduce the number of under-
5 deaths by two-thirds by 2015 compared to the number of deaths in 199010. Per-
tussis is estimated to cause 2% of childhood deaths each year in the world11. To 
achieve MDG 4 it will be important to make progress in the prevention and treat-
ment of pertussis in children. 
Subsection 2.1 - Children 
Pertussis (whooping cough) is a significant cause of childhood morbidity 
and mortality. The World Health Organization (WHO) estimates that 16 million 
children contract pertussis each year resulting in 195,000 deaths11.  The distribu-
tion of pertussis, however, is not equal; 95% of pertussis cases are thought to 
occur in developing countries12. A systematic review of the causes of <5 child 
mortality in 2008 found the regional estimates of proportion of deaths attributable 
to pertussis as follows: Europe and Western Pacific <1%, Americas 1%, Africa 
and Eastern Mediterranean 2%, and Southeast Asia 4%11. Pertussis suffers from 
substantial underreporting, which increases with age, making precise burden es-
timates difficult13. 
The highest quality estimates of childhood pertussis burden are found in 
aP vaccine clinical trial data from studies conducted during the 1990s testing the 
aP vaccine in various populations [Table 1.1]. The incidence of pertussis ranged 
from 0.10 to 11.02 cases per 100 person-years (PY) in children who were unim-
munized or who received one or more doses of the wP vaccine14-20. One study, 
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which may provide the most accurate pertussis incidence estimate in children, 
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lowed (weekly) by a home fieldworker visit to monitor for cough >7 days15. The 
pertussis incidence estimate in this study ranged from 2.05-7.03 cases per 100 
PY and varied according the vaccination group (aP vs. wP) and laboratory crite-
ria used for diagnosis (DNA amplification, serology, culture, or epidemiological 
linkage). In other aP vaccine studies the follow-up was less frequent and some 
required parental reporting instead of active case finding by field workers, which 
may have led to underestimates of disease burden19. Furthermore, in all of these 
studies, testing was restricted to those with a cough of minimum 7 days duration. 
If these children had atypical pertussis, especially the adolescents or youngest 
infants, this screening threshold may have limited mild pertussis case detection. 
Lastly, these data are not based on recent cohorts. More recent data suggests 
that the epidemiology in children has changed with an increased incidence in ad-
olescent populations21. 
Subsection 2.2 - Infants 
The majority of studies on the incidence of pertussis in infants <6 months 
are hospital based or derived from passive surveillance. Reported pertussis cas-
es and deaths based on passive surveillance, seroepidemiology, and hospital 
studies show the burden of disease is highest in infants less than 6 months22-30. 
A 2001-2004 prospective study in Brazil, Costa Rica, Germany, Singa-
pore, Spain, Taiwan, and Uruguay investigated the incidence of pertussis in in-
fants presenting to pediatric intensive care units31. Infants <1 year were eligible 
for enrollment if they had any of the following symptoms: respiratory failure, ap-
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nea, bradycardia or cough accompanied by paroxysms, vomiting, whoop or cya-
nosis. Twelve percent of infants enrolled in the study had laboratory confirmed 
pertussis with a mean age of 2.6 (standard deviation (SD) = 2.2) months. 
In an early 1990s French pediatric hospital study, where whole cell vac-
cine was used, the estimated incidence in children was 95 cases per 100,000 
PY22. In France, a retrospective study conducted in 2000 examined community 
acquired bacterial causes of death in children 10 days to 18 years32. Pertussis 
was responsible for 13% of the deaths. Furthermore, in infants <2 months of age, 
pertussis was the leading causative factor of death. Reported cases in King 
County, Washington State (2002-2007) estimated pertussis incidence at 136 per 
100,000 infant population25. 
The reported incidence from the aP vaccine trials [Table 1.1] may provide 
some indication of the burden in infants <6 months but the applicability of these 
data may be limited for several reasons. First, most of these studies did not 
monitor children for pertussis until a certain period after the 1st pertussis vaccina-
tion, or more commonly after the final pertussis vaccination. Infants in these sur-
veillance windows are generally older than 4 months and most likely older than 6 
months if monitoring commences after a child is fully immunized. Second, these 
studies did not include unimmunized controls and therefore these incidences are 
in a semi-immunized and/or fully immunized population, which may underesti-
mate the burden in children too young to be immunized or who are delayed in 
receiving doses in the pertussis vaccine series. Further, these studies were con-
ducted in the 1990s. Pertussis incidence has substantially increased in recent 
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years so data from this period may not adequately represent current epidemiolo-
gy29,33-35. 
In the U.S. infants less than 1 year have the highest rate of reported per-
tussis at 70.9 cases per 100,000 population21. In 2009 the number of pertussis 
cases in in the U.S. in infants less than 6 months was reported as 126.9 per 
100,000 infants36.  
Subsection 2.3 - Adults 
Multiple studies have investigated the proportion of prolonged cough ill-
nesses in adults attributable to pertussis with the range approximately 12-
32%4,9,37-47.  Adult serum specimens were tested using enzyme-linked immuno-
sorbent assay (ELISA) and nasopharyngeal specimens were tested by polymer-
ase chain reaction (PCR), direct fluorescent antibody (DFA), or standard culture. 
Laboratory testing was conducted using at least one or a combination of these 
methodologies.  In one study, 21% of adults with prolonged cough illness pre-
senting to U.S. emergency departments tested pertussis positive (via culture or 
ELISA)40. Another study looking at a U.S. urban population found 12% of adults 
with prolonged cough >2 weeks tested positive for pertussis using the ELISA 
method. The investigators estimated the incidence of pertussis in adults in the 
U.S. is 176 per 100,000 PY (95% Confidence Interval (CI)): 97-255)38. An addi-
tional population-based study of adults in Minneapolis estimated the incidence in 
the U.S. is 507 cases per 100,000 PY using a combination of ELISA, culture, and 
PCR methods (95% CI: 307-706)37. 
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One of the best estimates of the incidence of adult pertussis comes from a 
1997-1999 U.S. clinical trial of the aP vaccine48. Participants, ages 15-65 years, 
were randomized to receive either the aP vaccine or a hepatitis A vaccine as the 
control arm. Those enrolled were called every 2 weeks to determine if they had a 
cough for greater than 5 days. Persons with persistent cough had specimens 
(nasopharyngeal aspirate and blood) collected for laboratory confirmation.  The 
incidence of pertussis among those in the control arm was estimated to be be-
tween 370 and 450 cases per 100,000 PY depending on the pertussis definition 
utilized.  
Use of serology increases the sensitivity for detecting asymptomatic and 
mild pertussis cases. The adult aP trial ascertained the total number of cases 
through serologic testing and found that there are 5 asymptomatic or clinically 
insignificant infected persons for every confirmed case of pertussis49. The results 
showed 1% of the population is infected with pertussis annually. A study of the 
U.S. National Health and Nutrition Examination Survey (NHANES) in persons 
ages 10-49 provided a higher prevalence of pertussis infection at 2.98% translat-
ing to an annual prevalence of 2,890 per 100,000 persons50.  A cross-sectional 
study from China estimated the incidence of pertussis infection as determined 
from a single serological specimen51. The investigators estimated that the inci-
dence of pertussis in persons aged 2-20 years in China was 7,000 per 100,000 
PY. Another recent China study found the pertussis incidence to be 9,395 cases 
per 100,000 PY in those over 7 years52. As there is no absolute antibody titer 
level that correlates with protection or recent infection, these results based on a 
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single sample overestimate the incidence. Similar to infants, pertussis is resurg-
ing in adolescent and adults21,35,53. 
Subsection 2.4 – Asia and Nepal Burden 
While community-based data on the incidence of pertussis in developed 
countries is limited, it is almost non-existent in Nepal and other Asian countries 
where surveillance is less robust and based on nationally reported cases or 
seroepidemiology studies54,55.  Reported numbers of pertussis deaths from pas-
sive surveillance are not adequate to measure pertussis morbidity and mortali-
ty55-57.  In the WHO Southeast Asia region the reported pertussis incidence on 
the 2014 Joint Reporting Form was 2,027 cases per 100,000 PY58. An estimated 
4% of all childhood deaths in Southeast Asia are due to pertussis according to a 
global systematic review11. 
A seroepidemiology study in Iran estimated approximately 7% of the popu-
lation aged 7-35 years had a recent pertussis infection (based on high PT immu-
noglobulin G (IgG) titers)56. Two Chinese studies show a lower prevalence with 
approximately 7-9 cases per 1,000 population based on serology51,52. A pertussis 
resurgence was found in vaccinated children of Pakistan during recent surveil-
lance (2004-2006)59 and in Iran60. A modeling study from Thailand found no in-
crease in pertussis in recent years61. 
In Nepal specifically, pertussis is estimated to contribute to 2% of child-
hood deaths based on the aforementioned global systematic review11. 3,431 
cases were reported in 2013 giving a population incidence of 12,343 cases per 
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100,000 PY62.  Reported cases over time have not substantially increased as has 
been found in other countries. 
Section 3 – Microbiology, Pathology, and Immunology 
Subsection 3.1 - Microbiology 
 Bordetella pertussis is a small, non-
motile, gram-negative coccobacillus whose 
habitat is the mucosal layer and cilia of the hu-
man respiratory tract [Figure 1.1]12. Bordetella 
pertussis is a member of the Bordetella spe-
cies, which also includes genetically related B. 
parapertussis and B. bronchiseptica4,63.  B. 
parapertussis causes similar disease as B. per-
tussis, however the symptoms are milder; it is 
also found in sheep. Non-human animals (dogs, rabbits, horses, pigs) are the 
typical host of B. bronchiseptica although human cases have been document-
ed2,64.  The difference between these three species lies mainly in differential 
gene expression and polymorphisms in certain genes65. The Bordetella species 
also includes B. avium (birds), B. hinzii, B. holmseii, B. trematum, B. petrii, and B. 
ansorpii which are poorly understood but are thought to infect both animals and 
humans64-66.  
Source: CDC – public health image library 
#2121  
FIGURE 1.1 - GRAM-STAINED 
PHOTOMICROGRAPH OF BOR-
DETELLA PERTUSSIS 
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Subsection 3.2 Pathology 
  B. pertussis is transmitted from person to person contact through pertus-
sis-containing respiratory droplets12. Once a 
susceptible host is infected, the bacteria will 
colonize and multiply in the mucous mem-
branes of the respiratory tract [Figure 1.2]2. 
The organism specifically resides on the cili-
ated epithelial cells of the trachea and bronchi 
and does not enter the sub-mucosal cells or 
the bloodstream.  B. pertussis bacteria se-
crete toxins, which paralyze the cilia and in-
flame the respiratory tract. An infected person then has difficulty clearing respira-
tory secretions67. The specific pathway through which B. pertussis infects a per-
son, destroys/inflames the respiratory tract, and evades the immune system has 
not been fully characterized.  
 B. pertussis expresses a variety of virulence factors including pertussis 
toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), fimbriae (FIM) type 
2 and type 3, adenylate cyclase toxin (ACT), tracheal colonization factor (TCF), 
tracheal cytotoxin (TCT), dermonecrotic toxin (DNT), lipopolysaccharide (LPS), 
B. pertussis endotoxin, Bordetella resistance to killing factor (Brk), heat-labile tox-
in, and Type III secretion system (bscN)4,12,68-71. Depending on its environmental 
conditions B. pertussis may alter expression of certain virulence factors. The ma-




FIGURE 1.2 - COLONIZATION OF 
TRACHEAL EPITHELIAL CELLS 
BY BORDETELLA PERTUSSIS 
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nome2.  While related organisms may secrete many of the same factors, PT is 
specific to B. pertussis72. Interestingly, other Bordetella species (bronchioseptica 
and parapertussis) have the gene for PT, however it is not expressed due to nu-
cleotide polymorphisms in the promoter regions65. 
Bordetella pertussis infection involves attachment, evasion of the host 
immune system, localized damage, and then systemic effects73. Filamentous 
hemagglutinin, Prn, PT, LPS, TCF, Brk, and FIM are thought to aid in the strong 
attachment of B. pertussis to the epithelial cells of the upper respiratory tract12.   
Pertussis toxin and ACT play a role in helping the organism to evade the host’s 
immune system. Local tissue is damaged through TCT and ACT73. Pertussis tox-
in may cause lymphocytosis or hyperinsulinemia.   
Subsection 3.3 - Immunity 
There are multiple factors thought to stimulate an immune response to B. 
pertussis. Four of these (PT, FHA, Prn, FIM) are included in various combina-
tions of aP vaccines; not all vaccines contain all four antigens. Pertussis toxin is 
one of the most important factors in pertussis virulence and is a strong immuno-
gen in the human host72.  While B. pertussis itself does not invade systemically, 
PT is excreted into the blood causing systemic side effects.  In mouse models 
antibodies to PT protect mice from both intracerebral and aerosol challenges.  
Pertactin antibodies are crucial for facilitating phagocytosis of B. pertussis, which 
may contribute to their role in immunity74. Filamentous hemagglutinin and Prn are 
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both highly immunogenic and antibodies to these proteins are protective against 
respiratory but not intracerebral murine challenge model. 
During the initial weeks of the infection several immune defense factors 
enter the lungs including macrophages, dendritic cells, neutrophils, natural killer 
cells, and T cells75 Animal studies have demonstrated the importance of cell me-
diated immunity in clearing pertussis infections. 
There is no established serologic correlate of immunity to B. pertussis. 
Studies from the mid 20th century indicated high levels of antibodies to LPS, Prn, 
and FIM type 2 and 3 conferred protection from pertussis disease. More recent 
studies show that high antibody levels to Prn and FIM types 2 and 3 are predic-
tive of protection against pertussis disease74,76-79.  
Section 4 – Epidemiology 
Prior to the introduction of the wP vaccine, pertussis was widespread [Fig-
ure 1.3]7.  Despite high levels of vaccination, pertussis remains an endemic dis-
ease throughout the world with periodic epidemic cycles every 3-4 years7,80,81. 
Subsection 4.1 Resurgence   
In the pre-vaccine era pertussis was mainly a disease detected in child-
hood with >93% of reported cases occurring in children <10 years and >80% in 
children <5 years6,82. Since the 1980s there has been an increase in pertussis 
reporting in the U.S. and other mostly high-income countries, in infants, adoles-
cents, and adults [Figure 1.4]6,21,23,34,83-85. Outbreaks and epidemic levels of per-
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tussis have been reported in Australia86, Sweden87, Spain88, Argentina89, 
Pakistan59. Iran60, South Korea30 and the United States90-92. In contrast, Thailand 
has not experienced a pertussis resurgence61. A Strategic Advisory Group of Ex-
perts (SAGE) on immunization review of evidence from 19 countries however in-
dicated that the resurgence is not global with only 5 of 19 countries showing in-
creased pertussis incidence93. Several factors are associated with this increase. 
First, substantial evidence exists of worldwide genetic changes in B. per-
tussis, perhaps accelerated by adaptation to pertussis vaccines3,94-101. In Austral-
ia, strains with polymorphisms in Prn and PT are increasing in prevalence indi-
cating selection for pertussis strains that are not present in current aP vaccines86. 
Source - CDC MMWR, ACIP Tetanus, Pertussis, and Diphtheria Prevention Recommendations for Pregnant and Post-partum 
Women and their Infants  - 2008 
FIGURE 1.3 – U.S. PERTUSSIS CASES 1920-2006 
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FIGURE 1.4 – U.S. PERTUSSIS INCIDENCE 
1981 - 2011 
A retrospective study in the Netherlands examining changes from 1949-2010 
found several single nucleotide 
polymorphisms, which resulted in 
a switch in the predominant circu-
lating strain95. A novel circulating 
PT promoter allele (ptxP3) was 
shown to result in higher expres-
sion of virulence factors; in a 
mouse intranasal infection model 
the ptxP3 variant was significantly 
better in colonization of the lungs and trachea than ptxP198. Pertactin-deficient 
strains, first reported in 1994, have dramatically increased since 2010 and are 
present in several countries102-105. Recent data show these Prn-negative strains 
may be more virulent than strains containing Prn106. These Prn-deficient strains 
arose independently multiple times and not from a single mutation event107  
There are differences in vaccine-induced immunity from those who re-
ceived aP vaccines exclusively versus those who had one or more doses of wP 
vaccines92,108. While the aP vaccine trials in the 1990s showed similar immuno-
genicity and efficacy for wP versus aP vaccines, follow-up indicates these vac-
cines are not comparable in long-term protection across age groups15,81,108-112. 
One reason for this may be that wP vaccines contain the entire killed B. pertussis 
organism and therefore a greater number of antigens to stimulate the immune 
response than the acellular vaccine, which contains only a select few purified an-
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tigens92. Acellular vaccines and wP vaccines also stimulate the immunity re-
sponse differently113,114. Acellular vaccines induce a Th2 favored immune re-
sponse and reduced Th1 response for cell-mediated immunity94. Whole cell per-
tussis vaccine generates a broader cytokine response compared to aP vac-
cines113. A study in non-human primates found that while vaccination with aP 
vaccine prevented severe infection it did not prevent colonization, nor facilitate 
more rapid infection clearance nor stop transmission to unvaccinated non-human 
primates115. The aP vaccines also elicited a mixed Th1/Th2 immune response 
compared to the Th1 and Th17 response induced by wP vaccines. Evidence 
from this study provides some of the strongest mechanistic data to explain the 
relative vaccine effectiveness inferiority of aP versus wP. Similar data in mice 
showed aP vaccines were not able to limit shedding or disease transmission 
compared to wP vaccines116. A current SAGE review found 4 of the 5 countries 
experiencing resurgence were using aP vaccines exclusively93. In the one coun-
try using wP vaccine other factors were thought to be the primary contributors to 
the pertussis resurgence such as increased surveillance, changes in laboratory 
methods, and low vaccination uptake. 
Waning immunity from both wP and aP vaccines might also contribute to 
the increase53,115,117. 
Next, especially in high-income countries such as the United States, there 
has been increased resistance to vaccination leading either to non-vaccination or 
delays in vaccination25,118. Data from California indicate that non-medical exemp-
tions for pertussis vaccination are associated with increased pertussis risk119. 
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Advances in and greater availability of pertussis laboratory diagnostics in-
cluding serology and PCR may have led to increased pertussis detection34,93.  
Finally, there may be greater awareness today of pertussis, especially in 
older persons, increasing the chances that pertussis may be suspected as a dif-
ferential diagnosis in those presenting with prolonged cough34. 
Subsection 4.2 – Risk Factors 
4.2.1 Age 
Infants have the highest incidence of pertussis and are at the greatest risk 
of morbidity and mortality from pertussis compared to any other age group [Fig-
ure 1.5]23,24,120. In the U.S., during the period 2000-2006, infants <1 year contrib-
uted to 93% of pertussis-related 
deaths83. Among infants <1 year, 
infants <6 months experienced 
the highest burden of disease 
with the mean age of infection 
from one hospital study at 2.6 
months and another study 
showing highest burden in those 
<3 months [Figure 1.6]7,26,31,121,122. 
Since the 1980s the incidence of pertussis in infants in the U.S. has increased24. 
Source - CDC MMWR, Summary of Notifiable Diseases – 2011 FIGURE 1.5 – U.S. NUMBER OF REPORTED 
PERTUSSIS CASES BY AGE GROUP 2011 
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 In addition to infants, serologic studies found peaks in pertussis-
associated antibodies in in a period immediately following the final childhood 
vaccine administration and again in adolescence50,51,123-125. In Nashville, adoles-
cents ages 13-17 years had the highest pertussis antibody titers compared to 
other age groups125.  In the U.S. APERT study 15-20 year old participants had 
the highest PT IgG antibody concentrations124. A study in China also found 2 
age-related peaks in the distribution of antibody titers; one peak at 6-8 years, 
which is probably a result of recent receipt of the final pertussis vaccine dose and 
an additional peak in the 12-20 year range most likely indicative of recent natural 
infection due to waning immunity51.  South Korean national surveillance found a 
shift in the age distribution to adolescents30. 
For adults, a study of U.S. healthcare workers found annual serological 
evidence of infection in 1.3% of medical residents and 3.6% of emergency de-
partment staff126. A study of University of California Los Angeles female 
Source: Tanaka  JAMA, Trends in Pertussis Among Infants in the United States, 1980-1999 
FIGURE 1.6 – U.S.  NUMBER OF REPORTED PERTUSSIS CASES <1 YEAR 2011 
  19 
healthcare workers found a much higher annual rate of infection ranging from 
24% - 43%, however the researchers did not measure antibodies to PT, the most 
specific antibody for pertussis infection127. Additionally they included increases as 
low as 1.9 fold to represent a recent infection, which may have lower specificity 
than a more stringent threshold. 
4.2.2 Sex 
Age modifies the relationship between sex and pertussis with almost equal 
incidence between sexes in children <1 year. As age increases, the female to 
male case ratio increases8. For those <1 year South Korean and Tunisian sur-
veillance showed an increased incidence in males compared to females26,30. In 
Japan similar incidence was found between the sexes27. 
Overall, females have a slightly elevated risk of pertussis compared to 
males8,9,82,128.  In the U.S., females have a slightly higher infection rate compared 
to males (6.6 vs. 5.4 cases per 100,000 PY) 21. In Wales and England from 1945 
to 1982 the incidence of pertussis was higher in females than in males with 0.88 
males cases for each female case (95% CI: 0.84-0.92)7. The reason for these 
sex differences in incidence is unknown.  
4.2.3 Ethnicity/Race 
In King County Washington, infants who were in ethnic and racial minority 
groups had higher risk for pertussis compared to while infants25. Black infants 
  20 
had 3.4 (95% CI: 2.6 – 4.4) times the risk of pertussis compared to white infants. 
Hispanic infants are also at higher risk than non-Hispanic infants24,25. 
4.2.4 Maternal and household characteristics (for infants) 
A 1993 retrospective, matched, case-control study from Chicago found no 
difference between cases and controls with regards to sex, birthweight, age, 
mother’s education, or number of persons in the household or per room129. Con-
trols were more likely to receive public assistance compared to cases. In another 
study young maternal age was a risk factor for infant pertussis with an infant’s 
risk of pertussis increased by 11% for every 1-year decrease in maternal age129. 
Maternal history of antecedent cough was also associated with infant pertussis.  
In U.S. Centers for Disease Control and Prevention (CDC) reported pertussis 
deaths, a substantial proportion (51%) were in infants born before 37 weeks, and 
29% were in infants born before 35 weeks23. 
4.2.5 Co-Infections 
Co-infection with pertussis is common.  In a 1990s study of co-infections 
during a pertussis clinical trial, 21% of children infected with pertussis were also 
infected with other organisms including Mycoplasma pneumonia and Chlamydia 
pneumonia130.  One study in hospitalized infants in England found that among 
children who had pertussis, 33% were co-infected with respiratory syncytial virus 
(RSV)131. In Finland, 67% of infants <6 months hospitalized with pertussis were 
also infected with RSV132.  A smaller proportion of infants were co-infected with 
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rhinovirus and influenza A. Another study in Finland found that 8% of infants 
hospitalized with RSV also had pertussis infection133.  A multi-country study of 
infants found that 21% of infants with pertussis were co-infected with another or-
ganism (9% RSV, 9% influenza B, 3% influenza)31.  In the U.S., among reported 
pertussis infant deaths, 18% were co-infected with RSV, and 15% were infected 
with other viruses including influenza, parainfluenza, cytomegalovirus, and ade-
novirus23.  Bacterial pathogens were also found in cultures from blood or autopsy 
lung tissue in 15% of infants such as Streptococcus pneumonia and Haemophi-
lus influenzae. 
Co-infection with B. parapertussis was found in approximately 10% of Tu-
nisian infants infected with B. pertussis26. An outbreak study in Ohio also found a 
small percent of co-infections with B. holmseii90. 
4.2.6 Pre-existing conditions 
One study found patients with asthma had a 17% increased risk for per-
tussis134. 
4.2.7 Season 
It remains unclear whether pertussis has a distinct seasonality with some 
experts claiming no seasonality while others argue for differing periods of peak 
pertussis transmission7,8,80. Peaks in winter or spring were seen in England and 
Wales in the pre-vaccination period. In Japan, U.S., and Hungary summer peaks 
of pertussis have been documented82,135.  Two small studies in the early 1970s in 
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India found seasonality of pertussis infection with increased infections from No-
vember to June, which is consistent with a more recent 2009 study136. A 1959-
1966 study in the U.S. found a peak in July and August and a nadir December 
through March128.  In the 1990s infants had a peak incidence in July and August 
and adolescents in the fall23,24.  Immunization uptake rates and school opening 
dates may confound seasonality findings80. A South Korean study found in-
creased pertussis cases between May and November30. 
Subsection 4.3 Transmission 
Pertussis is transmitted through airborne respiratory secretions from per-
son to person. The bacterium is fastidious and survives externally for just a few 
hours4.  Humans are the only known reservoirs of pertussis disease8,137. Pertus-
sis is highly infectious with a >80% secondary attack rate in susceptible per-
sons138.  Recent estimates of the basic reproductive number are in the range of 5 
to 1113,139. In a non-human primate model those vaccinated with aP vaccines 
were still able to transmit pertussis to other close contacts115. Household con-
tacts are a main source of exposure, especially for young infants22,23,25,129,140,141.  
Parents are the most commonly identified source of infection for infants followed 
by siblings and other household members28,142-146.  In a multi-national study look-
ing at sources of infant infection, mothers constituted 50% of the transmitters fol-
lowed by siblings (17%)31.  A United Kingdom study of infants hospitalized with 
pertussis found 42% had a parental source of infection and 27% were infected by 
an older sibling131.  An Australian study found siblings constituted 36% of pertus-
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sis infection sources followed by mothers (15%), other family members (21%) 
and friends147. A literature review summarized that mothers, fathers grandpar-
ents, and siblings, were the source of pertussis infection 39%, 16%, 5%, and 16-
43% of the time, respectively148 
Subsection 4.4 Carrier State 
Prior to PCR testing, culture was the primary method for pertussis diagno-
sis.  Using culture detection methods, pertussis is exceedingly rare or non-
existent in healthy individuals but the sensitivity of culture is quite low4,137,149-151. 
In Sweden, 391 healthy close-contacts of pertussis cases were tested by culture 
for pertussis152.  Only one healthy contact tested positive for pertussis indicating 
healthy carriers may play little to no role in pertussis transmission.   
However, diagnostic advances, namely PCR, allowed for detection of 
smaller numbers of pertussis organisms than possible through culture. Results 
using PCR have demonstrated carriage in otherwise healthy contacts143,149,153,154.  
For example, in an outbreak among Israeli soldiers, investigators found 20% of 
healthy contacts were PCR positive for pertussis during the outbreak149.  Howev-
er, at least one study using PCR found no asymptomatic carriers in pre-school 
children exposed to pertussis as all children who tested positive by PCR exhibit-
ed at least a mild cough155.  
Non-human primates who had previously experienced a pertussis infec-
tion had no colonization when challenged with B. pertussis115. On the contrary, 
wP and aP vaccinated non-human primates were subject to colonization after B. 
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pertussis challenge peaking around 2 weeks and were able to transmit the bacte-
ria to naïve cage-mates. Non-human primates vaccinated with wP vaccine 
cleared the colonization quicker than those vaccinated with aP vaccine (18 ver-
sus 30 days). 
Section 5 – Clinical Presentation 
Subsection 5.1 - Children 
Before the introduction of the pertussis vaccine young children were the 
primary age group infected with pertussis and they exhibited the classical pertus-
sis clinical presentation. Pertussis begins with a 7-10 day incubation period 
(range 5-21 days)156,157.  It then progresses through three phases: catarrhal, par-
oxysmal, and convalescent66. During the catarrhal phase, lasting 1 to 2 weeks, 
an infected person experiences symptoms similar to those of the common cold 
such as rhinorrhea, sneezing, and intermittent cough; fever is generally not pre-
sent. However, instead of resolving, the disease progresses to the paroxysmal 
stage, characterized by spasmodic coughing followed by an inspiratory whoop 
and sometimes vomiting. The coughing episodes may be grouped together with 
periods of non-coughing followed by heavy paroxysmal coughs73. This period 
usually lasts 1 to 6 weeks but may extend for 10 weeks. Eventually symptoms 
begin to wane as a person enters the convalescent phase. Complications of the 
disease may include hospitalization, bronchopneumonia, seizures, acute en-
cephalopathy, pneumonia, and death. 
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Children who have a history of pertussis vaccination are significantly less 
likely to have severe morbidity and recover more quickly than their unvaccinated 
counterparts158-160. 
Subsection 5.2 – Infants 
Infants usually experience symptoms atypical from the “classic” pertussis 
presentation with a shorter catarrhal stage, increased apnea, and sometimes the 
absence of the classic whoop157,161. Infants with pertussis are found to exhibit 
some of the following symptoms: paroxysmal cough, post-tussive vomiting, ap-
nea, cyanosis, inspiratory whoop, wheezing, bradycardia, and poor feed-
ing25,162,163. The atypical presentation may lead to delays in pertussis laboratory 
testing and pertussis-specific treatment.   
Pertussis is most serious in children younger than 6 months, especially in 
preterm infants and under-immunized infants. Infants who have had fewer per-
tussis vaccinations are more likely to be hospitalized for pertussis compared to 
infants of similar age24. Complications in infants include pneumonia, apnea, pro-
found lymphocytosis, pulmonary hypertension, bronchiolitis, seizures, encepha-
lopathy, conjunctiva bleeding, and death23,83,164.  Infants younger than 2 months 
have a 1% case fatality rate that drops to 0.5% in infants less than 1 year. Older 
infants are more likely to experience whooping and vomiting and less likely to 
experience apnea or be hospitalized24.  Persons who contracted pertussis as in-
fants have a greater risk of having asthma and respiratory infections compared to 
similar infants with no pertussis history165. 
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Subsection 5.3 - Adults 
Adults have a clinical presentation of pertussis that is milder than that 
seen in children and is usually non-specific40. Detection of pertussis is limited in 
adults as they usually come for treatment weeks into the illness when the organ-
ism is more difficult to isolate. The catarrhal phase is usually mild or absent in 
adults due to previous natural of vaccine-induced exposure to pertussis166. Adults 
may experience post-tussive emesis, syncope, problems sleeping, incontinence, 
fractures of the rib and pneumonia157. 
Section 6 – Diagnosis 
Subsection 6.1 - Clinical 
Clinical diagnosis of pertussis is difficult as pertussis encompasses a 
broad range of symptoms and some pertussis may manifest atypically.  In 1991 
the WHO created an expert panel to develop a consensus case definition of per-
tussis in anticipation of the upcoming efficacy trials for aP vaccines72. The WHO 
definition required a paroxysmal cough of at least 21 days plus confirmation 
through either laboratory methods or an epidemiologic link. While this definition 
helped to standardize the subsequent trials it still led to difficulties in interpreta-
tion of results. Use of WHO’s definition led to differential sensitivity of case detec-
tion in unvaccinated versus vaccinated populations. B. pertussis was more likely 
to be detected in unvaccinated populations and therefore it artificially raised the 
demonstrated efficacy of the vaccines.  The current WHO definition includes clin-
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ically and laboratory confirmed cases [Figure 1.7]167.  Clinically confirmed cases 
must be either diagnosed by a physician or have a cough of at least 14 days 
(shorter period than pervious definition) plus an additional pertussis-related 
symptom. A laboratory confirmed case must have laboratory confirmation by cul-
ture, PCR, or positive paired serology in addition to meeting the clinical case def-
inition. 
 
FIGURE 1.7 – WHO PERTUSSIS CASE DEFINITION 
Subsection 6.2 - Laboratory 
Determining who has pertussis is difficult. In many areas laboratory and 
technical capacity to test for pertussis is limited or non-existent.  Non-specific la-
boratory findings may include leukocytosis due to lymphocytosis or thrombocyto-
sis23,128. A chest radiograph may be normal or indicate some irregularities, which 
include peribronchial cuffing, perihilar infiltrates, interstitial edema or atelecta-
sis23,168,169.  Specific laboratory findings may also be difficult to interpret, as they 
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are prone to low sensitivity depending on specimen collection method, collection 
timing, and testing method. Furthermore, most of the assays lack standardization 
for comparability between testing centers170,171. 
6.2.1 Direct Isolation 
6.2.1.1 Specimen Collection 
The CDC and WHO recommend collection of pertussis specimens through 
either nasopharyngeal swab (NPS) or nasopharyngeal aspirate (NPA) although 
the aspirate provides higher yields66,172-176. Studies to date consistently cite that 
throat and nasal swabs (NS) have unacceptable rates of recovery. However, this 
guideline was established when culture was the gold standard in testing method-
ology. No published studies to date have used NS alone or specifically in com-
parison to NPA or NPS for pertussis testing131.  One Australian study included 
NPA, throat swabs, and NS specimens for PCR pertussis detection177. While 
85% (445) of specimens were NPA, some were throat swabs (71) and nasal 
swabs (5). Surprisingly, NS had the highest percent positive rate (40%) com-
pared to 30.1% for throat swabs and 9.2% for NPA.  While the numbers were too 
low to draw definite conclusions regarding comparison of collection methods, it 
demonstrated that pertussis may be detected from NS. An unpublished 
(submitted) manuscript found similar sensitivity in detecting B. pertussis 
comparing posterior nasopharyngeal swab collection with mid-nasal swab 
collection178. 
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Some studies have looked at differ-
ences in sensitivity and specificity for NPS 
versus NS for other respiratory pathogens179. 
Meerhoff found NS to have reduced sensitivi-
ty (67%) compared to NPS (92%) using a 
consensus gold standard (positive in either 
test).  For RSV and rhinovirus the reduced 
sensitivity was significant, 51% and 75%, re-
spectively.  In Guinea-Bissau researchers 
found 27-32% reduced sensitivity of NP compared to NPS for detection of 
RSV180.  A study in Finland found NPS to have comparable sensitivity to NS 
specimens with the exception of RSV181. Another study comparing combination 
nose-throat swabs to NPS also found comparable sensitivity between methods 
for respiratory viruses180.  However, the ideal specimen collection location is or-
ganism dependent and these differences may not be comparable to differences 
seen for pertussis.  
A diagram of the proper collection method is shown in Figure 1.8. Naso-
pharyngeal swab specimens are collected by (1) inserting a swab through the 
nostril into the nasopharyngeal cavity, (2) holding the swab for 10 seconds and 
turning, and then (3) removing the swab156.  Nasopharyngeal aspirates are col-
lected in a similar manner but instead of a swab, a small tube connected to a 
mucus trap is inserted while secretions are aspirated. 
Source: CDC Vaccine Preventable Disease 
Surveillance Manual, 5th Edition, 2011 
FIGURE 1.8 - PROPER TECH-
NIQUE FOR OBTAINING A NASO-
PHARYNGEAL SPECIMEN FOR 
ISOLATION OF B. PERTUSSIS 
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6.2.1.2 Culture 
The gold standard for B. pertussis testing is the culture of nasal secretions 
due to culture’s superior specificity compared to other testing methods66,156,172.  
However, the sensitivity of culture is quite low (15-60%). After the first few weeks 
the sensitivity continues to decrease for the duration of the disease182. Moreover, 
treatment with antimicrobials, history of previous pertussis vaccination, or non-
NPA/NPS specimens will also decrease the sensitivity.  Culture on infant speci-
mens yields the highest sensitivity compared to older age groups66. Culture re-
mains useful in typing of B. pertussis and testing for antibiotic resistance alt-
hough this is uncommon68. 
Once the specimen is obtained, plates containing media such as RL me-
dium or Bordet-Gengou are inoculated with the pertussis specimen66,172.  The re-
covery rate decreases commensurately with the length between specimen collec-
tion and plating. Colonies will start to appear by day 3 but culture incubation 
should continue for at least 7 days. B. parapertussis grows more rapidly than B. 
pertussis but both will generate small colonies (approximately 1mm in diame-
ter)66. 
6.2.1.3 RT - Polymerase Chain Reaction (PCR) 
Real-Time polymerase chain reaction (RT - PCR) assays have substan-
tially improved pertussis diagnostic capabilities183.  Polymerase chain reaction 
has superior sensitivity compared to culture due to its ability to amplify small 
segments of DNA and reduced susceptibility to interference from antimicrobial 
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therapy184. Moreover, results can be obtained relatively quickly in 1 to 2 days. 
PCR is most sensitive when used on specimens collected within the first three 
weeks of symptoms and sensitivity generally declines thereafter173,185. Polymer-
ase chain reaction is more sensitive for samples obtained from children com-
pared to adult specimens156.  Compared to culture PCR also has higher sensitivi-
ty as the disease progresses and is more sensitive for mild pertussis cases.   
Polymerase chain reaction for B. pertussis was developed in 1989, how-
ever standardization of assays across laboratories has been limited and no Food 
and Drug Administration (FDA) approved standardized PCR kit exists68,183,186. 
Polymerase chain reaction can be prone to contamination and difficulties with 
transport, so careful technique must be used from specimen collection through 
detection. Initial pertussis PCR assays amplified only a single gene sequence, 
such as insertion sequence IS481, with potential for false-positives and false-
negatives184,187,188. These PCR assays yielded sensitivity and specificity as high 
as 95% and 99.3%, respectively174.  
Recent developments have improved the sensitivity and specificity of test-
ing through multi-target real-time PCR186,189.  In addition to IS481, other targets 
include IS1001, IS1002, h-IS1001, ptx, and recA66. Compared to single-target 
PCR, triple-target PCR (IS481,ptx and recA) increases the proportion of positive 
findings by 1.25 fold, and double-target increases positive results by 1.10 – 1.24 
fold186. 
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6.2.2 Indirect Detection 
6.2.2.1 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) may be used to diagnose 
pertussis either through a single serum sample or through positive paired serolo-
gy68.  After infection, antibodies to B. pertussis may be detected within 1 to 2 
weeks. B. pertussis primarily elicits IgG antibodies although IgA antibodies are 
also generated.  After infection, antibody levels fall below a defined threshold by 
4 to 5 months on average and for the vast majority of patients by 1 year190.  Anti-
body testing cannot differentiate between recent infection and recent vaccination.  
Serologic assays most commonly include testing for PT and FHA, which also 
may be supplemented with Prn and FIM76,191,192.  Pertussis toxin is the only anti-
body specific for B. pertussis as other antibodies may cross-react with similar 
species (e.g. B. parapertussis and Haemophilus influenzae elicit FHA re-
sponse)156.  Pertussis toxin is therefore the antigen of choice for antibody detec-
tion50.  There is no standard ELISA pertussis assay, making comparability be-
tween laboratories is difficult193-195.  Recent efforts have worked to standardize 
ELISA PT quantification between laboratories196,197. One group has recently de-
veloped a rapid ELISA to detect antibodies to PT, FHA, Prn, Fim2, and Fim3198. 
No correlate of protection or immunity exists and therefore pertussis is 
most accurately diagnosed with positive-paired serology from acute and conva-
lescent samples68.  The acute specimen should be collected as early as possible, 
ideally within the first two weeks, and the convalescent sample 4-6 weeks there-
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after. A 3-4 fold increase in antibody levels is generally accepted to indicate re-
cent infection. Positive paired serology is more specific than a single sample di-
agnostic test156.  Serology is considered the most sensitive of all pertussis diag-
nostic techniques50. 
Many, especially adolescents and adults, present late in the illness when 
antibody levels have already risen and so paired specimens are not available. 
Paired serology diagnosis is also less useful; a definitive result is usually availa-
ble near the conclusion of the disease and therefore is of little utility in guiding 
treatment of the patient68.  A single antibody specimen taken at least 2 weeks in-
to the illness may be used but has lower sensitivity and specificity than paired 
serology and is not useful if a person has been vaccinated in the preceding two 
years.  A PT IgG antibody test above 100 – 125 ELISA units/mL (EU/mL) may 
indicate recent infection. A study in the Netherlands found a value of 100 EU/mL 
to have 89.9% sensitivity and 99% specificity when compared to a gold standard 
of a greater than 4-fold rise in antibody titers199.  Baughman and colleagues used 
a mixture model to develop a PT IgG cut-off point of 94 EU/mL50.  Applied to a 
previous study in Minnesota the diagnostic sensitivity and specificity of this level 
was 80% and 93%, respectively using culture as the gold standard comparison. 
6.2.2.2 Direct fluorescent antibody technique (DFA) 
Direct fluorescent antibody technique (DFA) is another method used to de-
tect B. pertussis although it is not commonly used. Advantages of DFA are its 
  34 
ability to obtain results quickly and its high specificity (99.6%)172. Disadvantages 
are that it requires specialized training and has low sensitivity. 
Section 7 - Treatment 
For B. pertussis infected infants and children, supportive care to minimize 
adverse effects is most important. A systematic review concluded that antimicro-
bial treatment has no effect on the course of the disease, however in many of the 
studies treatment was not started until later stages of the disease200.  Some stud-
ies show antimicrobial therapy is an adequate treatment for patients with pertus-
sis, however its utility is limited to early in the disease course and will have no 
effect if given at more advanced, paroxysmal stages of the disease201,202.  As la-
boratory confirmation is not immediate, it is recommended that a case with high 
clinical suspicion of pertussis be presumptively treated with antimicrobial therapy.  
Treatment has also been shown to eliminate carriage of pertussis in the naso-
pharynx and therefore it is useful in reducing transmission of disease to suscep-
tible persons even if it cannot change the clinical course of disease in those al-
ready infected203.  If antibiotics are indicated, macrolide antibiotics (e.g. azithro-
mycin) should be given. A course of treatment may vary from 5-14 days depend-
ing on the specific antibiotic. Prophylactic treatment may also be given to close 
contacts to minimize the spread of disease although limited evidence indicates 
this is not effective204. 
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Section 8 - Prevention 
Subsection 8.1 Natural Infection  
Previously, pertussis infection was thought to confer near lifelong immuni-
ty8.  However recent studies indicate that neither natural infection nor vaccination 
provides complete or long-lasting protection.  Modeling of pertussis disease in 
1940 found that on average an adult could expect to experience 2.3 cases (most-
ly mild) of pertussis in his or her lifetime205. More recent studies in the Nether-
lands and Senegal have documented re-infection in children.  In the Netherlands, 
4 children had a serologically confirmed 2nd pertussis infection with the second 
infection occurring between 3.5 and 12 years after the first infection206.  In Sene-
gal recurrent infections were documented in approximately 2.5% of children with 
a mean duration between infections at 7.1 years in non-vaccinated and 5.1 years 
in vaccinated populations207.  Experts now believe that infection-acquired pertus-
sis immunity persists 7-10 years208. 
Confirming duration of immunity is difficult as there is no established sero-
logical marker of immunity and antibodies to B. pertussis may drop below detect-
able levels after 2 years despite persisting immunity208.  In addition, exposure to 
B. pertussis without clinical disease may boost immune response leading to an 
overestimate of the protective immunity conferred by pertussis disease. 
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Subsection 8.2 Vaccines 
The WHO estimates that since the end of the 1980s, 80% of children 
worldwide have received pertussis vaccine and pertussis vaccination prevents 
about 38 million cases and 600,000 deaths annually209. Pertussis vaccines are 
available in two formulations: whole cell (wP) [DPT] and acellular (aP) [DTaP and 
Tdap]. DPT and DTaP are given to children and Tdap is given to adolescents 
and adults. 
8.2.1 Whole-cell pertussis vaccines 
8.2.1.1 Development 
Soon after the 1906 discovery of B. pertussis as the causative agent of 
pertussis, researchers attempted to develop a vaccine against the disease210.  In 
1933 Madsen reported efficacy of his vaccine formulation against pertussis mor-
bidity and mortality in two pertussis epidemics211. In the 1930s and 1940s large 
randomized controlled trials were conducted to examine the efficacy of the vac-
cines. Efficacies between these early vaccines varied tremendously ranging from 
53% to 91%210. Pertussis vaccines came into routine use in the U.S. and else-
where in the 1940s and 1950s. Whole cell pertussis vaccines are composed of 
formalin-inactivated pertussis cells67. 
8.2.1.2 Efficacy 
Studies to measure the efficacy of the vaccines continue to yield varying 
results195.  Explanations for the differences include variable vaccine formulations 
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and ingredients, study design (case-control, cohort, secondary-attack rate, ran-
domized-control trial), case ascertainment methods and definition, strain of circu-
lating pertussis, dose and timing of vaccinations, and age of participants among 
other factors.  A systematic review found the pooled efficacy of pertussis vac-
cines was 78% but efficacy remained heterogeneous between vaccine formula-
tions212.  
8.2.1.3 Duration of Immunity 
No study has specifically looked at the duration of immunity following wP 
vaccination but indirect estimates are that immunity persists for 4-12 
years182,208,213,214.  Protection against pertussis disease persists longer than pro-
tection against pertussis infection as asymptomatic infections are reported to 
have occurred within 1 year following wP vaccination215. 
8.2.1.4 Safety 
Several local and systemic adverse reactions are associated with wP vac-
cines216.  Local adverse events include erythema, induration, swelling, and pain 
at the vaccination site.  Associated systemic effects include fever, drowsiness, 
prolonged crying in children and anorexia. Rare adverse events include convul-
sions, hypotonic hyporesponsive episodes, and acute encephalopathy12.  Local 
reactions increase with age and as a result wP vaccines in the form of diphtheria, 
pertussis, and tetanus (DPT) are only given to children.  Due to safety concerns 
with the wP vaccines, aP vaccines were developed in the 1980s, which have less 
reactogenicity and an improved safety profile. 
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8.2.2 Acellular pertussis vaccines 
8.2.2.1 Development 
In 1981 the first aP vaccine was developed in Japan12. The superior safety 
profile of the aP vaccines led to their adoption in most of the developed world.  
Acellular pertussis vaccines contain a mixture of purified pertussis antigens. They 
differ in the composition and quantity of antigens12.  Components included in aP 
vaccines include PT, FHA, Prn, and FIM type 2 and 3.  Filamentous hemaggluti-
nin, Prn, and FIM type 2 and 3 are all surface proteins, which promote adhesion 
to the tracheal epithelial cells65. Pertussis toxin is an A/B (2-sub-unit exotoxin) 
that enters the host cells and causes a cascade leading to increased cyclic 
adenosine monophosphate (cAMP) production. 
Adding to antigenic differences, each manufacturer purifies antigens from 
distinct bacterial clones and the detoxification, purification, preservatives and ad-
juvants used are variable12. Acellular pertussis vaccines are usually combined 
with diphtheria and tetanus toxoids although sometimes, additional antigens are 
included in combination vaccines, such as hepatitis B (HepB) or Haemophilus 
influenzae type b (Hib).  There is no pertussis only vaccine formulation.  Pediatric 
(DTaP) and adult formulations (Tdap) are available with the adult versions con-
taining lower amounts of diphtheria and tetanus toxoids.  In the U.S., the pediat-
ric version was licensed in 1991 and the adult version was licensed in 200567.  
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8.2.2.2 Efficacy 
In the late 1980s and 1990s several studies were conducted to measure 
the efficacy of DTaP vaccines in infants [Table 1.1]14-20,217-220. Comparisons be-
tween the studies are not straightforward as they varied in the type of vaccine, 
dosing schedule, case definition and ascertainment, and laboratory detection 
method212,221,222.  Multi-component aP vaccines containing 3-5 pertussis antigens 
have higher efficacy than single or 2 component aP vaccines. One or 2 compo-
nent aP vaccines range in efficacy from 67% - 70% while vaccines containing 3 
or more components have between 80% - 84% efficacy. Comparison of aP to wP 
vaccine efficacy is difficult due to the heterogeneity of wP vaccines and variable 
number of aP vaccine antigen components. Three and 5 component aP vaccines 
appear to be more efficacious than wP vaccines in preventing pertussis as de-
fined by the WHO. A study by Olin et. al found the wP vaccines more efficacious 
than aP, although this study is an outlier compared to other studies19.  According 
to the CDC, aP vaccines are generally more efficacious than wP vaccines67.  The 
WHO states that the best aP vaccines are more efficacious than low-performing 
wP vaccines but are not as efficacious as the best wP vaccines12. After the first 
dose of pertussis there is 15-20% protection and this level increases with each 
dose thereafter in the series72. 
One study in the U.S. was conducted to measure the efficacy of an aP 
vaccine formulated for adolescents and adults48. The vaccine was 92% effective 
(95% CI: 32-99%). The confidence interval around this estimate is large as only 
10 pertussis cases met the primary case definition.  Prior studies looking at the 
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immunogenicity and reactogenicity of the aP vaccines found them to be effective 
and safe49,223-227. While no aP vaccine efficacy studies have been conducted in 
older adults, results from a randomized trial demonstrated the aP vaccine was 
immunogenic and safe228. 
8.2.2.3 Duration of Immunity 
While the duration of immunity following aP vaccines was previously 
thought to be similar to wP vaccines208, more recent immunology and efficacy 
data indicate those receiving aP have lower protection than those vaccinated 
with wP vaccines15,81,108,109,111-113. Outbreak data from Australia and the U.S. 
found that priming with wP vaccine was associated with lower pertussis inci-
dence compared to priming with aP vaccine108,109. Complementary data show 
there was a reduced risk for pertussis among persons ever vaccinated with wP 
vaccine versus persons with a history of 5 aP vaccinations112. 
Most studies estimate the duration of protection to be 5-6 years229-231. 
Vaccine efficacy for aP vaccines in children decreases substantially after receipt 
of the 5th dose111,232-234; those whose last vaccine was given greater than 60 
months prior had 71% vaccine efficacy compared to 95% efficacy for those who 
had received the vaccine between 1-2 years prior. In infants the effectiveness of 
3 doses drops even more quickly; vaccine efficacy between 3 and 4 years de-
clines to 59%235. Similar waning immunity occurs in adolescents after a booster 
dose of Tdap236. Adolescents who received wP vaccines in childhood had greater 
protection against pertussis than those who received aP vaccines237. A study of 
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the adult aP vaccine found antibody levels to PT, FHA, and Prn significantly de-
creased 3 years post-vaccination238. While FHA and Prn antibody levels were still 
higher than pre-vaccination, PT antibody levels approached pre-vaccination lev-
els, indicating potential susceptibility to pertussis infection. 
8.2.2.4 Safety 
Acellular pertussis vaccines are associated with many of the same ad-
verse events as wP vaccines however the frequency and severity of these ad-
verse events are reduced in the aP formulation212.  There are no known serious 
adverse events caused by the aP vaccine. The final 2 doses of aP-containing 
vaccines containing diphtheria and tetanus antigens are associated with in-
creased adverse reactions compared to the first three doses. 
8.2.3 Novel vaccine development 
Work is underway to develop new pertussis vaccines that have greater ef-
ficacy than current aP vaccines while maintaining their excellent safety pro-
file239,240. Theoretical candidates including adding or changing virulence factors in 
aP vaccines, modifying the adjuvant to improve the Th1 response, creating pro-
tein conjugate vaccines, using outer membrane vesicles (nanoparticles) to deliv-
er a multitude of pertussis antigens, and reducing the level of endotoxin in wP 
vaccines239,241-248. Phase 1 studies are underway for a live attenuated pertussis 
vaccine241. 
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8.2.4 Vaccination Schedule Recommendations 
8.2.4.1 U.S. Schedule 
The pertussis vaccine is administered intramuscularly in the thigh for in-
fants or deltoid for adolescents and adults in 0.5 mL volume12. In the U.S. five 
doses comprise the primary vaccination sequence (DTaP) to be given at 2, 4, 6 
months, between 15-18 months, and a last dose between 4-6 years249. An ado-
lescent booster (Tdap) should be given between years 11-12.  
Adults should receive one dose of Tdap as a booster shot250. Pregnant 
women should receive one dose of Tdap vaccine during each pregnancy regard-
less of prior vaccination history251. Ideal timing for vaccination during pregnancy 
is 27 to 36 weeks gestation for optimal transport of antibodies to infants. 
8.2.4.2 Expanded Programme on Immunization Schedule 
Primary vaccination series schedules vary by country (e.g. 2, 4, 6 months 
or 2, 3, 4 months or 3, 5, 12 months)12. The WHO recommends a three dose 
primary series at 6 weeks, 10-14 weeks, and 14-18 weeks. All three doses 
should be administered by 6 months of age. An additional booster dose is rec-
ommended at age 2 years. The WHO does not recommend pertussis vaccines 
for adolescents and adults. 
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8.2.5 Immunization Programs 
8.2.5.1 Global 
The WHO goal for pertussis vaccination is >90% coverage of 3 doses in 
infants12.  While both aP and wP vaccines are generally safe and efficacious, the 
aP vaccine is considerably more expensive and therefore its use has been lim-
ited to middle and upper income countries. Whole cell pertussis vaccines are 
standard in low-income countries.  In 2001 a collaboration of global pertussis ex-
perts formed The Global Pertussis Initiative to recommend pertussis vaccination 
strategies and identify research gaps55,252. The panel recommended that coun-
tries with high infant vaccination coverage add a booster dose at 4-6 years, a 
booster to adolescents, and to target adult groups.  Universal adult vaccination 
was recommended in countries with resources to support adult immunization 
programs. 
SAGE recently provided updated guidance on the choice of pertussis vac-
cines for countries93. Based on current evidence aP vaccines are less efficacious 
and have more rapidly waning immunity compared to wP vaccines. In settings 
where less than 5 doses of pertussis vaccine are given wP vaccines should con-
tinue to be used for the primary vaccination series. The use of wP vaccines is 
likely a more effective strategy to protect infants than aP vaccines when booster 
doses are not readily available. Countries should only consider switching to aP 
vaccines if they have adequate resources and are prepared to provide several 
booster doses to reduce transmission to young children. 
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8.2.5.2 Nepal 
Nepal started its National Immunization Programme (NIP) in 1979 with the 
Bacillus Calmette-Guérin (BCG) and DPT vaccines253. Nepal’s current schedule 
includes BCG, oral polio vaccine (OPV), DPT-HepB-Hib, and measles for chil-
dren, Japanese encephalitis in districts with high risk of transmission, and teta-
nus toxoid (TT) for pregnant women, all of which are provided without cost at 
government facilities. Combination measles-rubella (MR) vaccines were initially 
introduced in June 2013.  Diphtheria, Pertussis, Tetanus (DPT) vaccine coverage 
has increased substantially in Nepal with only 54% of children fully vaccinated by 
12-23 months of age in 1995 compared to 90% in 2012253. The most recent data 
from 2011 give DPT1, DPT2, and DPT3 coverage at 96%, 95%, and 92%, re-
spectively254. In the central terai region, where Sarlahi District is located, 96%, 
92%, and 87% of children have received one, two, and three doses, respectively, 
of DPT by ages 12-23 months. While the coverage is high many receive vaccines 
on a delayed schedule and not by the 6-month deadline recommended by the 
WHO.  As a result the under-immunized are vulnerable to disease when the 
morbidity and mortality consequences are greatest.  In Nepal, male children and 
those who have lower birth order are more likely to be fully vaccinated than fe-
male children and those with a higher birth order254. 
Nepal considers its NIP a high priority and the country is on track to achieve 
MDG 4 on child mortality reduction255,256. Nepal’s immunization program is sup-
ported mainly through GAVI (46%), Nepal’s government (45%), and the WHO 
(9%)147. The United Nations Children’s Fund (UNICEF) and Japanese Interna-
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tional Cooperation Agency (JICA) also contribute.  The NIP has eight objec-
tives147,255: 
1. Achieve and sustain 90% coverage of 3 DPT doses by 2008 and all anti-
gens in all districts by 2010; 
2. Maintain polio free status; 
3. Sustain maternal and neonatal tetanus elimination status; 
4. Initiate measles elimination initiatives from 2010; 
5. Expand vaccine preventable diseases (VPD) surveillance; 
6. Accelerate control of other VPD through introduction of new vaccines; 
7. Improve and sustain immunization quality; 
8. Expand immunization service beyond infancy. 
The recommended schedule for infant DPT vaccine in Nepal is 6, 10, and 14 
weeks. For pregnant women 2 doses of tetanus toxoid are recommended. Per-
tussis is not currently recommended as a booster immunization for adolescents 
and adults, including pregnant women. 
8.2.5.3 Vaccination delay 
Children who are unimmunized or under immunized are at increased risk 
for pertussis and pertussis hospitalization compared to their more fully immun-
ized peers27,118,158-160. National immunization coverage figures do not fully cap-
ture the excess pertussis risk period attributable to delays in vaccination. Further 
some countries’ official reporting may overestimate the coverage in part to reach 
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donor targets such as GAVI’s immunization services support (ISS)257. National-
level reporting may mask within-country variation in vaccination timeliness258.  
Globally, WHO and UNICEF use officially reported data and sample sur-
vey data to measure DPT coverage of children 12-23 months257. As result if there 
are substantial delays in vaccination, but DPT vaccines are complete by age 2, a 
child is still considered as vaccinated on schedule. In the U.S. and elsewhere 
standard national reporting statistics obscure delays when infants are at risk for 
vaccine-preventable diseases27,258-260. For example, Japan’s reported DPT3 cov-
erage was 98% in 2013, however data from a representative city in Japan 
showed less than 50% DPT coverage by age 12 months27. In the U.S. a study 
found almost half of children with some delay in receiving a DTaP vaccine dose 
and 16% under vaccinated for more than 6 months in the first two years259, while 
national DPT3 coverage in 2013 was high at 94%. A study examining the timing 
of vaccination in low and middle income countries, based on surveys and imput-
ed data, found median DPT1 coverage at 6 months was 82% (95% CI: 67-89%) 
and DPT3 was 36% (95% CI: 23-54%)258. 
In the U.S. vaccination delay is associated with a mother who is unmar-
ried, less educated, non-Hispanic black, and the use of public vaccination pro-
viders259. Reasons for vaccination delay in low and middle-income countries in-
clude poor immunization supply, access to health services, and family character-
istics260-262. Parents may also be hesitant to vaccinate or not view the costs in-
volved with vaccination worth the benefit. A longitudinal study in Ghana reported 
that while DPT3 coverage was 95% at 12 months, only 10% of infants were vac-
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cinated within 1 week of the scheduled time (14 weeks); median delay for DPT3 
was 4.0 weeks261. Infants who were poorer, had less educated mothers, and 
lived in rural versus urban areas were significantly more likely to be delayed in 
vaccination compare to urban infants whose mothers were educated and in a 
higher income grouping. A study of 31 low and middle income countries also 
found that children in poorer families and families with more than one child were 
at increased risk for vaccination delay260. 
8.2.6 Infant Immunization Strategies 
The majority of pertussis deaths occur prior to 3 months of age, before an 
infant is able to be fully vaccinated121. Multiple strategies are available to prevent 
pertussis infection in this youngest age group. 
8.2.6.1 Adolescent boosters 
While an analysis of the U.S. adolescent Tdap program found it was asso-
ciated with a decrease in adolescent pertussis, the authors found no indirect 
benefit to infants263. The cost-effectiveness of this strategy to prevent pertussis in 
infants is unclear264. 
8.2.6.2 Cocooning 
A potential strategy to protect infants is to vaccinate close-contacts, in-
cluding post-partum mothers in an effort to cocoon the infant from disease expo-
sure. A systematic review found, unsurprisingly, that mothers followed by fathers, 
are most likely to transfer disease to their infants and therefore should be priori-
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tized for the cocooning strategy148. Cocooning was recommend by the ACIP in 
2006, however uptake has been poor83. High vaccination costs, feasibility of vac-
cinating all contacts, and lack of demonstrated efficacy continue to hamper ef-
forts265. 
The cocooning strategy is highly resources intensive. A Canadian study 
found the number needed to vaccinate to prevent one infant death was 1 million 
parents and to prevent 1 ICU admission was 100,000 parents266, similar to find-
ings from other studies267. Cocooning has had most success when family mem-
bers are vaccinated during the hospital delivery stay rather than at a later time 
point in the community268,269. 
Cocooning is among the most expensive strategies to protect infants270. 
Cost-effectiveness studies show mixed results on the effectiveness of post-
partum vaccination264,271,272, although cost-effectiveness analysis is highly de-
pendent on the assumed disease incidence. Post-partum vaccination was less 
cost-effective and efficacious than vaccination during pregnancy273. 
While one modeling study found a modest effect of cocooning146, data 
from implementation studies have shown no effect of vaccinating mothers in the 
post-partum period in reducing pertussis illness in their infants265,274. If mothers 
are vaccinated in the immediate post-partum period there is also a lag period of 
approximately 2 weeks until they are immune when the infant is still at risk275.  
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8.2.6.3 Immunization at Birth 
Another strategy is immunization with pertussis vaccine at or near the time 
of birth. As the burden of disease is large in the youngest infants, initial studies of 
pertussis vaccine examined the earliest possible timing of immunization that 
would elicit an infant immune response276,277.  Researchers found that wP im-
munization in early infancy was not effective; between 2 and 7 months was found 
to be an ideal time for pertussis vaccination121,278. Recent studies with the aP 
vaccine have re-examined this concept with mixed results; some studies indicate 
it primes and stimulates the immune system for subsequent aP immunizations279-
281 while others demonstrate birth immunization inhibits future aP immuniza-
tion282. A modeling study showed moving the age of vaccination up 2 weeks in 
the U.S. would reduce infant pertussis hospitalizations by 9%122. More studies 
are needed to further elucidate the benefits/risks of this strategy. Even if this 
strategy is successful in boosting infants’ immune response, infants will still re-
main at risk in the window between birth and the stimulation of the immune sys-
tem against pertussis. 
Two reasons for poor immune response at birth are competing maternal 
antibodies and an immature infant immune system278,283. An explanation for ma-
ternal antibody inhibition is that the maternal antibodies mask pertussis vaccine 
epitopes, interfering with antigen binding by infant B cells284. One recent study 
comparing children born to HIV positive and negative mothers found that HIV-
exposed but uninfected children born to HIV positive mothers had lower levels of 
maternally-derived pertussis antibodies at birth, but a subsequently higher re-
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sponse to wP vaccine284. Maternal antibody vaccine interference appears to be 
dependent on vaccine type (aP versus wP).  Some studies have demonstrated 
that infants born with high cord blood pertussis antibody titers have reduced re-
sponse to wP vaccination; in contrast, circulating maternal antibodies provide lit-
tle to no interference with infant immune response to the standard aP vaccine 
schedule278,279,285-290. 
8.2.6.4 Maternal Immunization 
8.2.6.4.1 Recommendations 
The most favorable strategy to protect infants is to immunize women dur-
ing pregnancy with an aP vaccine to boost maternal pertussis antibody levels 
prior to birth; passive transfer of antibodies through the placenta will confer pro-
tection until the infant is able to be vaccinated himself291. Acceptance and rec-
ommendation of maternal immunization has rapidly evolved in recent years with 
increasing pertussis infant incidence. In 2005 the U.S. ACIP recommended the 
vaccine to post-partum mothers83. In June 2011 the ACIP recommended pertus-
sis vaccine during pregnancy for women who had not previously received Tdap 
due to the increasing number of infant deaths, especially in those less than two 
months292. Subsequently in October 2012 the ACIP revised its recommendation 
to support a Tdap vaccine in each pregnancy, regardless of prior immunization 
status. While the vaccine can be given at any time during pregnancy, optimal tim-
ing is between 27 to 36 weeks gestation251. The United Kingdom also imple-
mented a maternal vaccination program in response to infant pertussis resur-
gence293,294. 
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Maternal vaccination is a promising strategy today as there is a licensed 
aP vaccine recommended for adults and there is a licensed aP vaccine for chil-
dren, which is not inhibited by high levels of maternal antibodies291,295-297. While 
the safety of Tdap in pregnancy warrants further investigation, initial studies 
raised no safety concerns293,298. Pregnant women already interact frequently with 
health care workers for antenatal care visits. Acellular pertussis vaccines could 
be given in combination with other vaccines routinely given in pregnancy (U.S. – 
influenza, tetanus, and diphtheria; Nepal – tetanus). An advantage of maternal 
immunization compared to infant or postpartum immunization is that protection 
would be available at birth instead of a lag while the infant or mother develops 
her own immune response275. In addition, it would benefit both the mother and 
child. Providing Tdap in pregnancy versus in the post-partum period is also more 
cost effective with an estimated $414,523 versus $1,172,825 per quality-adjusted 
life year saved273. 
8.2.6.4.2 History 
Maternal immunization during pregnancy as a strategy to protect infants 
from pertussis was investigated as early as the 1930s276. In early studies, infant 
antibody titers were between 50-100% of their vaccinated mothers276,299-302. One 
randomized trial showed infants of pertussis immunized mothers had almost 
three times higher antibody levels than infants of mothers in the control arm (un-
vaccinated)300.  In another trial, serum from infants of immunized mothers was 
given to mice that were then challenged with virulent pertussis; the serum was 
found to be quite protective in the mouse model301. While no safety concerns 
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were raised, maternal vaccination was not pursued extensively due to concern 
that maternal antibodies would interfere with subsequent infant immune response 
to wP vaccine123. In addition, the previous research was conducted with wP vac-
cine, which is not currently recommended for adults in any setting due to in-
creased reactogenicity.  
8.2.6.4.3 Maternal Antibody 
Maternal antibodies may protect infants from morbidity or prevent severe 
morbidity although this depends on the level of maternal antibodies, the efficacy 
of transfer and the rate of antibody decay in the infant121.  While high levels of 
pertussis-associated antibodies are correlated with protection from disease, a 
specific cutoff has not been established74,76-79. Therefore the proportion of infants 
born with protective levels of antibodies is unknown.  Historical U.S. data (1938-
1940) indicate potential protection from maternal antibodies; infant pertussis 
deaths in the first month of life were one-third of that in the 2nd and 3rd months303.  
More recent data shows no difference in the rates of death between the first and 
3rd months of life24. One explanation for this is lower levels of endemic pertussis 
in the vaccine era led to lower pertussis exposure in pregnant women. Lower 
levels of pertussis exposure may lead to lower levels of maternal antibodies. 
Higher exposure due to circulating pertussis in previous eras may have boosted 
maternal antibody levels high enough to provide protection to their infants. Sup-
port for this hypothesis comes from pertussis serological data. While not directly 
comparable, pertussis antibodies were detected in 30-50% of women in the pre-
vaccine era304,305, while a lower percentage of contemporary women harbor high 
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levels of pertussis antibodies123,279,286,306. A recent study of mother-infant pairs 
found only 21% of mothers had PT antibody >5 EU307. 
Pertussis vaccinated women have a rapid response with IgG titers that 
peak at day 14 and IgA titers peaking at day 10275. This potentially indicates that 
maternal vaccination may protect transplacentally (IgG) and through breastmilk 
(primarily IgA). Mothers with a chronic disease(s) were found to have lower PT 
antibodies than mothers with no chronic health condition306. However, HIV infec-
tion was not shown to be associated with lower PT antibodies compared to those 
mothers who are HIV negative284. 
8.2.6.4.4 Infant Antibody 
Infants whose mothers have higher antibody levels due to recent infection 
or vaccination have higher antibody levels than infants of unexposed or unvac-
cinated mothers307-309. Pre-term infants have lower antibody concentrations com-
pared to term infants310-312. Uninfected infants born to HIV positive women have 
lower PT antibody compared to infants born to HIV negative women284.  
Pregnancy history, occupation, education, ethnicity, marital status and 
number of household members have previously been found to have no associa-
tion with infant PT antibody levels307. The effect of maternal age on infant anti-
body levels is mixed with some studies showing an association with increased 
maternal age and higher PT antibody284,307.  
8.2.6.4.5 Maternal to Infant Antibody Transfer 
Immunoglobulin G is transferred from mother to fetus through the placenta 
during pregnancy121,285.  The exact mechanism of transport is unknown. Briefly 
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placental Fc receptors bind maternal IgG resulting in active transport of antibod-
ies to the fetus313,314. The IgG1 subclass is transferred with greater efficiency 
than other subclasses or IgM, IgA, and IgE315. Maternal antibody transfer begins 
at approximately 16 weeks gestation and increases until time of delivery316. While 
this is an active process the transfer efficacy has been shown to range from 20% 
to 200% for various antibodies317.  Research from the 1940s measured low effi-
ciency of maternal to infant pertussis IgG transport with only 2-12% of infants 
having higher antibody levels than their mothers at birth121. However, a strong 
correlation between mother and infant pairs was found. Unsurprisingly, mothers 
who previously contracted pertussis or were immunized with wP vaccine during 
pregnancy gave birth to infants with the highest pertussis antibody titers.   
Multiple recent studies have examined the association of pertussis anti-
bodies between mother and infant pairs as a proxy for efficiency of antibody 
transfer and have found a strong association [Table 1.2]. Transfer is active from 
mother to child with the ratio of infant to maternal antibody concentration (term 
infants) at 107-169% for PT, 120-178% for FHA, 112-157% for FIM and 120-
131% for Prn123,284,307,309,311,312,316,318,319.  
Transplacental antibody transfer efficiency in general (non-pertussis-
specific) has not been found to be associated with parity, maternal age, height or 
weight310,318. Transport is associated with maternal ethnicity, vaccination and 
health status310. Pre-term infants have lower antibody concentrations compared 
to term infants310-312. Moreover, protective antibodies persist for shorter duration 
in pre-term infants. The lack of protective antibodies combined with an immature 
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immune system puts these pre-term infants at increased risk of contracting per-
tussis. 
For mothers who receive Tdap in pregnancy, antibodies between mothers 
and infants are highly correlated309. Newborns of vaccinated mothers had higher 
concentrations of pertussis antibodies and were more likely to have serological 
protection from pertussis compared to unvaccinated mothers309,320. The timing of 
maternal vaccination is important; immunization pre-partum and in early preg-
nancy provides less protection to infants than vaccination in the third trimester308. 
Maternal IgG antibodies to PT and FHA transferred to infants have an ap-
Mother Infant
196 196 1.64 0.8 (?) 9.9 8.6 - 11.3 (95% CI) 16.2 14.2 - 18.3 (95% CI) de Voer (2009)
101 103 0.98 (PC) 4.4 2.6 (SDE) 5.6 3.0 (SD) Gonik (2005)
64 61 1.69 2.4 1.9 - 3.1 (95% CI) 4.1 3 - 5.5 (95% CI) Healy (2004)
39A 42A 1.30 5.2 3.5 - 7.8 (95% CI) 6.2 4.1 - 9.4 (95% CI)
88B 96B 0.64 7.3 6.0 - 9.9 (95% CI) 5.4 4.2 - 6.9 (95% CI)
58 54 1.51 0.89 (SD) 23.6 12.9 - 54.7 (IQR
F) 36.1 20.4 - 76.3 (IQR) Jones (2011)
52 52 0.16 (P) 11.0 1.8 (SEMG) Gall (2011)
99 96 1.56 0.71 (S) 18.7 15.3 - 22.8 (95% CI) 29.1 23.4 - 36.3 (95% CI) Jones (2013)
100A 100A 1.07 0.95 (P) 18.2 15.0 - 22.0 (95% CI) 19.5 15.7 - 24.1 (95% CI)
100B 100B 0.68 0.80 (P) 19.4 15.5 - 24.3 (95% CI) 13.2 10.2 - 17 (95% CI)
195 192 1.62 0.87 (?) 21.5 18.6 - 24.8 (95% CI) 34.8 30.1 - 40.1 (95% CI) de Voer (2009)
101 103 0.90 (P) 26.6 3.1 (SD) 10.2 3.2 (SD) Gonik (2005)
64 61 1.78 6.9 5 - 9.5 (95% CI) 12.3 8.8 - 17.3 (95% CI) Healy (2004)
39A 42A 1.37 10.2 7.3 - 14.1 (95% CI) 14.1 10.3 - 19.4 (95% CI)
88B 96B 0.65 15.1 12.0 - 19.0 (95% CI) 9.8 7.9 - 12.2 (95% CI)
52 52 0.17 (P) 26.8 4.0 (SEM) Gall (2011)
100A 100A 1.20 0.95 (P) 16.0 13.1 - 19.5 (95% CI) 19.2 15.6 - 23.6 (95% CI)
100B 100B 0.72 0.86 (P) 20.3 16.6 - 24.8 (95% CI) 14.6 11.6 - 18.2 (95% CI)
196 195 1.31 0.84 (?) 13.5 11.7 - 15.6 (95% CI) 17.7 15.2 - 20.5 (95% CI) de Voer (2009)
101 103 0.96 (P) 12.3 2.9 (SD) 10.2 3.2 (SD) Gonik (2005)
39A 42A 1.20 4.1 2.8 - 6.1 (95% CI) 4.7 3.2 - 6.8 (95% CI)
88B 96B 0.66 4.9 3.7 - 6.6 (95% CI) 3.2 2.4 - 4.3 (95% CI)
52 52 0.97 (P) 26.8 4.0 (SEM) Gall (2011)
64 61 1.57 13 9. 2 - 18.5 (95% CI) 20.4 14.0 - 29.6 (95% CI) Healy (2004)
39A 42A 1.12 10.4 6.4 - 17.0 (95% CI) 10.1 6.8 - 14.8 (95% CI)
88B 96B 0.69 12.3 9.0 - 17.0 (95% CI) 8.7 6.5 - 11.7 (95% CI)
52 52 0.29 (P) 82.8 14.6 (SEM) Gall (2011)
Pertussis Antibody in Unimmunized Mothers and Infants 




van den Berg (2010)
Erener Ercan (2013)
Antigen





FIM van den Berg (2010)
A Term Infants; B Preterm Infantsl C  Pearsons correlation; D  Spearmans correlation;E standard deviation, F interquartile range; G standard error of the 
mean
FHA van den Berg (2010)
Erener Ercan (2013)
PRN
van den Berg (2010)
TABLE 1.2 
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proximately 5-week half-life in the infant. In unvaccinated mothers detectable per-
tussis antibodies persist for at most 2-4 months and in vaccinated mothers this 
extends to 6 months123,278,285,299. High maternal antibodies from Tdap in pregnan-
cy were associated with a lower infant response to the primary vaccination se-
ries; however, responses equalized after the booster dose320.  
8.2.6.4.6 Efficacy of maternal antibodies in protecting infants 
Animal models support the hypothesis that higher pertussis antibody titers 
confer protection against pertussis challenge321-323. A case control study compar-
ing infants <6 months who contracted pertussis to controls found lower pertussis 
antibody levels at birth in the case compared to control infants although the dif-
ferences did not reach statistical significance289. 
Until recently, no studies had measured the efficacy of maternal aP vac-
cination on protecting infants from pertussis121. Two randomized controlled trials 
of aP vaccine in pregnancy are ongoing in the U.S. and Canada to assess its 
safety, efficacy in protecting infants from pertussis, and its effect on infants’ sub-
sequent response to the primary pertussis immunization series324,325. Early re-
sults from the U.S. clinical trial found pertussis vaccination in pregnancy to be 
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Section 1 - Aims 
The objective was to prospectively characterize pertussis epidemiology in 
rural Nepal including pertussis vaccination coverage, infant pertussis incidence, 
and pertussis antibody transfer between mothers and their infants. The rationale 
for this study was that without a well-defined burden of pertussis disease it is dif-
ficult to demonstrate a need for public health interventions. Such knowledge is 
critical to justify further pertussis research and potential adoption of maternal im-
munization in developing countries to reduce disease in infants too young to be 
directly immunized.  
Subsection 1.1 – Primary Aims 
1. Estimate the timing of pertussis vaccination in infants 0 to 6 months in Ne-
pal. 
2. Estimate the incidence of B. pertussis infection in infants 0 to 6 months in 
Nepal. 
3. Estimate the ratio of infant to maternal pertussis toxin (PT) antibody at 
birth in Nepal. 
Subsection 1.2 – Secondary Aims 
1. Identify infant, maternal, and household characteristics associated with 
pertussis vaccination delay. 
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2. Estimate the incidence of B. parapertussis infection in infants 0 to 6 
months in Nepal.  
3. Describe the clinical, infant, maternal, and household characteristics as-
sociated with infant pertussis. 
4. Identify infant, maternal, and household characteristics associated with in-
fant PT antibody titers. 
5. Identify maternal and household characteristics associated with maternal 
PT antibody titers. 
6. Identify infant, maternal, and household characteristics associated with PT 
antibody transfer ratio. 
Section 2 – Study Design 
This prospective cohort study was based in Sarlahi District, Nepal, a 
densely populated, low-lying area near the Indian border. The study population 
included 3,690 pregnant women and their live born infants followed from delivery 
through 6 months post-partum. The study was nested within a community-based 
randomized controlled trial to test the efficacy of influenza vaccine in pregnancy 
for protecting mothers and infants from influenza1. 
Subsection 2.1 – Setting  
2.1.1 Nepal 
The study was conducted in Sarlahi District located in the central terai (low 
lying plains) region of the Federal Democratic Republic of Nepal2. As a recently 
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democratic multiparty republic, its first president was elected in 2008. Topograph-
ically Nepal is portioned into three unique ecological zones: mountain, hill, and 
terai [Figure 2.1]2.  The terai region is home to half of Nepal’s population and is 
relatively fertile and flat compared to the hill and mountain regions.  The hill re-
gion, which includes Kathmandu, the capital, holds 43% of the population. Only a 
small fraction of Nepalese live in the mountain region due to its harsh environ-
ment and inaccessibility; the elevation in the mountain region ranges from 4,877 
to over 8,000 meters.  In addition to the geographic divisions there are adminis-
trative divisions with 5 development regions (Eastern, Central, Western, Mid-
Western, and Far-Western Nepal is further subdivided into 75 administrative dis-
tricts within which are village development committees (VDCs), each of which 
contains 9 wards.  
FIGURE 2.1 – NEPAL COUNTRY MAP 
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The majority (83%) of the estimated 26.6 million Nepalese live in rural ar-
eas2.  One hundred three ethnic/caste groups exist in Nepal including Chhetri, 
Brahmins, Magar, Tharu, Tamang, and Newar.  Over 92 languages are spoken, 
however Nepali is the official language.  The majority of Nepalese practice Hin-
duism and a smaller fraction practice Buddhism, Islam, and Kirat.  Life expectan-
cy is approximately 69 and 67 for females and males, respectively3.  The total 
fertility rate in 2012 was 2.4. 
Nepal is one of the poorest countries in the world with approximately one-
fourth of the population living below the poverty line2.  Political instability, internal 
conflict and poor policy and planning have contributed to lack of development.  
The majority of the population’s occupation involves agriculture. Remittances are 
a source of income for over half the population.  
2.1.2 Sarlahi District 
 Approximately 636,000 people live in Sarlahi in predominately rural, farm-
ing communities4,5.  Two major ethnic groups comprise the majority of the popu-
lation5. The Madeshis, whose language is Maithili are mostly lower castes and 
the Pahadis are mostly higher castes and speak Nepali.  Pahadis currently resid-
ing in Sarlahi migrated down from the hill region 30-40 years ago when malaria 
was first eradicated from the area; they are of Tibeto-Burmese origin. The Ma-
deshi population is of north Indian ethnicity. The total fertility rate in the terai re-
gion in 2011 was 2.5 and the median age of first birth was 19.5 years2. In the 
central terai the proportion of women delivering has increased in recent years 
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with an estimated 32% of women giving birth in a health facility. In the terai re-
gion under-five mortality was 62 deaths per 1,000 live births and infant mortality 
was 53 deaths per 1,000 live births2. Child nutrition is an important problem in 
central terai with 41% of children stunted, 10% wasted, and 32% underweight. 
The location of the study was the field site of the Nepal Nutrition Interven-
tion Project (NNIPS). The site was established in 1989 for a large, community-
based Vitamin A supplementation intervention trial6. Since then, Johns Hopkins 
Bloomberg School of Public Health re-
searchers have worked continuously in 
the district performing other communi-
ty-based randomized control trials and 
follow-up studies. Sarlahi contains 99 
VDCs and the maternal influenza vac-
cination study site included VDCs in 
northern Sarlahi (orange) [Figure 2.2].  
The VDCs include Raniganj, Jabdi, 
Lalbandi, Netraganj, Sasapur, Hariaun, 
Dhungrekhola, Karmaiya, and 
Ghurkauli1. Two other community trials were concurrently conducted in neighbor-
ing VDCs, however there was no overlap in study areas.  
	
FIGURE 2.2 - NNIPS STUDY AREAS 
IN SARLAHI DISTRICT 
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Subsection 2.2 – Parent Maternal Immunization Trial  
2.2.1 Aims 
The parent study was a community-based randomized trial to test the efficacy 
of maternal administration of influenza vaccine for mothers and their children.  
Individual mothers were randomized to receive either an influenza vaccine or a 
placebo.  The three co-primary aims were: 
1. To compare the incidence of laboratory confirmed influenza illness epi-
sodes among newborn infants (through 6 months of age) born to women 
randomized to receive either influenza vaccine or control during pregnan-
cy. 
2. To compare the incidence of low birthweight (<2500 grams) of newborn in-
fants born to women randomized to receive either influenza vaccine or 
control during pregnancy. 
3. To compare the incidence of influenza-like illness (ILI) episodes among 
pregnant women (through 6 months postpartum) in women randomized to 
receive either influenza vaccine or control during pregnancy. 
2.2.2 Study Population 
The study population included all pregnant women identified with gestational 
age between 17 and 34 weeks during a 24-month period  (2 12-month cohorts) in 
9 VDCs of Sarlahi District, Nepal1.  At the start of the trial, prevalent pregnancies 
were identified through a survey census of all households in the catchment area 
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and women between 17 and 34 weeks gestation were randomized to receive in-
fluenza vaccine or a saline placebo. Thereafter, field workers visited homes of 
married women of reproductive age every 5 weeks to monitor for incident preg-
nancies. All pregnant women meeting the eligibility requirements and providing 
informed consent were enrolled. Women were excluded from the study for the 
following reasons:  
 Planned to give birth outside of the study area 
 Already vaccinated with current influenza vaccine 
 Already enrolled in the same trial during previous pregnancy 
 Known allergies to any component of the vaccine (e.g. eggs) 
 Infant delivery occurred <2 weeks after receipt of immunization (influenza 
or placebo) 
 Did not provide consent to participate in the trial 
All women meeting the eligibility requirements were recruited to enroll in the 
trial.  The study was described to prospective participants.  If a woman agreed to 
enroll her consent to participate in the trial was obtained.  Following consent, her 
information was recorded in a pregnancy tracking roster.  All participants re-
ceived ancillary benefits, which included a 90-day supply of iron-folic acid tablets, 
deworming medicine (single dose of albendazole), clean birthing kit, chlorhexi-
dine ointment for umbilical cord care, a tetanus toxoid (TT) vaccine, if indicated, 
and health education messages, in addition to antenatal services according to 
the local standard of care.  
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2.2.3 Intervention 
The trial intervention was a trivalent inactivated influenza vaccine, licensed 
for use in North America, Europe, or Australia. The vaccine was updated 
throughout the trial as new formulations with the current season’s strains became 
available.  
The women assigned to the control group were given a placebo (saline in-
jection).  The justification for a placebo arm was twofold. First, the influenza vac-
cine is not currently recommended in Nepal and the Ministry of Health is highly 
interested in the results of the study to help inform future immunization policy. 
Second, no placebo-controlled studies have been conducted to examine the ef-
fect of maternal influenza vaccination on respiratory morbidity in early infancy.  
By including a placebo arm, this study will be able to answer important questions 
regarding the efficacy of maternal vaccination on protecting mothers and their 
infants. 
2.2.4 Randomization 
Pregnant women were individually randomized at enrollment to receive ei-
ther a placebo or influenza vaccine.  Randomization of women, in block size 8, 
was stratified by VDC and gestational age at time of vaccination (17-25 and 26-
34 weeks) to ensure balanced distribution of immunization assignment in each 
geographic area and by gestational age. In the first cohort (April 25, 2011 – April 
24, 2012) women were vaccinated as soon as possible after 17 weeks gestation.  
In the second cohort, in addition to randomization stratified by VDC and the two 
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previously noted gestational age periods, women were randomized to the timing 
of immunization between 17 and 34 weeks gestation to ensure an equal propor-
tion of women vaccinated at different times during pregnancy rather than at 17 
weeks as in cohort 1. At study headquarters a random number generator created 
individual randomization assignments to which investigators and study workers 
were blinded to treatment group. However, since the influenza vaccine and pla-
cebo syringes looked different, the vaccinators were not blinded to treatment 
group. Vaccinations were conducted with individual women alone in a closed 
room with the vaccinator to avoid unblinding of other study staff. Study outcomes 
were assessed by study staff who were not vaccinators. Four treatment codes 
were created (A, B, C, and D); two of these corresponded to placebo doses and 
two of these corresponded to influenza doses. Vaccinations for cohort 1 com-
menced April 25, 2011 and ended April 24, 2012. For cohort 2, vaccinations 
commenced April 25 2012, enrollment of pregnancies ended April 24, 2013 and 
the last vaccination was administered September 9, 2013. This lengthened vac-
cination period was due to the randomized timing of vaccinations in cohort 2. 
2.2.5 Sample Size 
The sample size for the larger trial was based on the necessary power for 
each of the three primary outcomes and was adjusted for multiple outcomes (to 
produce an overall type I error across the 3 aims of 5%).  The calculated neces-
sary sample size was 1,850 mothers and their live born infants for each annual 
cohort. 
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2.2.6 Data collection 
2.2.6.1 Interview and measurement data 
Data were collected at several periods during the study: 
 A house-to-house census was conducted at baseline to identify all married 
women of reproductive age (15-40 years). Informed consent was obtained 
from eligible households and individual consent from women of reproduc-
tive age. Following consent, information was collected on household struc-
ture, socioeconomic status, and demographic information.  
 Women of reproductive age who identified themselves as being pregnant 
during the baseline were enrolled and vaccinated if they were between 17 
and 34 weeks gestation. Those who were less than 17 weeks were 
scheduled for vaccination once they reached 17 weeks. Following the 
baseline survey, a female health worker visited each household every 5 
weeks to test for incident pregnancies. If a woman has not had a menstru-
al period within the preceding 5 weeks, a urine-based pregnancy test and 
date of last menstruation was obtained.  If a woman had a positive preg-
nancy test, she was invited to participate in the study and individually con-
sented and enrolled. 
 Once enrolled, the following information was collected: mother’s age, 
pregnancy history, medical history, date of last menstrual period, anthro-
pometric measurements (weight and height), and expected delivery loca-
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tion.  The date of last menstrual period was used to estimate gestational 
age. 
 As soon as possible after delivery the mother and child were visited at the 
household to collect information on the birth. This information included the 
delivery process, newborn care practices, delivery complications, infant’s 
weight, length, head circumference and temperature. 
 From enrollment in early pregnancy through six months post-partum a Flu 
Data Collector (FDC) visited enrolled households weekly.  During the visit 
field staff asked the mothers about their and their infant’s current health 
and health during the previous week. If a respiratory illness was identified 
(separate definitions for mothers and infants) then a mid-nasal swab was 
collected from one nare. In addition, other morbidities and whether care 
was sought (type of provider and treatment received) were assessed.  
Further, information was obtained on breastfeeding status and whether 
specific immunizations were received. Women were followed through 6 
months post-partum regardless of the pregnancy outcome (miscarriage, 
stillbirth). 
 A field supervisor visited households to conduct a verbal autopsy if a 
mother or infant died during the study.  The supervisor used a revised 
WHO instrument to obtain information on illness and care-seeking behav-
ior history. Two local physicians reviewed the report and independently 
assigned a cause of death. If there were discrepancies a consensus was 
formed, with the aid of a third physician if necessary. 
  99 
2.2.6.2 Biological specimen collection 
Nasal Swabs 
Nasal swabs were collected during the weekly visit for mothers if on at 
least one day in the prior week a woman reported a fever plus at least one addi-
tional symptom: cough, sore throat, nasal congestion/runny nose or myalgia. Na-
sal swabs were collected for infants if the mothers reported any one of the follow-
ing symptoms on at least one day in the prior week: fever, cough, wheeze, diffi-
culty breathing, nasal congestion/runny nose or ear infection.  On August 17, 
2012 additional respiratory symptoms were added to infant weekly morbidity as-
sessment to increase the sensitivity in detecting pertussis. The additional symp-
toms that would trigger an infant nasal swab were the following: apnea, cyanosis, 
whoop, and cough with vomiting.  
To collect the nasal swab a sterile nasopharyngeal swab with a nylon-
flocked tip was inserted into one nare approximately one-half the distance be-
tween the external nostril and the nasal bridge. Once inside, the swab was rotat-
ed 360° to obtain a mid-nasal specimen. The procedure lasts approximately 10-
15 seconds, is not painful and does not cause side effects, although the process 
may be irritating.  The swab was then removed and placed directly into 2.0 mL of 
Primestore (Longhorn Diagnostics, San Antonio, TX) buffer and swirled briefly 
before breaking the handle so that only the swab remained in the tube. Prime-
store is a transport and storage medium that lyses the cells, stabilizes the nucleic 
acid, and preserves the sample.  
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After transport to field headquarters 3 aliquots were made into 0.5mL cryo-
tubes.  Primestore aliquots were kept at room temperature or refrigerated until 
processing by the U.S. testing laboratory. 
Blood Specimens 
Maternal blood specimens were collected pre-vaccination (enrollment), 
one-week post-partum, and three months post-partum. Study nurses collected 
5cc of blood by venipuncture in the woman’s arm using standard sterile tech-
nique. The vials were placed on ice and transported to the field headquarters.  
Approximately one month prior to delivery a sterile plastic cup was left with 
the women to collect umbilical cord blood after birth. The women or their birth at-
tendant were requested to collect umbilical cord blood that drips from the cut end 
of the cord into the cup until at least 3-5cc of blood were collected. The women 
then covered the cup and called the study nurse to notify her of the birth. For 
mothers who delivered in health facilities in the area, facility staff obtained cord 
blood, which was then collected by study staff for normal processing. The blood 
was transported on ice to the central field-processing laboratory. 
Once maternal and infant blood was sufficiently clotted it was centrifuged 
and the sera aliquoted into several vials. Serum samples were stored and 
shipped to the United States at -80° Celsius. 
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Subsection 2.3 – Pertussis Study  
The pertussis prospective observational study was nested within the par-
ent community immunization trial harnessing the extensive trial infrastructure to 
answer important questions regarding pertussis epidemiology in Nepal. The per-
tussis study added additional testing for specimens (nasal swabs and blood) al-
ready collected for the main study [Figure 2.3]. 
 
FIGURE 2.3 - PERTUSSIS KEY OUTCOMES DATA COLLECTION 
2.3.1 Aim 1 – Estimate the timing of pertussis vaccination in infants 0 to 6 
months in Nepal. 
This aim characterized the timing of the primary DPT vaccination series (3 
doses) in Nepal. DPT1, DPT2, and DPT3 coverage was estimated at 14 weeks 
(recommended age for completion of series) and 6 months (end of follow-up) 
delivery 6 months 
infant cord blood 
mom venous blood 
infant nasal swab 
Paired blood 
tested by ELISA 
for pertussis 
toxin (PT) 
Nasal swabs  
tested by multi-target PCR 
for Bordetella pertussis & 




One or more symptoms trigger nasal swab:  
cough, wheeze, difficulty breathing, fever, ear infection, 
cyanosis, apnea, cough with vomit, whoop 
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based on the weekly recall interviews with parents. Infants were included in this 
analysis if they were followed for a minimum of 14 weeks.  
Pertussis vaccination in infancy is the primary pertussis prevention strate-
gy globally. In low and middle-income countries the primary vaccination series is 
the only pertussis prevention method. Infants who are delayed in receiving their 
pertussis vaccine or who do not complete the entire series are at increased risk 
for pertussis compared to their more fully vaccinated peers7-11. Nepal immuniza-
tion coverage estimates reported to the WHO do not capture vaccination delay in 
infancy when pertussis risk is greatest11-14. This aim was to improve the under-
standing of pertussis vaccination timing in the first 6 months in Nepal. Under-
standing what delays exist is important to better characterize how well the prima-
ry pertussis prevention strategy is implemented. 
Secondary Aims 
1.1 Identify infant, maternal, and household characteristics associated 
with pertussis vaccination delay. 
The purpose of this secondary aim was to identify infant, maternal, and 
household factors associated with under immunization at 14 weeks and 6 
months. Previous research in low and middle-income has shown risk factors for 
vaccination delay include poor immunization supply and access to health ser-
vices, having mothers who were poorer, less educated, living in rural areas, and 
with more than one child14-16. A better understanding of Nepal-specific factors 
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contributing to vaccination delay can help programs focus on at-risk populations 
to increase on-time vaccination. 
2.3.2 Aim 2 – Estimate the incidence of B. pertussis infection in infants 0 to 
6 months in Nepal. 
 The incidence study was a prospective cohort study nested within the par-
ent maternal influenza trial. Infants were included if they were followed for any 
length (0 to 180 days) during a 2 year-period from August 17, 2011 to August 16, 
2013. The outcome of interest was symptomatic laboratory confirmed pertussis 
infection in infants.  An infant was considered an incident pertussis case if he/she 
had a positive B. pertussis PCR test and met the following clinical criteria based 
on a weekly parental recall of symptoms: 
 
New symptoms were added in year 2 to increase the sensitivity for detect-
ing pertussis cases that might have been missed with the year 1 criteria. Addi-
tional positive tests were considered related to the primary positive finding and 
were not considered a re-infection.  Therefore, once an infant tested positive for 
pertussis they were not considered at risk for a subsequent pertussis infection (6 
months maximum). The primary purpose of the nasal swab collection was to test 
Respiratory Illness Definitions 
Year 1 - Experienced at least one of the following symptoms: cough, wheeze, difficulty breath-
ing, fever or ear infection. 
Year 2 – Any of the symptoms from year 1 or any of the following: cyanosis, apnea, cough 
with vomit, whooping cough/whoop. 
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for influenza and other viral infections. Pertussis-specific PCR testing was con-
ducted on these same nasal swab specimens.  
Only one population-based study on pertussis including infants from birth 
has been published to-date17. However, infants are known to have the highest 
risk of pertussis and to suffer the greatest pertussis morbidity and mortality from 
passive reporting and hospital-based studies18.  Data from aP vaccine efficacy 
trials has provided some insight into the burden of pertussis in older infants. 
However, these studies had more stringent criteria for testing and less robust 
surveillance than our pertussis study19. Combined, these factors likely led to an 
underestimation of pertussis disease, especially atypical or mild pertussis that did 
not trigger testing or reporting.  Further these studies monitored infants at a min-
imum > 3 months of age after at least 1 vaccination. Therefore the data did not 
capture the unvaccinated infant population <3 months for whom the disease bur-
den is most severe. Moreover, only one aP vaccine trial was conducted in a low-
income setting (Senegal) and there are no active surveillance data from Asia17.  
This study provides the first population-based active pertussis surveillance in in-
fants in Asia. 
Secondary Aims 
2.1       Estimate the incidence of B. parapertussis infection in infants 0 to 6 
months in Nepal 
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The same methodology used to ascertain B. pertussis incidence in Aim 2 
was also used to estimate the incidence of the less common and serious B. par-
apertussis20.  
 
2.2         Describe the clinical, infant, maternal, and household characteris-
tics associated with infant pertussis. 
In additional to respiratory symptoms, infant, maternal and household 
characteristics, assessed through questionnaires conducted at baseline and fol-
low-up points, were used to describe pertussis infants and non-pertussis infants 
[Table 2.1]. 
TABLE 2.1 - INFANT, MATERNAL, AND HOUSEHOLD CHARACTERISTICS 
 
Classical pertussis disease is most likely to occur in children.  Pertussis is 
recognized as a severely under-diagnosed disease and therefore the true global 
burden is unknown21.  Pertussis in young infants is often “atypical” and therefore 
may go unrecognized22.  This study aimed to elucidate symptoms associated 
with pertussis illness in infants to help clinicians better recognize the disease, 
which may have a mild or non-traditional presentation, especially in young in-
fants.  
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Previous literature has documented risk factors for reported pertussis in 
infants such as being female, younger, under-immunized, preterm, born to a 
younger mother and a member of an ethnic or racial minority group23-25.  Our 
study aimed to add to knowledge of pertussis risk factors. First, the multitude of 
data collected on potential risk factors is highly comprehensive compared to the 
majority of studies with less comprehensive tracking of participants. Second, the 
study was community-based with less potential for bias in assessing risk factors 
compared to hospital-based or outbreak-based studies. Further, the majority of 
studies on pertussis risk factors have been conducted in high-income countries. 
This study adds to literature on the burden of disease in a typical rural Asian 
population for which we expect the disease burden to be highest.  
2.3.3 Aim 3 – Estimate the ratio of infant to maternal pertussis toxin (PT) 
antibody at birth in Nepal.  
The third aim was to estimate the ratio of infant to maternal pertussis anti-
bodies for PT. The ratio is an approximation of the efficacy of maternal to infant 
antibody transfer. A convenience sample of mothers and infants, for whom blood 
samples for both could be obtained, were included. ELISA testing for PT antibod-
ies was added to maternal and cord blood samples originally collected for influ-
enza antibody testing. The study was a prospective cohort of mother-infants 
pairs. 
Previous literature has documented that there is active transfer of pertus-
sis-related antibodies from mother to infant26-34. However, none of these studies 
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was conducted in a low-income country setting with high prevalence of malnutri-
tion and prematurity.  
Secondary Aims 
3.1 Identify infant, maternal, and household characteristics associated 
with infant PT antibody titers. 
The purpose of this secondary aim was to identify factors associated with 
the presence and level of infant PT antibodies at birth. Infant PT antibody at birth 
is the result of maternal placental transfer during gestation. An infant’s level of PT 
antibody at birth is dependent on the maternal level. A recent study found only a 
quarter of infants at birth had PT antibody >5 EU34. Passively derived PT anti-
bodies in infants can protect them from pertussis until they are able to be vac-
cinated themselves35. Factors previously shown to decrease infant PT antibody 
titers are lower maternal age, maternal HIV infection, and being born pre-
term28,30,32,34,36. However, few studies have been conducted in Asia and include 
multiple potential factors associated with infant PT antibody levels.  
3.2 Identify maternal and household characteristics associated with 
maternal PT antibody titers. 
This secondary aim was to estimate the association of maternal and 
household characteristics with maternal PT antibody titers at delivery. Maternal 
antibodies to PT in Nepal are either due to lingering antibodies from the child-
hood vaccination series or a pertussis infection. As there are no adolescent or 
adult boosters in Nepal high PT antibodies in mothers are likely due to recent in-
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fection. High maternal antibodies can lead to protection from pertussis for both 
mother and infant35. However, many women do not have detectable PT antibody 
and the proportion with detectable antibody is thought to have decreased in re-
cent decades26. A recent study found only a fifth of women at delivery with PT 
antibody levels > 5 EU/mL34. There are few data on the factors association with 
the presence or high levels of PT antibodies in pregnant and post-partum wom-
en. One study found no difference in PT antibody levels between HIV positive 
and HIV negative pregnant women. More data are needed in Asia on the preva-
lence of pertussis and factors that are associated with higher levels of PT anti-
body. 
3.3 Identify infant, maternal, and household characteristics associated 
with PT antibody transfer ratio. 
An additional secondary aim was to estimate the association of infant, ma-
ternal, and household factors on maternal to infant antibody transfer. Reduced 
PT antibody transport has most commonly been associated with lower gestation-
al age28,32,36. While other factors such as maternal ethnicity have been found to 
affect maternal to infant IgG transport in general there are few data on specific 
factors associated with PT IgG transport efficiency, especially in Asia36.  
  109 
Section 3 – Laboratory Assays 
Subsection 3.1 PCR 
Real-time PCR testing was conducted at the University of Washington’s 
Molecular Virology Laboratory according to previously published methods37.  
Two-target PCR was used to assess the presence of three Bordetella species: B. 
pertussis, B. parapertussis, and B. brochispetica. Multi-target PCR is more sensi-
tive than single target and this particular assay may distinguish between B. per-
tussis and B. parapertussis.  Positive controls were obtained using freeze-dried 
cultures from ATCC diluted 1:100 using Life Technologies’ Hank’s Balanced Salt 
Solution, extracted, and further diluted 1:1000 in TE pH7. Specimen and control 
DNA were extracted using MagNa Pure LC nucleic acid extraction method and 
stored at minus 80°C until testing. 
The two independent pertussis sequence targets amplified were chromo-
somal repeated insertion sequence IS481 (IS) and the polymorphic pertussis tox-
in ptxA promoter region (PT) [Table 2.2]. There were 2 sets of primers for PT to 
accommodate small differences (2 bases) between pertussis strains (used in 
combination for one PCR reaction).  
The pertussis PCR assay uses fluorescence resonance energy transfer 
SYBR green chemistry. SYBR green, a free-floating, DNA-binding dye, binds to 
double stranded DNA as it is replicated in the PCR reaction, the amount of fluo-
rescence increases proportionally and can then be used to monitor the amplifica-
tion of the target sequence. A commercial master mix, iQ SYBR green Supermix 
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(Bio-Rad, Hercules, CA), was used.  The master mix (30 μl) was pipetted into 
each well of a 96-well plate. Each sample required 2 wells testing IS and PT pri-
mers with 10 μl of specimen added per well.  The PCR cycle for PT amplification 
was as follows: 95°C for 3 minutes, followed by 45 cycles of 95°C for 10 seconds 
and 71°C for 45 seconds. The PCR cycle for IS amplification was as follows: 
95°C for 2 minutes, followed by 45 cycles of 94°C for 30 seconds, 68°C for 30 
seconds, and 72°C for 30 seconds and then 72°C for 5 minutes for extension.  
TABLE 2.2 – PCR PRIMER TARGETS AND MELTING TEMPERATURES 
 
After completion of the 45th replication cycle, the melting points of the am-
plicons were measured in an iCycler (Bio-Rad) using a melt curve step that in-
creases the temperature in small increments from approximately 60°C to 95°C, 
from which the melting temperatures of each of the Bordetella species can be 
measured. Each control should fall within the range of their individual expected 
temperatures to indicate a positive result. 
A sample is interpreted as positive when the targets described in Table 
2.2 have a melting temperature within the acceptable range and a Ct ≤42. A 
Primer Type and Name Sequence
Amplicon 
Length (bp) B. pertussis B. parapertussis B. bronchiseptica
IS481  (IS) 182 85-86°C - -
IS-F GATTCAATAGGTTGTATGCATGGTTC
IS-R TTCAGGCACACAAACTTGATGGGCG






 PCR primer targets and Melting Temperatures
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sample is negative if none of the targets test positive or a single positive target is 
not reproducible.    
Subsection 3.2 ELISA 
An immunoglobulin G (IgG) anti-PT enzyme-linked immunosorbent assay 
(ELISA) was performed at Vanderbilt University School of Medicine according to 
previously described methods.38. The reference standard was in house pooled 
sera calibrated to pertussis antiserum (human), lot 3 (CBER3 [US Food and Drug 
Administration]).  
First, PT antigen was coated on a Immulon 2HB microtiter plate. Following 
this was a 0.05 M carbonate-bicarbonate coating butter, which was incubated for 
16-24 hours at 28°C38. Between each step the plate was washed 5 times in 
phosphate-buffered saline (PBS)-0.05% Tween 20. Next, eight 2-fold serial dilu-
tions of serum were added to the plate and allowed to incubate for 2 hours at 
28°C. Then an enzyme-conjugated goat anti-human IgG was added to the plate 
to detect PT-specific IgG antibodies; incubation occurred at 28°C for 16-24 
hours. Para-nitrophenylphosphate (pNPP) substrate was added for a one hour 
incubation at 28°C. Lastly antibody concentrations were measured using a 
standard curve in SoftMax Pro/Molecular Devices software. The lower level of 
quantification (LOQ) was 1EU)/mL.  The lower level of detection (LOD) was 2 
EU/mL. However, titers below 10 EU/mL are non-reproducible and therefore not 
reported due to poor reliability. 
  112 
Section 4 – Precision and Power Calculations 
As the pertussis study was nested within the parent maternal influenza 
vaccination trial, sample size constraints are determined by the size of the larger 
trial. The sample size for the larger trial was based on the necessary power for 
each of the three primary outcomes and adjusting for multiple comparisons.  The 
calculated necessary sample size was 1,850 mothers and their live born infants 
for an annual cohort.  
Further, funding levels for the pertussis study limited the number of both 
nasal swab and blood specimens that could be funded. Lastly, due to delays in 
specimen shipping, not all results are available at present but will be available for 
final publication. 
Subsection 4.1 – Aim 1 calculation 
No sample size calculation was conducted a priori as this vaccine timing 
aim was not included in the original pertussis study. Given the coverage for at 
least 1 pertussis vaccine dose observed were able to calculate the percent vac-
cinated within +/- 2 percent, which is a precise estimate. 
Subsection 4.2  - Aim 2 precision calculation 
The sample size was fixed based on the aim of the parent trial to enroll 
approximately 1850 women and their infants in each cohort.  
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Limited population-based data on the incidence of pertussis in infants <6 
months of age was available, especially in resource-poor settings. The best pop-
ulation-based estimates of disease came from the aP vaccine trials [Table 1.1]. 
The range of infant pertussis incidence estimates was 0.1 – 11.09 cases per 100 
PY. Using these incidence estimates, our fixed sample size, and Equation 1, with 
type I error,    set at 0.05, we calculated the range of relative precision available 
[Figure 2.4]39,40. 
EQUATION 1 
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Two adjustments were made to the incidence estimates. First, as infants 
were only followed for 6 months we adjusted for infants contributing only half a 
year. Second, we expected 10% loss to follow-up and adjusted the sample size 
FIGURE 2.1 – PRECISION ESTIMATES FOR AIM 2 
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needs accordingly.  This loss to follow-up includes infant losses due to death and 
the time period following pertussis infection where the infant is no longer at risk. 
Figure 2.4 shows the relative precision estimates for various incidence scenarios.  
For example if the incidence was 0.04 cases per PY the relative precision of our 
incidence estimate would be 33.3%.  
Subsection 4.3  - Aim 3 precision calculation 
Aim 3 required a sample of mother infant pairs for whom sera were avail-
able near delivery. We expected to collect sera from 200 mother infant pairs. Us-
ing this sample size we calculated with what precision we would measure the ra-
tio of paired infant-mother antibody titers. If we have an unknown variance of this 
ratio, we can calculate the precision, d, relative to the standard deviation using 
Equation 2.   Given a sample size of 200 mother-infant pairs we would be able to 
estimate the ratio of infant to maternal antibody titers with a precision of 0.14 











                   [d = precision, σ = standard deviation] 
 
 







Section 5 – Statistical analyses 
Statistical analyses were conducted in both Stata/SE 13.1 and R version 
3.0.2 (2013-09-25). 
Subsection 5.1 Aim 1 
Vaccine coverage was calculated at 14 weeks (the recommended age for 
completion of the pertussis series) and 6 months (end of follow-up). For this 
analysis, infants were excluded if they were observed with weekly visits ending 
prior to 98 days (14 weeks) after birth to ensure all infants included had an op-
portunity to have recorded vaccinations at the recommended ages (6, 10, and 14 
weeks). The primary outcomes were the proportion in each vaccination category 
(0, 1, 2, or 3 doses) at 14 weeks and 6 months. Equation 3 gives an example 
calculation for the number of infants fully vaccinated (3 DPT doses) at age 6 
months. 
FIGURE 2.5 - PRECISION ESTIMATES FOR AIM 3 
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EQUATION 3 
            
                                   
                                    
    
Survival analysis was used to measure the time to pertussis vaccination, 
separately for each of the 3 doses. Kaplan-Meier curves were constructed with a 
vaccination considered the event of interest. Infants were right-censored once 
they had the event of interest (specific vaccine dose) or had no further follow-up 
recorded (which included deaths as well as migrations). 
Risk factors for time to 1st, 2nd, and 3rd pertussis vaccination were ana-
lyzed using a Cox-proportional hazards model. The recommended age of first 
pertussis vaccination dose, 42 days, was designated as time 0. Infants who were 
vaccinated prior to 42 days were assigned a date of vaccination immediately af-
ter time 0 (1x10-6). The same adjustment made for lost-to follow-up was made for 
those infants with no follow-up after 42 days. Infants who had at least one follow-
up visit but died before 42 days were excluded from the analysis. For the unad-
justed model, hazard ratios, 95% confidence intervals (CI), and p-values from the 
Wald test of the maximum likelihood estimate were reported. Risk factors meas-
uring similar characteristics were excluded to avoid any collinearity in the multi-
variate model. The multivariable model included adjusted hazard ratios, 95% 
confidence intervals (CI) and p-values from the Wald test of the maximum likeli-
hood estimate. The proportionality assumption was tested through graphical di-
agnostics and testing based on scaled Schoenfeld residuals. 
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Risk factors for being vaccinated at 6 months for the 1st, 2nd, and 3rd per-
tussis doses were analyzed using a logistic regression model. Statistical signifi-
cance was set at p<0.05 for all testing. All statistical analyses were conducted in 
R version 3.0.2 (2013-09-25). 
Subsection 5.2 Aim 2 
The primary outcome of Aim 2 was to estimate annual infant pertussis in-
cidence in Nepal. An infant was considered at risk from birth until end of follow-
up or until he contracted pertussis. Once an infant tested positive for pertussis he 
was not considered at risk for the remaining duration of follow-up. This analysis 
assumed that only 1 incident pertussis illness is possible in a 6-month period for 
infants. However, this assumption is consistent with current knowledge of no 
demonstrated pertussis re-infection within 6 months of natural infection. There-
fore, while a participant may test positive over the course of several weeks, each 
subsequent positive pertussis test will be assumed related to the primary positive 
pertussis test. 
The incidence was calculated as the number of B. pertussis cases per 
1000 PY at risk [Equation 4]. 95% confidence intervals were constructed using 
Poisson exact confidence intervals. The same calculation was conducted to 
measure the incidence of B. parapertussis. 
EQUATION 4 
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Characteristics of all non-pertussis respiratory episodes were examined in 
comparison to pertussis episodes. T-tests were used to compare associations 
with continuous predictors and Fisher’s exact test was used to compare categori-
cal associations since the number of pertussis cases was small. Characteristics 
of pertussis cases were compared to non-pertussis cases. Continuous predictors 
were transformed to dichotomous factors to calculate incidence rate ratios for 
pertussis risk. The cutoff for statistical significance in all testing was p<0.05. All 
statistical analyses were conducted in Stata/SE 13.1.  
Subsection 5.3 Aim 3 
To quantify the level of maternal and infant PT antibody levels, geometric 
mean concentrations and bootstrapped-derived 95% confidence intervals were 
constructed separately for mothers and infants [Equation 5]. PT Antibody levels 
below the LOQ were assigned one-half of the assay LOQ (5 EU/mL).  
EQUATION 5 
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Reverse cumulative distribution curves were created to visualize and 
compare the distribution of log transformed antibody titers for mothers and in-
fants.41 To examine differences in PT levels by infant, maternal, and household 
characteristics, non-parametric testing was performed for binary (Wilcoxon rank 
sum test with continuity correction) and nominal (Kruskal-Wallis rank sum test) 
variables. Non-parametric testing was performed because log transformation of 
the antibody titers did not result in a normal distribution. For this testing continu-
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ous predictors were transformed to dichotomous and nominal factors. Bivariate 
and multivariate logistic regression models were used to assess the association 
of risk factors with the presence of PT antibodies separately for mothers and in-
fants. 
Placental transfer for each mother-infant pair was defined as the ratio of 
cord antibody concentration to maternal antibody concentration [Equation 6].  
EQUATION 6 
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For primary Aim 3, the overall transfer ratio was the geometric mean of the 
infant to mother pair ratios [Equation 7]. 95% CI were constructed for the overall 
transfer ratio.  
EQUATION 7 
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The ratio of infant to maternal PT GMC was also calculated in the subset 
of mother infant pairs where at least one of the pair had an antibody level above 
the LOQ. This subset therefore excluded pairs where both mother and infant had 
antibody level below the LOQ. Additional analysis of the transfer ratio for a sec-
ondary aim was restricted to the pairs in this subset. 
Spearman’s rank correlation rho was calculated for the correlation of 
mother and infant PT antibody. Unadjusted and adjusted linear regression mod-
  120 
els were created for examining the association of log ratio of infant to maternal 
PT antibody levels with infant, maternal, and household characteristics.  
The cutoff for statistical significance in all testing was p<0.05. All statistical 
analyses were conducted in R version 3.0.2 (2013-09-25). 
Subsection 5.4 Infant, Maternal, and Household Characteristics 
At baseline, data on household structure was gathered, including age and 
sex of all household members. Households were categorized as crowded if 10 or 
more people resided in the home. The number of children under 5 years was 
transformed into a binary variable for households with 1 or fewer children <5 ver-
sus households with more than 1 child <5 years of age. Similarly, households 
were dichotomized into those with >3 children <15 years of age versus house-
hold with 3 or less children under 15 years. At enrollment women reported their 
literacy status (binary) and pregnancy history. The field workers identified their 
ethnicity (Pahadi or Madeshi) from names and observation. For parity analysis 
women were categorized as nulliparous or multiparous.  
Twenty-five questions were asked to develop a construct to measure the 
socioeconomic status of households. The questions were the following: (1-3) 
construction materials for ground, first, and roof, (4) number of living and sleep-
ing rooms, (5) water source, (6) type of latrine, (7) number of servants, (8-9) 
number of cattle and goats, (10-11) amount of khet and bari (measures of arable 
and non-arable land owned), (12-17) number of bullock carts, bicycles, motorcy-
cles, cars/jeeps, trucks/buses, tractors, (18-23) number of clocks, radios, televi-
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sions, satellite dishes, landline phones, mobile phones, (24) electricity in the 
home, and (25) household member working in another country. Responses for 
each of the 25 questions were dichotomized. Ground and first floor construction 
were counted as positive if construction materials were wood planks, brick or 
stone with mortar. Roof construction was coded as one if tin or cement were 
used. The presence of two or more living rooms was considered positive. For all 
other SES variables the presence of at least one (where applicable) item was 
considered as positive.  The results were averaged (to account for differences in 
level of missing data in the denominator) and divided into SES quartiles for anal-
ysis. 
Gestational age was measured using a woman’s report of date of last 
menstrual period during pregnancy surveillance (an average of 3-4 weeks recall). 
Gestational ages <37 complete weeks were categorized as preterm. Birthweight 
was collected as soon as possible after birth using a digital scale [Tanita model 
BD-585, precision to nearest 10g]. Birthweights collected >72 hours after birth 
were excluded from the analysis of birthweight. Infants were categorized as low 
birthweight if weight was <2500 grams (g). Small for gestational age was calcu-
lated using the sex-specific 10th percentile cut-off described by Alexander42 and 
the 3rd percentile cut-off described by Oken. 
Women were asked within how many hours of birth maternal breastfeed-
ing was initiated (if any). Binary breastfeeding categories were created with 
women initiating breastfeeding within 1 hour compared to those initiating >1 hour 
post-delivery. Anthropometry measures were calculated from the 6-month weight 
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and length measurements. The z-scores for underweight (weight for age), stunt-
ing (length for age), and wasting (weight for length) were calculated using the 
WHO Child Growth Standards from the igrowup Stata package. 
Section 6 – Quality Control 
The principal investigators of the maternal influenza immunization trial 
have over 25 years of experience conducting community-based trials worldwide 
and in Nepal. This experience has led to the development of a tested quality con-
trol organizational system.  Multiple levels of field staff were responsible for carry-
ing out the study’s data collection.  
The first group, Flu Data Collectors (FDC), consisted of 81 married women 
who lived in the communities they covered. Each woman was responsible for 80-
100 families in a given area.  Prior to the trial start these FDCs underwent exten-
sive training on the details of the trial protocol. FDC’s specific responsibilities in-
cluded identifying incident pregnancies through surveillance, working with partici-
pants’ families to ensure they are notified as soon as possible after delivery, and 
conducting weekly morbidity home visits. During these visits they conduct a mor-
bidity assessment and collected a nasal swab where indicated. 
The Birth Assessment Team Members were responsible for collecting 
pregnancy outcomes as soon as possible after birth (with the aim of within 24 
hours) and completing the 6 month post-partum follow-up. 
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Team Leader-Interviewers’ (TLI) duties included enrolling women, obtain-
ing informed consent, pregnancy follow-up and post-delivery interviews. In addi-
tion they retrieved nasal swab specimens weekly from the FDCs and supervised 
FDCs through weekly meetings. 
Field Supervisors were responsible for the entire study area and were the 
bridge between the field headquarters and the staff in the field.  Field Supervisors 
were integral to the project’s training program and provided overall management 
support to the project. Field Supervisors oversaw TLIs through weekly meetings 
and random checks of TLI reports. They were also responsible for conducting 
verbal autopsies.    
Auxiliary nurse midwives (ANMs) administered the study vaccine, moni-
tored the cold chain during field transport, and collected, processed, and shipped 
biospecimens. 
The Field Coordinator and Field Manager oversaw the entire field opera-
tion. They supervised the FSs and helped to resolve issues as they arose. The 
Field Coordinator and Field Manager helped to develop the data collection in-
struments including pre-testing them in the field. They were also responsible for 
interviewing, hiring, and training all levels of field workers working below them. 
The Field Manager was specifically responsible for managing the vaccine supply 
including transport to and from Kathmandu. 
The Medical Director, based in Kathmandu, was responsible for all field 
activities and was a liaison between U.S. based investigators. The Medical Direc-
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tor reviewed all adverse event report forms and led study form translations (Ne-
pali – English). 
Section 7 – Data Management 
The parent maternal influenza vaccination study personnel had responsi-
bility for the entirety of field data collection and management.  The field site had 
extensive experience in managing data from large-scale field trials.  Project 
Headquarters office was in Kathmandu and Field Headquarters were in Sarlahi.  
Data collection forms were developed by investigators in the US and Nepal and 
underwent extensive field testing, including focus groups before forms were final-
ized.  English versions of the data collection and consent forms were translated 
to Nepali and then back to English to ensure meaning of terms was not lost in 
translation.   
Subsection 7.1 Form Generation 
Each participant was assigned a unique designated identification number 
used on all patient-specific study forms and specimens. After the baseline cen-
sus, all women eligible for pregnancy surveillance were entered into the data-
base used to track women who were monitored for incident pregnancies.  Once 
pregnant women were enrolled in the study (and vaccinated), individual forms 
were generated for her data collection needs through 6 months post-partum.  
All data forms completed at field sites were transported to the Field Head-
quarters and then sent to Project Headquarters on a regular basis.  
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Subsection 7.2 Data Entry 
A Data Center manager, responsible for supervision of Data Entry Opera-
tors and generating regular data reports, oversaw the data center. Data Opera-
tors entered data on screens that emulated the paper data collection forms at 
Project Headquarters. The Data Operators were responsible for data entry, edit-
ing, and form storage management. The computerized forms were custom-
programmed with numerous levels of data validation to identify missing, incon-
sistent, or out of range data. In addition all form header information was double 
entered and select form data were double entered. Entering forms was required 
in a fixed order to ensure that forms in a data collection sequence were not miss-
ing. 
Once a form was entered, it was stored in a household specific folder that 
ultimately contained all data on that participant and her infant. The folder cover 
listed the name, NNIPS number, and address of the participant. Once a form was 
entered the Data Entry Operator stamped the date on the form and also this in-
formation was stored in the electronic database. Folders were filed by NNIPS 
number in a secure area. 
Subsection 7.3 Identification and Resolution of Data Inconsisten-
cies 
At the time of data entry, computerized checks were conducted to identify 
missing, inconsistent or out of range data. A data error query was produced and 
either resolved within the data center by reviewing other data collected on the 
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individual, or the query was returned to the field with a copy of the original form 
for resolution, either at the clinic or by visiting the participant to ascertain the ap-
propriate data to resolve the problem. A specific error correction form was only 
used for error corrections that originated in the field or were sent back to the field 
from the data center. Some errors were resolved in the data center without using 
the form. If it was determined that corrections were needed on the source data 
form itself (date error for example), the field staff put a single line through the er-
ror, initialed and dated the change. An electronic audit trail tracked any change 
made to the database after initial data entry. 
An external monitoring group visited the site once every two months to 
monitor the study’s compliance with Good Clinical Practice (GCP). Part of this 
process involved random checking and verification of form logic and comparison 
of paper form data to electronic data.  
Subsection 7.4 Electronic Data Back-Up and Transfer 
Study data were backed up daily.  A master copy of the data was backed 
up on a weekly basis and kept in an alternate location in case of unexpected 
damage (e.g. fire) at the main data site. The data were transmitted periodically 
(compressed and encrypted) to Baltimore from Nepal. 
Subsection 7.5 Data Security and Protection of Subject Confident i-
ality 
All information from study subjects was kept confidential. Only those au-
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thorized had access to these data. All forms were held a secured set of rooms at 
study headquarters in Kathmandu. Access to identifiable records was limited to 
study staff and their grounds for employment was contingent on their maintaining 
the security of study records and any identifiable information. Computer files 
were secured via logon password protection for study accounts and database 
files. The Data Center was located in a secured location in the Project Headquar-
ters in Kathmandu, locked and/or guarded at all times. All data files transferred to 
Baltimore via encrypted software were kept on our Johns Hopkins server behind 
the local firewall. 
The two academic centers who processed the blood and nasal swab 
specimens received specimens labeled with a specimen ID number and no iden-
tifiable information. Once specimens were processed, the data, by specimen ID, 
was entered into an Excel spreadsheet. The Excel document was transmitted to 
Baltimore where the specimen IDs were linked to participant IDs for analysis. 
Identifiers will be kept on all data files until the study is closed out. Primary 
data collection sources will be kept for at least 3 years following the publication of 
the primary results from this trial. Once that time elapses and the electronic data 
files are fully cleaned, paper forms will be destroyed. 
Section 8 – Human Subjects 
The study was nested within the maternal influenza trial, which included test-
ing specimens for other pathogens beyond influenza. An amendment was ap-
proved for the maternal influenza trial research plan to include pertussis testing 
  128 
of nasal swab and blood specimens. The study was approved by the following 
Institutional Review Boards (IRBs): 
1. Cincinnati Children’s Medical Center (FWA #00002988) 
2. Johns Hopkins Bloomberg School of Public Health (JHSPH) (FWA 
#00000287) 
3. Seattle Children’s Hospital (FWA #00002443) 
4. Institute of Medicine at Tribhuvan University/Nepal Health Research 
Council (FWA #00000957) 
Subsection 8.1 Confidentiality 
Data collection forms will be maintained in locked cabinets in the guarded 
Kathmandu study headquarters. Electronic databases will be stored only at the 
Kathmandu site and in Baltimore. Access will be granted only to those with valid 
login and passwords. Study identification numbers will be used whenever possi-
ble in lieu of a personal identifier. Identification will be kept on biospecimens until 
testing is complete but include only ID numbers, not names. Data collection 
sources will be kept for at least 3 years following the publication of the primary 
results from this trial. Once that time elapses and the electronic data files are fully 
cleaned, paper forms will be destroyed. 
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Subsection 8.2 Consent 
Consent to participate in the study occurred at multiple stages. Prior to the 
start of the study senior investigators met with community leaders and health 
care providers to discuss the proposed trial and answer specific questions. Dur-
ing the baseline census, at all households where a married woman 15-40 years 
of age resided, the head of household was read an informed consent script. 
Women residing in consenting households were read an individual informed con-
sent script, which included consent to participate in pregnancy surveillance and 
to participate in the trial if a pregnancy occurred. If a woman did not consent the 
household was not contacted further. Household and individual consent was 
documented on the household enrollment roster. Once a woman delivered her 
child she was asked if she agreed to enroll her infant although not using the full 
consent script. A woman’s consent for herself and/or her child was obtained 
again at the time of potential nasal swab and blood collection. The consent was 
documented on the participant-specific specimen collection form.   
Verbal consent was the method used for all participants and a waiver of 
written consent was approved by all participating IRB’s. One reason for non-
written consent is that the majority of the participants were illiterate.  Moreover, 
signatures or fingerprints in Nepal are generally reserved for important financial 
transactions and may cause great suspicion regarding the intentions of the study 
team. Once the verbal consent was read to a participant and the participant ver-
bally consented, the field worker recorded on the form that the consent was read, 
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any questions were answered, and the participant’s agreement or refusal to par-
ticipate.  
Subsection 8.3 Risks 
Risks to participants were similar to those for a comprehensive physical 
exam. The risks included potential privacy loss, slight discomfort during nasal 
swab and blood specimen collection, and discomfort and adverse reactions from 
the influenza vaccine. 
Many steps were taken to minimize these risks. Interviews were conduct-
ed in a private area of the home and data were stored in a secure environment to 
protect the risk of privacy invasion. The risk of discomfort during various speci-
men collection was minimized by using well-tested and sterile techniques and 
monitoring participants for adverse effects. Discomfort during vaccine administra-
tion was minimized by using well-trained vaccinators skilled in sterile technique 
and close monitoring for adverse events following immunization. 
Subsection 8.4 Benefits 
All participants in the study received potential benefits. Women random-
ized to receive the influenza vaccine may have protected themselves and their 
infants from influenza illness. Those women randomized to receive placebo re-
ceived an influenza vaccine at the completion of follow-up.  
Women also received improved antenatal services compared to the local 
standard of care including 90 days of iron-folic acid supplements (if not yet re-
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ceived from local health facility), single dose 400 mg albendazole (deworming) (if 
not yet received from local health facility), tetanus toxoid vaccination if indicated, 
tube of 4% chlorhexidine ointment for the umbilical cord, and educational mes-
sages on nutrition and safe birthing practices.  
There were no extra direct benefits to those who participated in the study.  
Society will benefit from the study through understanding of the effect of maternal 
influenza immunization on mothers and infants. Further, society will benefit from 
the pertussis study through understanding of the burden and risk factors of per-
tussis in infants. The knowledge gained may help influence maternal and child 
immunization policies and programs in Nepal and throughout the world. 
Subsection 8.5 Research Burden  
Households incurred a small burden through participation in this study. 
Households where women of reproductive age resided were visited at baseline 
and then every 5 weeks to monitor for new pregnancies. If a woman became 
pregnant and enrolled in the study the household was visited weekly through 6 
months post-partum.  Based on past experience conducting studies in this popu-
lation, weekly visits are not considered a significant burden, as households are 
rarely hesitant to participate in these visits. 
Subsection 8.6 Payments  
No payment were made to study participants. 
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Subsection 8.7 Monitoring  
The maternal influenza trial had two committees to provide organizational 
support. The Executive Committee was responsible for the scientific and admin-
istrative conduct of the trial. The Field Operations Committee was responsible for 
implementing the study protocol under the direction of the Executive Committee.  
The study Data Safety and Monitoring Board (DSMB) provided external 
oversight of the safety of the intervention and was responsible for meeting yearly 
to review the data. The DSMB conclusions were written and provided to the Ex-
ecutive Committee. The lead investigator then forwarded the DSMB conclusions 
to all participating IRBs. The DSMB included members with the following exper-
tise: biostatistics, obstetrics, pediatrics, epidemiology, and research ethics.  Sen-
ior members of the investigator team were non-voting members of the DSMB.  
An external clinical research organization also monitored the trial with a 
review of data, procedures, and IRB documents every two months for the dura-
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Abstract 
Background: Pertussis is a significant contributor to infant morbidity and mortali-
ty in low and middle-income countries where the majority of cases occur. Pertus-
sis vaccination in infancy is the sole prevention strategy in many countries sup-
ported by the WHO’s Expanded Programme on Immunization. Data capturing the 
timing of and delays in vaccination in first 6 months of life, when severe disease 
occurs, are lacking. 
Objective: To estimate the time to pertussis vaccination and risk factors for de-
lay in infants <6 months of age in Sarlahi District, Nepal. 
Design/Methods: Infants, enrolled in a randomized controlled trial of maternal 
influenza vaccination during pregnancy, were visited in their homes weekly to as-
certain if any vaccinations had been given in the prior week from birth through 
age 6 months. Infant, maternal, and household characteristics were captured at 
enrollment and birth. DPT1, DPT2, and DPT3 vaccination coverage at 14 weeks 
and 6 months was estimated; a logistic regression model was used to examine 
risk factors for delay. Time to vaccination was estimated through Kaplan-Meier 
curves; a cox-proportional hazards model was used for risk factor assessment. 
Results: The median age of DPT1 receipt was 18 weeks, which translates to a 
12-week delay from the recommended schedule. Only 7% of infants had re-
ceived DPT3 by age 6 months. Infants born small-for-gestational age or whose 
mothers were of Madeshi ethnicity or failed to initiate early breastfeeding were at 
high risk for delayed immunization. 
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Conclusion: A substantial delay in receipt of the primary pertussis vaccination 
series was found in a prospective population-based cohort in Sarlahi District, Ne-
pal. In addition to targeting groups most at risk for immunization delay, countries 
should consider improved immunization monitoring to capture these delays in in-
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Introduction 
Immunization is the primary means of pertussis prevention, dramatically 
reducing pertussis burden since pertussis vaccine’s initial introduction in the 
1940s1. The World Health Organization (WHO) estimates that since the end of 
the 1980s, 80% of children worldwide have received pertussis vaccines, prevent-
ing approximately 38 million cases and 600,000 deaths annually2. Worldwide 
childhood pertussis vaccination coverage rates have increased substantially 
since the introduction of the Expanded Programme on Immunization (EPI) in 
19743. The WHO recommends a three dose primary series, in combination with 
diphtheria and tetanus, at 6 weeks (DPT1), 10-14 weeks (DPT2), and 14-18 
weeks (DPT3).  Prior to EPI global DPT3 coverage was less than 5%; DPT3 
coverage in 2012 was 83% (measured at 12-23 months of age)4,5. Despite tre-
mendous progress, global coverage remains below the target of 90% DPT3 cov-
erage6.  
In recent years several high-income countries have experienced a resur-
gence of pertussis, particularly in infants and adolescents7,8. Several factors are 
thought to contribute to the epidemic levels including genetic changes in the Bor-
detella pertussis bacteria, waning immunity, lower and shorter duration of immun-
ity from acellular versus whole cell pertussis vaccines, heightened awareness, 
increased surveillance, and vaccination delay and refusal9-18.  
 Delay in vaccination in the primary series is especially important for infants 
who are at greatest risk for severe morbidity and mortality8,19. While infants might 
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have partial protection from passive transfer of pertussis antibodies from their 
mothers, this immunity eventually wanes, requiring active immunization. 
The distribution of pertussis burden is not equal with 95% of cases thought 
to occur in low-income countries resulting in 4% of <5 deaths in Southeast Asia 
attributable to pertussis6,20. In Nepal DPT3 vaccine coverage increased from 54% 
of children fully vaccinated by 12-23 months of age in 1995 to 90% in 201221. 
Even though this coverage is relatively high this measure does not capture vac-
cine delays in the first 6 months of life when infants are at high risk. Recent stud-
ies found DPT3 coverage at 6 months in low and middle-income countries was 
just 36%22.  Population-based data of early vaccination coverage using active 
surveillance in low-income countries are lacking. This prospective, population-
based cohort study aimed to estimate pertussis vaccination timing and risk fac-
tors for delay in the first 6 months of life in Sarlahi, Nepal. This information is im-
portant for policy makers to understand potential delays in vaccination and which 
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Methods 
Settings and population 
The setting of the study was Sarlahi District, located in the central terai 
(low lying plains) region of Nepal. The study was nested within a randomized 
controlled trial of maternal influenza vaccination during pregnancy. At the start of 
the trial, prevalent pregnancies were identified through a survey census of all 
households in the catchment area. For the duration of the trial field workers visit-
ed all households in the community where married women (15 – 40 years) resid-
ed every 5 weeks for surveillance of incident pregnancies. Once a pregnancy 
was identified women were asked for their consent to participate in the trial. Over 
a two-year period between April 25, 2011 and April 24, 2013 women between 17-
34 weeks gestation were randomized and vaccinated with either an influenza 
vaccine or placebo. All participants received ancillary benefits, which included a 
90-day supply of iron-folic acid tablets, deworming medication (single dose of al-
bendazole), clean birthing kit, chlorhexidine ointment for umbilical cord care, a 
tetanus toxoid vaccine, if indicated, and health education messages, in addition 
to antenatal services according to the local standard of care. The study was a 
population-based prospective cohort of infants followed from birth through 6 
months post-partum. Ethical approval for the study was obtained from the Johns 
Hopkins Bloomberg School of Public Health Institutional Review Board and the 
local ethical review board (Institute of Medicine at Tribhuvan University/Nepal 
Health Research Council). 
Data collection 
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At baseline information was collected on household structure, socioeco-
nomic status, and demographics. At study enrollment, date of last menstrual pe-
riod and pregnancy history data were collected. As soon as possible after deliv-
ery the mother and infant were visited to collect detailed birth information includ-
ing infant weight and breastfeeding status. From birth through 6 months post-
partum (180 days) infants were visited weekly by a field worker who recorded 
any vaccinations and which specific ones were received in the past 7 days. 
Analytic Dataset 
Infants were included in this analysis if they were followed for any length 
(0 to 180 days) during a 2 year-period from May 24, 2011 to January 14, 2014. 
[Complete data from trial pending]. Of 3,689 women vaccinated, 12 were missing 
a maternal delivery assessment (due to incomplete data entry at time of analysis) 
leaving 3,677 women with delivery assessment information [Appendix 3.1]. There 
were 5 maternal deaths, 9 miscarriages, and 4 abortions. Twenty-five twin preg-
nancies were excluded from the analysis. Of the 3,634 singleton births, there 
were 3,571 live births, 58 stillbirths, and 5 had missing birth information. Of the 
3,571 live singleton births, 23 died with no weekly morbidity follow-up in the neo-
natal period, 145 were live born but had no follow-up and 4 were followed up only 
after 180 days and thus were excluded from the analysis. The final dataset con-
sists of 3,399 infants with at least one follow-up visit during the first 6 months. 
At baseline, data on household structure was gathered, including age and 
sex of all household members. Households were categorized as crowded if 10 or 
more people resided in the home. The number of children under 5 years was 
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transformed into a binary variable for households with 1 or less children <5 ver-
sus households with >1 child <5. Similarly, households were dichotomized into 
those with >3 children <15 versus households with 3 or less children under 15 
years. At enrollment women reported their literacy status (binary) and pregnancy 
history. The field workers identified their ethnicity (Pahadi or Madeshi) from 
names and observation. For parity analysis women were categorized as nullipa-
rous or multiparous. Twenty-five questions were asked to develop a construct to 
measure the socioeconomic status (SES) of households. The questions were the 
following: (1-3) construction materials for ground, first, and roof, (4) number of 
living and sleeping rooms, (5) water source, (6) type of latrine, (7) number of 
servants, (8-9) number of cattle and goats, (10-11) amount of khet and bari 
(measures of arable and non-arable land owned), (12-17) number of bullock 
carts, bicycles, motorcycles, cars/jeeps, trucks/buses, tractors, (18-23) number of 
clocks, radios, televisions, satellite dishes, landline phones, mobile phones, (24) 
electricity in home, and (25) household member working in another country. Re-
sponses for each of the 25 questions were dichotomized. Ground and first floor 
construction were counted as positive if construction materials were wood 
planks, brick or stone with mortar. Roof construction was coded as one if tin or 
cement were used. The presence of two or more living rooms was considered 
positive. For all other SES variables the presence of at least one (where applica-
ble) item was considered as positive.  The SES variable was the percent of items 
on the 25-item scale that were positive. If any items were missing, the score was 
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the percent positive out of the number of non-missing items. These percentages 
were divided into SES quartiles for analysis. 
Gestational age was measured using a woman’s report of date of last 
menstrual period during pregnancy surveillance (an average of 3-4 weeks recall). 
Gestational ages <37 complete weeks were categorized as preterm. Birthweight 
was collected as soon as possible after birth using a digital scale [Tanita model 
BD-585, precision to nearest 10g]. Birthweights collected >72 hours after birth 
were excluded from the analysis of birthweight. Infants were categorized as low 
birthweight if weight was <2500 grams (g). Small for gestational age (SGA) was 
calculated using the sex-specific 10th percentile cut-off described by Alexander23. 
Women were asked within how many hours of birth maternal breastfeeding was 
initiated (if any). Binary breastfeeding categories were created with women initiat-
ing breastfeeding within 1 hour compared to those initiating >1 hour post-
delivery.  
Statistical Analysis 
Vaccine coverage was calculated at 14 weeks (the recommended age for 
completion of the pertussis series) and 6 months (end of follow-up). For this 
analysis, infants were excluded if they were observed with weekly visits ending 
prior to 98 days (14 weeks) after birth to ensure all infants included had an op-
portunity to have recorded vaccinations at the recommended vaccination ages 
(6, 10, and 14 weeks). The primary outcome was the proportion in each vaccina-
tion category at 14 weeks and 6 months. 
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Survival analysis was used to measure the time to pertussis vaccination, 
separately for each of the 3 doses. Kaplan-Meier curves were constructed with a 
vaccination considered the event of interest. Infants were right-censored once 
they had the event of interest (specific vaccine dose) or had no further follow-up 
recorded (which included deaths as well as migrations). 
Infant, maternal, and household risk factors for time to 1st, 2nd, and 3rd per-
tussis vaccination were analyzed using a Cox-proportional hazards model. The 
recommended age of first pertussis vaccination dose, 42 days, was designated 
as time 0. Infants who were vaccinated prior to 42 days were assigned a date of 
vaccination immediately after time 0 (1x10-6). The same adjustment made for 
loss-to follow-up was made for those infants with no follow-up after 42 days. In-
fants who had at least one follow-up visit but died before 42 days were excluded 
from the analysis. For the unadjusted model, hazard ratios, 95% confidence in-
tervals (CI), and p-values from the Wald test of the maximum likelihood estimate 
were reported. Risk factors measuring similar characteristics were excluded to 
avoid any collinearity in the multivariate model. The multivariable model included 
adjusted hazard ratios, 95% CI and p-values from the Wald test of the maximum 
likelihood estimate. The proportionality assumption was tested through graphical 
diagnostics and testing based on scaled Schoenfeld residuals. 
Risk factors for being vaccinated at 6 months for the 1st, 2nd, and 3rd per-
tussis doses were analyzed using a logistic regression model including infant, 
maternal and household risk factors. 
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Statistical significance was set at p<0.05 for all testing. All statistical anal-
yses were conducted in R version 3.0.2 (2013-09-25). 
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Results 
3,339 infants were visited at least once from age 0-180 days. The visit 
dates ranged from May 24, 2011 to January 14, 2014. For binary pertussis cov-
erage and logistic regression estimates, 266 infants were excluded due to having 
no data at or beyond 98 days (age when 3rd dose recommended). 3,133 infants 
were observed to at least age 98 days. For these infants, the mean age of last 
follow-up visit was 168 days (SD = 16.1). Mean ages of first, second, and third 
pertussis doses were 83, 114, and 128 days, respectively among those who had 
observations up to 98 days or beyond. A subset of infants was vaccinated prior to 
the recommended age of vaccination. 106 infants were vaccinated with a pertus-
sis vaccine prior to age 42 days. For the 2nd and third dose the numbers of early 
vaccinated were 39 and 20, respectively.   
The majority (60%) of infants had received no pertussis immunization by 
age 14 weeks, the recommended age for completion of all 3 doses. By age 6 
months, 43% of infants remained unvaccinated for pertussis [Figure 3.1]. Only 
1% were fully vaccinated by 14 weeks with the percentage increasing slightly to 
7% fully vaccinated by 6 months. 
The median age at first pertussis vaccination, estimated using survival 
curves, was 128 days (95% CI: 124 -134) [Figure 3.2]. 
Cox proportional hazard models were used to estimate the relative hazard 
of being unvaccinated in unadjusted (bivariable) and adjusted (multivariable) 
models [Table 3.1]. The proportionality assumption was tested through graphical 
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diagnostics [Appendix 3.2] and testing based on scaled Schoenfeld residuals 
[Appendix 3.3]. Parity, SES, and the two childhood crowding-associated varia-
bles all had statistical significance for non-proportionality. Modeling a time inter-
action term for these variables showed no significant interaction so variation with 
time was not included in the model. 
Factors associated with a higher hazard of being unvaccinated in bivaria-
ble models were being born SGA, failure to initiate breastfeeding in first hour af-
ter birth, maternal illiteracy and Madeshi ethnicity, and household crowding both 
for all household members and members under the age of 15 years. The strong-
est associations were for ethnicity (HR 1.35; 95% CI: 1.23 - 1.50) and breast-
feeding initiation (HR 1.18; 95% CI: 1.07 - 1.29). A multivariable model was con-
structed removing variables measuring similar outcomes as those included in the 
final model (birthweight, crowding, children <5 years). Ethnicity, breastfeeding, 
and SGA remained significant in the multivariable model.  
For the model of time to second vaccination, SGA, breastfeeding, ethnici-
ty, and crowding remained statistically significant in the bivariable model [Appen-
dix 3.4].  In the multivariable model only SGA remained statistically significant. 
Modeling time to third vaccination showed only SGA and breastfeeding were sta-
tistically significant in the bivariable model [Appendix 3.5]. In the full model both 
of these factors remained significant and children <15 rose to statistical signifi-
cance. Of note however is that the models to second and third vaccination had 
less power to detect statistical significance given lower numbers for these out-
comes compared to the first vaccination. 
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Logistic regression was also used to look at the binary outcome of having 
at least 1, 2, or 3 doses completed by age 6 months. In the bivariable logistic 
model for having received at least 1 pertussis dose the same factors were signifi-
cant as in the Cox proportional hazards model; the exception was literacy, which 
was not statistically significant [Appendix 3.6]. Only ethnicity remained statistical-
ly significant in the full model. SGA, ethnicity, and crowding were significant in 
the model estimating the odds of at least 2 doses completed by age 6 months. 
Only SGA status was a statistically significant predictor of having at least 2 doses 
by 6 months in the adjusted model [Appendix 3.7]. In the unadjusted model for 
fully vaccinated (all 3 doses) at 6 months, SGA, breastfeeding, and SES were 
statistically significant [Appendix 3.8]. In the full model only early breastfeeding 
initiation was a statistically significant predictor of full vaccination status at 6 
months. 
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Discussion 
Substantial delays in uptake of the primary pertussis vaccination series 
were found in infants <6 months in Sarlahi District, Nepal. The median age of 
DPT1 vaccination was 18 weeks, a 12-week delay from the recommended age of 
6 weeks. Only 7% of infants were fully vaccinated with DPT3 by age 6 months. 
This significant delay is not captured by WHO estimates. The most recent Nepal 
data from 2013 give DPT1 and DPT3 coverage at 94% and 92%, respectively4. 
In the central terai region, where Sarlahi District is located, 96%, 92%, and 87% 
of children have received one, two, and three doses, respectively, of DPT by ag-
es 12-23 months24. While these official coverage estimates are high, our data 
show many infants receive vaccines on a delayed schedule. Globally, WHO and 
UNICEF use officially reported data and sample survey data to measure DPT 
coverage of children 12-23 months3. As a result, if there are substantial delays in 
vaccination, but DPT vaccines are complete by age 2, a child is still considered 
as vaccinated on schedule. In the U.S. and elsewhere standard national report-
ing statistics obscure delays when infants are at risk for vaccine-preventable dis-
eases22,25-27. National-level reporting may also mask within-country variation in 
vaccination timeliness22.  
Our finding of significant vaccination delay is consistent with data from 
other countries. For example, Japan’s reported DPT3 coverage was 98% in 
2013, however data from a representative city in Japan showed less than 50% 
DPT coverage by age 12 months26. In the U.S. a study found almost half of chil-
dren had some delay in receiving a DTaP vaccine dose and 16% were delayed in 
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vaccine receipt for more than 6 months in the first two years25 despite national 
DPT3 coverage at 94% in 2013. A longitudinal study in Ghana reported that while 
DPT3 coverage was 95% at 12 months, only 10% of infants were vaccinated 
within 1 week of the scheduled time (14 weeks); the median delay for DPT3 was 
4 weeks 28. A study examining the timing of vaccination in low and middle income 
countries, based on surveys and imputed data, found median DPT1 coverage at 
6 months was 82% (95% CI: 67-89%) and DPT3 was 36% (95% CI: 23-54)22. 
Our data from Nepal of DPT1 (57%) and DPT3 (7%) coverage at 6 months is 
significantly lower than these estimates from other similar countries. An interpre-
tation of this is that Nepal may in reality have increased vaccination delay com-
pared to similar countries. An alternative interpretation is that in general survey 
and imputed data lead to an overestimation of coverage. Our weekly active sur-
veillance data might have led to a more precise and unbiased estimation of vac-
cination coverage. 
 Despite the vaccination delays found, Nepal considers its National Immun-
ization Program a high priority with the country on track to achieve Millennium 
Development Goal 4 on child mortality reduction29,30. Timeliness of childhood 
vaccination is crucial in Nepal since no booster immunizations are recommended 
for adolescents and adults, including pregnant women. The delay is important as 
it leaves infants at risk for pertussis. Children who are unimmunized or under 
immunized are at increased risk for pertussis and pertussis hospitalization com-
pared to their more fully immunized peers16,26,31-33. 
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We modeled vaccination delay as both time to vaccination and vaccination 
status at 6 months. More factors reached statistical significance in the models of 
time to first pertussis vaccination or having at least 1 vaccine. This is likely due to 
the increased power of these models with more outcomes of interest observed in 
comparison to models for DPT2 or DPT3. In bivariate logistic (status at 6 months) 
and cox-proportional hazard (time to vaccination) models, being born SGA, fail-
ure to initiate breastfeeding in the first hour of birth, Madeshi ethnicity, and 
household crowding were all associated with vaccination delay. Maternal illitera-
cy was statistically significant in the cox-proportional model alone. When examin-
ing the risk factors in combination, SGA status, breastfeeding status, and ethnici-
ty remained the most important predictors of vaccination delay. We found no dif-
ference in vaccination status by sex or birth order in contrast to that found in the 
Nepal Demographic and health survey24. One reason why these factors might 
contribute to vaccination delay is that they are markers for poorer access to 
health services. Mothers who have lower utilization of antenatal care might be at 
higher risk for infants born SGA and have had less exposure to the importance of 
early initiation of breastfeeding. Women of Madeshi ethnicity have less mobility 
and empowerment, and are therefore less likely to access health care resources 
for themselves and their children.  These same factors might also lead to lower 
access of infant check-up visits where infants have an opportunity for vaccina-
tion. 
Reasons for vaccination delay in low and middle-income countries include 
poor immunization supply, lack of access to health services, and family charac-
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teristics27,28,34. Parents may also be hesitant to vaccinate or not view the costs 
involved with vaccination worth the benefit. In Ghana infants who were poorer, 
had less educated mothers, and lived in rural versus urban areas were signifi-
cantly more likely to delay vaccination compared to urban infants whose mothers 
were educated and in a higher income groups28. A study of 31 low and middle 
income countries also found that children in poorer families and families with 
more than one child were at increased risk for vaccination delay27. In the U.S. 
vaccination delay is associated with a mother who is unmarried, less educated, 
non-Hispanic black, and uses public vaccination providers25. In comparison in our 
Nepal population, literacy, a surrogate for maternal education was only significant 
in the bivariable cox-proportional hazard model of time to first vaccination. Low 
socioeconomic status was a significant predictor in being non-fully vaccinated at 
6 months only in an unadjusted model. Parity was not a significant predictor in 
our population, which differs from previous findings. Our study provides an im-
proved understanding of Nepal-specific factors contributing to vaccination delay 
that can help programs focus on at-risk populations to increase on-time vaccina-
tion. 
 A limitation of our study is that our surveillance extended only for the first 6 
months of life. We were not able to capture the timing of vaccination receipt to 
age 12 months. We cannot provide if or when vaccines were received to capture 
the full delay. This limited the direct comparability of our data to official data re-
ported at age 1 year. The infants in our surveillance population might have 
reached the officially reported coverage by 12 months. Official reporting in some 
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countries may overestimate the coverage in part to reach donor targets such as 
GAVI’s immunization services support (ISS)3. While, GAVI is the largest contribu-
tor to Nepal’s immunization budget providing 46% of necessary funds, it is not 
possible to know why our 6 month coverage data do not correspond to those at 
12-23 months35. The most likely explanation is that there is catch-up of vaccina-
tion beyond 6 months of age. Another may be that rural Sarlahi may not repre-
sent other parts of the country, especially urban areas, in terms of coverage data. 
 Another limitation of our study was that recording of vaccine receipt was 
reported by parents and not confirmed by review of immunization cards. This 
could have led to misclassification if the parent reported an incorrect vaccine. 
Overestimation of coverage could have occurred if parents over reported vaccine 
receipt or underestimation if parents forgot or were unaware of a vaccine the in-
fant previously received. However, parents were visited in their homes on a 
weekly basis limiting the chance for recall bias although it is possible that they 
did not correctly recall the type of vaccine provided. 
We have no qualitative data from parents on their perspective of the vac-
cination status of their children. While we were able to quantitatively examine risk 
factors we are limited in understanding the underlying reasons for vaccination 
delay. 
Strengths of this study are that it was a population-based cohort study fol-
lowing infants prospectively from birth through age 6 months. Surveillance was 
conducted at high frequency (weekly) in the homes of all participants. The cap-
ture of time of vaccination provides important information on vaccine delay for 
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Nepal policy makers. While the population was limited to one district in Nepal the 
results are likely generalizable to most of the Nepalese population. The majority 
of the Nepali population lives in the terai region, where Sarlahi District is located. 
Infant health and vaccination indictors are similar to country-wide estimates24. 
Sarlahi District, which borders India near sea level, has similar living conditions to 
many populations of South Asia36. 
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Conclusion  
We found substantial delay in receipt of the primary pertussis vaccination 
series in a prospective population-based cohort in Sarlahi District, Nepal. Nepal 
national immunization coverage figures do not fully capture the excess pertussis 
risk attributable to delays in vaccination. Timeliness of routine childhood immun-
ization should be emphasized to maintain the low pertussis incidence. Groups at 
higher risk for non-vaccination in Nepal including children born SGA, mothers 
who delay initiation of breastfeeding, and mothers of Madeshi ethnicity should be 
targeted for immunization timeliness interventions. Age appropriate vaccination 
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*Excludes infants observed only between ages 1-97 days. 


































At 14 Weeks At 6 Months 
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*Stars indicate the recommended age for each vaccine dose 
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Cox Proportional Hazard Model
No % HR
1 p-value3 HR p-value
Sex
Female 1601 47%
Male 1795 53% 1.07 0.975 - 1.17 0.15 1.04 0.930 - 1.15 0.53
Gestational Age4
Term 2983 88%
Pre-Term 408 12% 1.12 0.965 - 1.29 0.14 1.18 0.990 - 1.42 0.065
Birthweight5
Normal 2020 76%
Low Birthweight 645 24% 1.13 0.999 - 1.28 0.053
Small-for-Gestational Age6
non-SGA 1413 53%
SGA 1271 47% 1.12 1.02 - 1.25 0.025 1.13 1.01 - 1.26 0.038
Breastfeeding
Breastfed <1 hour 1170 35%
Non-breastfed 1st hour 2121 64% 1.18 1.07 - 1.29 <0.001 1.13 1.01 - 1.27 0.033
Literacy
Literate 1816 61%
Illiterate 1173 39% 1.11 1.00 - 1.22 0.050 1.06 0.926 - 1.20 0.42
Parity
Non-first pregnancy 1769 59%
First pregnancy 1244 41% 1.06 0.961 - 1.17 0.24 1.08 0.962 - 1.22 0.19
Ethnicity
Pahdai 1778 58%
Madeshi 1272 42% 1.35 1.23 - 1.50 <0.0001 1.20 1.05 - 1.36 0.0066
SES7
Lower vs. higher 3051 1.03 9 0.984 - 1.07 0.22 0.99 0.939 - 1.05 0.75
Crowding8
Uncrowded 1966 64%
Crowded 1086 36% 1.12 1.01 - 1.24 0.028
Children under 15 years
≤3 children 2292 75%
>3 children 760 25% 1.18 1.05 - 1.32 0.0055 1.08 0.943 - 1.23 0.27
Children under 5 years
≤ 1 child 2094 69%
>1 child 958 31% 1.05 0.942 - 1.16 0.40
1 Hazard Ratio; interpretation: ratio of the hazard of being unvaccinated in risk group compared to the reference group
2 95% confidence interval
3 P-values calculated from the Wald test of the maximum likelihood estimate (MLE) of the coefficient
4 Gestational age: Preterm (<37 weeks), Term (≥37 weeks)
5 Birthweight: Low birthweight (<2500 grams), Normal (≥2500 grams)
6 Small-for-gestational age: SGA (< than the 10%), non-SGA (≥ than the 10%)
7 Socioeconomic status (SES): Average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1-4)
8 Crowding: Crowded (≥10 persons living in household), Uncrowded (<10 persons living in household)
9 Interpretation example: hazard of being unvaccinated in the bottom quartile compared to 2nd lowest quartile
Unadjusted Adjusted
Risk Factor
Table 3.1 - Risk Factors for Time to First Pertussis Vaccination
95% CI95% CI2
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Cox Proportional Hazard Model
No % HR
1 p-value3 HR p-value
Sex
Female 1600 47%
Male 1794 53% 0.97 0.843 - 1.12 0.71 0.93 0.786 - 1.10 0.38
Gestational Age4
Term 2982 88%
Pre-Term 407 12% 0.98 0.791 - 1.22 0.88 1.18 0.90 - 1.56 0.23
Birthweight5
Normal 2019 76%
Low Birthweight 644 24% 1.19 0.978 - 1.44 0.082
Small-for-Gestational Age6
non-SGA 1412 53%
SGA 1270 47% 1.25 1.06 - 1.46 0.0070 1.33 1.114 - 1.59 0.002
Breastfeeding
Breastfed <1 hour 1169 36%
Non-breastfed 1st hour 2120 65% 1.16 1.00 - 1.35 0.047 1.12 0.939 - 1.33 0.21
Literacy
Literate 1815 61%
Illiterate 1172 39% 1.05 0.90 - 1.23 0.51 1.11 0.907 - 1.37 0.31
Parity
Non-first pregnancy 1767 59%
First pregnancy 1244 41% 1.09 0.93 - 1.27 0.30 1.07 0.887 - 1.28 0.50
Ethnicity
Pahdai 1777 58%
Madeshi 1271 42% 1.22 1.04 - 1.42 0.014 1.11 0.91 - 1.36 0.29
SES7
Lower vs. higher 3049 1.00 9 0.932 - 1.07 0.929 0.99 0.912 - 1.08 0.83
Crowding8
Uncrowded 1964 64%
Crowded 1086 36% 1.20 1.02 - 1.41 0.028
Children under 15 years
≤3 children 2290 75%
>3 children 760 25% 1.11 0.93 - 1.32 0.26 1.17 0.948 - 1.44 0.15
Children under 5 years
≤ 1 child 2092 69%
>1 child 958 31% 1.04 0.886 - 1.22 0.62
1 Hazard Ratio; interpretation: ratio of the hazard of being unvaccinated in risk group compared to the reference group
2 95% confidence interval
3 P-values calculated from the Wald test of the maximum likelihood estimate (MLE) of the coefficient
4 Gestational age: Preterm (<37 weeks), Term (≥37 weeks)
5 Birthweight: Low birthweight (<2500 grams), Normal (≥2500 grams)
6 Small-for-gestational age: SGA (< than the 10%), non-SGA (≥ than the 10%)
7 Socioeconomic status (SES): Average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1-4)
8 Crowding: Crowded (≥10 persons living in household), Uncrowded (<10 persons living in household)
9 Interpretation example: hazard of being unvaccinated in the bottom quartile compared to 2nd lowest quartile
Risk Factors for Time to Second Pertussis Vaccination
Risk Factor
Unadjusted Adjusted




Cox Proportional Hazard Model
No % HR
1 p-value3 HR p-value
Sex
Female 1599 47%
Male 1793 53% 0.86 0.654 - 1.12 0.26 0.86 0.628 - 1.18 0.35
Gestational Age4
Term 2981 88%
Pre-Term 406 12% 0.82 0.564 - 1.21 0.32 0.89 0.56 - 1.41 0.62
Birthweight5
Normal 2018 76%
Low Birthweight 643 24% 1.34 0.922 - 1.95 0.13
Small-for-Gestational Age6
non-SGA 1410 53%
SGA 1270 47% 1.45 1.07 - 1.96 0.016 1.40 1.000 - 1.96 0.050
Breastfeeding
Breastfed <1 hour 1169 35%
Non-breastfed 1st hour 2118 64% 1.43 1.09 - 1.88 0.009 1.49 1.076 - 2.05 0.016
Literacy
Literate 1814 61%
Illiterate 1171 39% 0.96 0.72 - 1.28 0.76 1.27 0.871 - 1.85 0.22
Parity
Non-first pregnancy 1765 59%
First pregnancy 1244 41% 1.05 0.786 - 1.40 0.74 0.97 0.691 - 1.37 0.88
Ethnicity
Pahdai 1776 58%
Madeshi 1270 42% 0.99 0.74 - 1.31 0.92 0.89 0.62 - 1.29 0.55
SES7
Lower vs. higher 3047 0.88 9 0.776 - 1.00 0.05 0.86 0.738 - 1.01 0.068
Crowding8
Uncrowded 1963 64%
Crowded 1085 36% 1.17 0.87 - 1.58 0.31
Children under 15 years
≤3 children 2289 75%
>3 children 759 25% 1.29 0.92 - 1.82 0.15 1.55 1.015 - 2.37 0.043
Children under 5 years
≤ 1 child 2092 69%
>1 child 956 31% 1.04 0.771 - 1.41 0.79
1 Hazard Ratio; interpretation: ratio of the hazard of being unvaccinated in risk group compared to the reference group
2 95% confidence interval
3 P-values calculated from the Wald test of the maximum likelihood estimate (MLE) of the coefficient
4 Gestational age: Preterm (<37 weeks), Term (≥37 weeks)
5 Birthweight: Low birthweight (<2500 grams), Normal (≥2500 grams)
6 Small-for-gestational age: SGA (< than the 10%), non-SGA (≥ than the 10%)
7 Socioeconomic status (SES): Average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1-4)
8 Crowding: Crowded (≥10 persons living in household), Uncrowded (<10 persons living in household)
9 Interpretation example: hazard of being unvaccinated in the bottom quartile compared to 2nd lowest quartile
Risk Factors for Time to Third Pertussis Vaccination
Risk Factor
Unadjusted Adjusted




















Breastfed <1 hour 675 61%





Non-first pregnancy 968 59%









Children under 15 years
≤3 children 1265 60%
>3 children 378 53%
Children under 5 years
≤ 1 child 1131 59%
>1 child 512 57%
1
2 95% confidence interval
3 P-values calculated from Wald z-statistic
4 Gestational age: Preterm (<37 weeks), Term (≥37 weeks)
5 Birthweight: Low birthweight (<2500 grams), Normal (≥2500 grams)
6 Small-for-gestational age: SGA (< than the 10%), non-SGA (≥ than the 10%)
7 Socioeconomic status (SES): Average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1-4)
8 Crowding: Crowded (≥10 persons living in household), Uncrowded (<10 persons living in household)
9 Interpretation example: odds of being unvaccinated in the bottom quartile compared to unvaccinated in the 2nd lowest quartile
Odds Ratio; interpretation: ratio of the odds of being unvaccinated in risk group compared to odds of being unvaccinated in the reference group
Risk Factors for No Pertussis Vaccination at 6 Months
Risk Factor
Logistic Regression Model
>0 Doses at 6 Months
OR1 p-value3 OR p-value
1.09 0.95 - 1.26 0.21 1.04 0.874 - 1.24 0.66
1.17 0.942 - 1.45 0.15 1.28 0.98 - 1.68 0.07
1.16 0.959 - 1.40 0.13
1.18 1.00 - 1.38 0.045 1.20 0.996 - 1.43 0.055
1.24 1.07 - 1.44 0.006 1.19 0.99 - 1.43 0.064
1.16 1.00 - 1.36 0.055 1.01 0.823 - 1.25 0.90
1.05 0.898 - 1.22 0.56 1.04 0.863 - 1.26 0.65
1.59 1.37 - 1.85 <0.0001 1.30 1.07 - 1.59 0.01
1.06 9 0.995 - 1.14 0.07 1.03 0.946 - 1.13 0.47
1.22 1.05 - 1.43 0.011
1.30 1.10 - 1.55 0.002 1.15 0.933 - 1.41 0.19
1.09 0.932 - 1.28 0.27
Unadjusted Adjusted



















Breastfed <1 hour 287 26%





Non-first pregnancy 414 25%









Children under 15 years
≤3 children 521 25%
>3 children 163 23%
Children under 5 years
≤ 1 child 468 24%
>1 child 216 24%
1
2 95% confidence interval
3 P-values calculated from Wald z-statistic
4 Gestational age: Preterm (<37 weeks), Term (≥37 weeks)
5 Birthweight: Low birthweight (<2500 grams), Normal (≥2500 grams)
6 Small-for-gestational age: SGA (< than the 10%), non-SGA (≥ than the 10%)
7 Socioeconomic status (SES): Average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1-4)
8 Crowding: Crowded (≥10 persons living in household), Uncrowded (<10 persons living in household)
9
Odds Ratio; interpretation: ratio of the odds of being vaccinated with less than 2 doses in risk group compared to odds of being vaccinated with 
less than 2 doses in the reference group
2 or 3 Doses at 6 months
Interpretation example: odds of being vaccinated with less than 2 doses in the bottom quartile compared to being vaccinated with less than 2 
doses in the 2nd lowest quartile
Risk Factors for One or Less Pertussis Vaccination Doses 6 Months
Logistic Regression Model
Risk Factor
OR1 p-value3 OR p-value
0.97 0.82 - 1.14 0.69 0.93 0.766 - 1.13 0.47
0.98 0.764 - 1.26 0.86 1.20 0.88 - 1.66 0.25
1.20 0.963 - 1.49 0.11
1.28 1.07 - 1.54 0.008 1.38 1.125 - 1.70 0.002
1.17 0.98 - 1.39 0.074 1.12 0.92 - 1.37 0.27
1.06 0.89 - 1.27 0.54 1.12 0.887 - 1.42 0.34
1.12 0.94 - 1.34 0.20 1.09 0.882 - 1.35 0.42
1.26 1.05 - 1.50 0.01 1.16 0.92 - 1.45 0.21
1.00 9 0.927 - 1.08 0.97 1.00 0.905 - 1.10 0.98
1.24 1.03 - 1.49 0.02
1.10 0.90 - 1.34 0.37 1.17 0.924 - 1.49 0.19
1.02 0.852 - 1.23 0.80
Unadjusted Adjusted




















Breastfed <1 hour 94 9%





Non-first pregnancy 118 7%









Children under 15 years
≤3 children 155 7%
>3 children 41 6%
Children under 5 years
≤ 1 child 134 7%
>1 child 62 7%
1
2 95% confidence interval
3 P-values calculated from Wald z-statistic
4 Gestational age: Preterm (<37 weeks), Term (≥37 weeks)
5 Birthweight: Low birthweight (<2500 grams), Normal (≥2500 grams)
6 Small-for-gestational age: SGA (< than the 10%), non-SGA (≥ than the 10%)
7 Socioeconomic status (SES): Average of 24 SES measures categorized into quartiles and modeled as a continuous variable (1-4)
8 Crowding: Crowded (≥10 persons living in household), Uncrowded (<10 persons living in household)
9
Odds Ratio; interpretation: ratio of the odds of being not fully vaccinated (<3 doses) in risk group compared to odds of being not fully vaccinated  in 
the reference group
Interpretation example: odds of being not fully vaccinated (<3 doses) in the bottom quartile compared to not being fully vaccinated in the 2nd 
lowest quartile
Risk Factors for Two or Less Pertussis Vaccination Doses 6 Months
Logistic Regression Model
Risk Factor
3 Doses at 6 months
OR1 p-value3 OR p-value
0.85 0.639 - 1.12 0.24 0.86 0.618 - 1.19 0.37
0.82 0.556 - 1.23 0.31 0.87 0.55 - 1.44 0.58
1.36 0.937 - 2.03 0.12
1.47 1.08 - 2.02 0.015 1.41 0.999 - 2.02 0.05
1.46 1.10 - 1.93 0.009 1.50 1.07 - 2.11 0.02
0.96 0.71 - 1.30 0.78 1.29 0.875 - 1.91 0.20
1.08 0.801 - 1.46 0.62 1.00 0.703 - 1.44 0.98
1.00 0.75 - 1.35 0.999 0.91 0.62 - 1.33 0.62
0.87 9 0.765 - 0.997 0.046 0.86 0.726 - 1.01 0.07
1.19 0.88 - 1.63 0.28
1.29 0.91 - 1.86 0.16 1.55 1.016 - 2.44 0.05
1.02 0.748 - 1.40 0.92
Unadjusted Adjusted
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Background: Pertussis is estimated to cause 2% of childhood deaths globally 
and is a growing public health problem in developed countries despite high vac-
cination coverage. Infants are at greatest risk of morbidity and mortality. Maternal 
vaccination during pregnancy may be effective to prevent pertussis in young in-
fants but population-based estimates of disease burden in infants, particularly in 
low-income countries are lacking.  
Objective: To estimate the incidence of pertussis in infants <6 months of age in 
Sarlahi District, Nepal.  
Design/Methods: Nested within a larger randomized controlled trial of influenza 
vaccination during pregnancy, infants were visited weekly from birth through six 
months to assess respiratory illness in the prior week. If any respiratory symp-
toms had occurred, a nasal swab was collected and tested with a multi-target 
pertussis PCR assay. Infants observed between August 17, 2011 and August 16, 
2013 were included in the analysis. 
Results: The incidence of PCR-confirmed Bordetella pertussis and Bordetella 
parapertussis was 5.2 cases per 1000 infant-years (95% CI, 2.1 – 10.7) and 3.0 
cases per 1000 infant-years (95% CI, 0.81 – 7.6) respectively, in a cohort of 
3,235 infants with at least one-week of follow-up.  
Conclusions: Population-based active home surveillance for respiratory illness 
found a low risk for pertussis among infants in rural Nepal. Nepal's immunization 
program, which includes a childhood whole cell pertussis vaccine, appears to be 
working in controlling pertussis in infants. 
 180 
Introduction 
A resurgence of pertussis across age groups has occurred in several 
countries in recent years1,2. Middle and high-income countries, using an acellular 
pertussis vaccine for the primary vaccination series, have been particularly af-
fected3. Moreover, age groups experiencing the greatest increase include infants 
and adolescents4. Several factors are thought to contribute to the increased per-
tussis levels, which include rapid waning immunity from those primarily or exclu-
sively vaccinated with acellular vaccines versus whole cell vaccines5,6, genetic 
adaption of Bordetella pertussis7, vaccination delay or refusal8,9, improved sur-
veillance and laboratory capabilities3, and overall increased awareness of the 
continuing circulation of B. pertussis2.  
As infants experience the greatest morbidity and mortality from pertussis 
some countries experiencing epidemic pertussis, namely the U.S. and U.K., now 
recommend pertussis immunization in pregnancy and vaccination of close con-
tacts10,11. The purpose of this strategy is to protect the youngest infants from per-
tussis before they can be vaccinated themselves12. Global estimates of pertussis 
place the highest childhood burden in Southeast Asia13. Maternal pertussis vac-
cination may be of public health interest here and in similar settings, as a meas-
ure to protect infants such as currently exists for tetanus toxoid vaccine.  Howev-
er, only one population-based estimate of pertussis in infants from birth has been 
conducted (Senegal)14 and surveillance and laboratory capabilities in Asia are 
lacking15,16. Further, the World Health Organization (WHO) recently recommend-
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ed that countries using whole cell pertussis vaccines continue to do so in light of 
recent data indicating that acellular pertussis vaccines are less effective than 
whole cell pertussis vaccines3. Population-based data are needed, especially in 
low-income settings, to provide a more accurate estimate of the burden of per-
tussis in infants to inform childhood and maternal immunization policies. This 
study was a two-year prospective cohort following infants in their homes to moni-
tor for pertussis from birth to age 6 months. The objective of this study was to 
provide the first population-based estimate of laboratory confirmed pertussis inci-





Settings and population 
The setting of the study was Sarlahi District, located in the central terai 
(low lying plains) region of Nepal. The study was nested within a randomized 
controlled trial of maternal influenza vaccination during pregnancy. At the start of 
the trial, prevalent pregnancies were identified through a survey census of all 
households in the catchment area. For the duration of the trial field workers visit-
ed all households in the community where married women (15 – 40 years) resid-
ed every 5 weeks for surveillance of incident pregnancies. Once a pregnancy 
was identified women were asked for their consent to participate in the trial. From 
April 25, 2011 through September 9, 2013 women between 17-34 weeks gesta-
tion were randomized and vaccinated with either an influenza vaccine or placebo. 
All participants received ancillary benefits, which included a 90-day supply of 
iron-folic acid tablets, deworming medicine (single dose of albendazole), clean 
birthing kit, chlorhexidine ointment for umbilical cord care, a tetanus toxoid vac-
cine, if indicated, and health education messages, in addition to antenatal ser-
vices according to the local standard of care. The study was a population-based 
prospective cohort of infants followed from birth through 6 months post-partum. 
Approval for the study was obtained from the Johns Hopkins Bloomberg School 
of Public Health Institutional Review Board and the local ethical review board (In-
stitute of Medicine at Tribhuvan University/Nepal Health Research Council). 
Data collection 
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At baseline information was collected on household structure, socioeco-
nomic status, and demographics. At study enrollment, date of last menstrual pe-
riod and pregnancy history data were collected. As soon as possible after deliv-
ery the mother and infant were visited to collect detailed birth information includ-
ing infant weight and breastfeeding status. From birth through 6 months post-
partum infants were visited weekly by a field worker, who recorded any infant 
respiratory symptoms in the past 7 days. If an infant had any of the following 
symptoms a mid-nasal swab was collected: fever, cough, wheeze, difficulty 
breathing, or ear infection. Starting on August 17, 2012 new symptoms more 
specific for pertussis were added to the weekly morbidity visit: apnea, cyanosis, 
cough with vomit, or whoop/whooping cough. In addition to these signs, mothers 
were asked which, if any, vaccinations were received in the past 7 days. At 6 
months child anthropometry measures were taken for weight and length. 
Laboratory Assays 
Real-time PCR testing was conducted at the University of Washington’s 
Molecular Virology Laboratory according to previously published methods17.  
Two-target PCR was used to assess the presence of three Bordetella species: B. 
pertussis, B. parapertussis, and B. bronchiseptica. The two independent pertus-
sis sequence targets amplified were chromosomal repeated insertion sequence 
IS481 (IS) and the polymorphic pertussis toxin ptxA promoter region (PT). There 
were 2 sets of primers for PT to accommodate small differences (2 bases) be-
tween pertussis strains (used in combination for one PCR reaction).  
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The pertussis PCR assay used fluorescence resonance energy transfer 
SYBR green chemistry. The PCR cycle for PT amplification was as follows: 95°C 
for 3 minutes, followed by 45 cycles of 95°C for 10 seconds and 71°C for 45 sec-
onds. The PCR cycle for IS amplification was as follows: 95°C for 2 minutes, fol-
lowed by 45 cycles of 94°C for 30 seconds, 68°C for 30 seconds, and 72°C for 
30 seconds and then 72°C for 5 minutes for extension. After completion of the 
45th replication cycle, the melting points of the amplicons were measured in an 
iCycler (Bio-Rad).  
A sample was interpreted as positive when the targets described in Ap-
pendix 4.1 had a melting temperature within the acceptable range and a Ct ≤42. 
A sample was negative if none of the targets tested positive or a single positive 
target was not reproducible.    
Analytic Dataset 
Infants were included in this analysis if they were followed for any length 
(0 to 180 days) during a 2 year-period from August 17, 2011 to August 16, 2013. 
[Complete data from the trial is pending]. See Appendix 4.2 – Vaccine Delay 
Sample for detailed sample selection procedures. Of 3,689 women vaccinated, 
12 were missing a maternal delivery assessment (due to incomplete data entry at 
time of analysis) leaving 3,677 women with delivery assessment information. 
There were 5 maternal deaths, 9 miscarriages, and 4 abortions. Twenty-five twin 
pregnancies were excluded from the analysis. Of the 3,634 singleton births, there 
were 3,571 live births, 58 stillbirths, and 5 had missing birth information. Of the 
 185 
3,571 live singleton births, 336 were born outside of the specified pertussis co-
hort period (August 2011 through August 2013). The final dataset consists of 
3,325 infants with at least one follow-up visit during the first 6 months. 
At baseline, data on household structure was gathered, including age and 
sex of all household members. At enrollment women reported their literacy status 
(binary), years of education and pregnancy history. The field workers identified 
their ethnicity (Pahadi or Madeshi) from names and observation. For parity anal-
ysis women were categorized as nulliparous or multiparous. Responses to twen-
ty-five questions about household construction, water and sanitation, and house-
hold assets were used to develop a construct to measure the socioeconomic sta-
tus (SES) of households. Binary variables for each of the 25 questions were cre-
ated and a score from 0 to 25 was obtained. A percentage was created from this 
score. If some variables were missing responses, percentages were created us-
ing the number of responses available as the denominator. The percentages 
were then divided into SES quartiles for analysis. 
Gestational age was measured using a woman’s report of date of last 
menstrual period during pregnancy surveillance (an average of 3-4 weeks recall). 
Birthweight was collected as soon as possible after birth using a digital scale 
[Tanita model BD-585, precision to nearest 10g]. Birthweights collected >72 
hours after birth were excluded from the analysis of birthweight. Small for gesta-
tional age was calculated using the sex-specific 3rd percentile cut-off described 
by Oken18. Women were asked within how many hours of birth breastfeeding 
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was initiated (if any). Binary breastfeeding categories were created with women 
initiating breastfeeding within 1 hour compared to those initiating >1 hour post-
delivery. Anthropometry measures were calculated from the 6-month weight and 
length measurements. The z-scores for underweight (weight for age), stunting 
(length for age), and wasting (weight for length) were calculated using the WHO 
Child Growth Standards from the igrowup Stata package.  
Statistical Analysis 
Incidence was calculated as the number of pertussis cases per 1000 in-
fant-years at risk. 95% confidence intervals were constructed using Poisson ex-
act confidence intervals. Descriptions of pertussis episodes and of maternal, 
household, and infant characteristics of pertussis cases are presented. Charac-
teristics of all non-pertussis respiratory episodes were examined in comparison 
to pertussis episodes. T-tests were used to compare associations with continu-
ous predictors and Fisher’s exact test was used to compare categorical associa-
tions since the number of pertussis cases was small. Characteristics of pertussis 
cases were compared to non-pertussis cases. Continuous predictors were trans-
formed to dichotomous factors to calculate incidence rate ratios for pertussis risk. 
Statistical significance was set at p<0.05 for all testing. All statistical analyses 




3,235 infants had 3,605 episodes of respiratory illness [See Respiratory 
Illness Definitions Text Box] over a two-year period. The mean incidence of res-
piratory illness was 2.81 episodes per infant-year (95% CI: 2.72 – 2.91) with a 
range of 0 to 8 episodes per child during a maximum of 6 months follow-up. Epi-
sode duration averaged 4.74 days (95% CI: 4.62 – 4.87). 424 episodes were not 
matched to a nasal swab and 323 nasal swabs were not tested by PCR for per-




Seven cases of Bordetella pertussis were identified from 8 nasal swabs 
(nasal swabs were positive on two consecutive weeks for one infant) [Tables 
4.1A-C]. The incidence of PCR confirmed B. pertussis was 5.2 cases per 1000-
infant years (95% CI: 2.09 – 10.71). Four cases of Bordetella parapertussis were 
detected with incidence 3.0 cases per 1000 infant-years (95% CI: 0.81 – 7.60) 
[Tables 4.2A-C]. No cases of Bordetella bronchiseptica were identified. 
Bordetella pertussis 
The average pertussis episode duration was 13 days [Table 4.3]. Mean 
age of onset of pertussis symptoms was 72 days with a range of 19 to 109 days. 
Respiratory Illness Definitions 
Year 1 - Experienced at least one of the following symptoms: 
cough, wheeze, difficulty breathing, fever or ear infection. 
Year 2 – Any of the symptoms from year 1 or any of the fol-
lowing: cyanosis, apnea, cough with vomit, whooping 
cough/whoop. 
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The most common symptoms were fever, cough, and wheeze. None of the in-
fants were reported to have an ear infection, cyanosis, or apnea. We added addi-
tional symptoms related to pertussis in year 2 (cyanosis, apnea, cough with vom-
it, and whoop) however none of those yielded additional nasal swabs beyond 
those already collected for the year 1 symptom list (fever, cough, difficulty breath-
ing, wheeze, and ear infection). All cases with the exception of one occurred be-
tween March and June of 2013. Three of the infants had one pertussis vaccina-
tion prior to disease onset although the spacing was short at 5, 16, or 22 days 
[Table 4.1C]. Comparison of infant characteristics in the population to pertussis 
cases showed some differences although none were statistically significant [Ta-
ble 4.4]. Given that our study does not have adequate power due to low number 
of pertussis cases the lack of a statistical association is not evidence of non-
association. Episode symptoms and timing were compared between pertussis 
positive episodes and pertussis negative episodes. Longer episode duration 
(p<0.001) and presence of a whoop (p=0.047) were the only statistically signifi-
cant characteristics associated with a pertussis episode. 
Bordetella parapertussis 
The average parapertussis episode duration was 4 days [Table 4.2A]. 
Mean age of onset of symptoms was 49 days with a range of 7 to 71 days. The 
most common symptoms were cough and wheeze. All parapertussis cases oc-
curred during the first year of follow-up (none in year 2). 
Bordetella bronchiseptica 
 189 




Low incidence of pertussis and generally mild case presentation was 
found in infants <6 months in Nepal. To our knowledge this was the first popula-
tion-based active surveillance of PCR confirmed pertussis in infants in Asia. 
While truly comparable data are sparse, the acellular pertussis vaccine trials 
conducted in the 1990s found the average pertussis incidence in the whole cell 
vaccine groups ranged from 1 to 37 cases per 1000 infant-years14,19-24. Our find-
ing of 5 B. pertussis cases per 1000 infant-years was on the lower end of this 
range. Further, given our highly sensitive case detection method, many of our 
pertussis cases would likely not have been detected in the previous trials. More 
stringent respiratory symptom criteria would have lowered our incidence estimate 
even further. These data support the WHO’s recommendation that countries us-
ing whole cell pertussis vaccine continue to do so given the pertussis resurgence 
has not been equally distributed and most outbreaks have been concentrated in 
countries using the acellular pertussis vaccine3. Recent studies also suggest that 
protection from acellular pertussis vaccine is not as strong or long lasting as that 
conferred by the whole cell pertussis vaccine5,6,25-29. Another contributing factor 
to the low pertussis incidence observed could be that we conducted the surveil-
lance during a period of low pertussis burden. Pertussis is a cyclical disease, 
thought to peak every 2 to 4 years, and we may have captured the burden at a 
low circulation period 6.  
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We observed almost 90% of our cases in a five-month period between 
February and June 2013. Only 1 case was observed in 2012 (February) but the 
case occurred in the same time window observed in 2013. The increase in cases 
in 2013 could indicate an upward trend of pertussis from a low in 2012. Previous 
research on pertussis seasonality has been mixed, with studies in different plac-
es and time periods demonstrating various periods of peak transmission or no 
discernable patterns30-35. While our data support a seasonal pattern, the numbers 
observed are too low to be conclusive. 
Pertussis symptom duration and severity were on average mild compared 
to the classic pertussis case presentation. While all cases were multi-target PCR 
confirmed, only two of the seven cases fulfilled the WHO criteria, which requires 
a minimum of 2 weeks of cough, whoop, or post-tussive vomiting36. One pertus-
sis case had symptoms reported for only 2 days. Studies on pertussis in infants 
have generally been clinic-based, hospital-based, or in an outbreak which there-
fore required a certain severity of illness for parents to recognize a need for med-
ical attention37,44. These study designs and passive surveillance efforts therefore 
may have missed milder pertussis cases. Our study, which required only 1 res-
piratory symptom for a nasal swab to be collected, had increased sensitivity to 
detect a range of pertussis case presentations. An alternative explanation for the 
mild cases seen could be an increase in the proportion of mild compared to se-
vere pertussis cases in Nepal. We do not have previous comparable data from 
Nepal with which to compare our findings. 
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While cough and wheeze were the most common symptoms, neither were 
present in all B. pertussis cases. During an epidemic period in Washington state 
(2002-2007) infants <1 year, who had a minimum of 14 days cough plus an addi-
tional symptom had the following symptom prevalence: 82% post-tussive emesis, 
29% apnea, 26% whoop and 42% cyanosis37.  A study of U.S. neonates with per-
tussis showed the symptom prevalence to be 97% for cough, 91% for cyanosis, 
58% for apnea, and 3% for fever38. In comparison our study found lower or equal 
symptoms prevalence with the exception of fever (fever prevalence was higher in 
our study); however our numbers are too low to make direct comparisons and the 
age groups, while similar, are not exact. 
The incidence of B. parapertussis was lower than for B. pertussis although 
the difference was not statistically significant. Our incidence of 3.0 cases per 
1000 person-years was comparable to that of 2.1 per 1000 person-years found in 
the Italian acellular pertussis vaccine trial in 1992-9322,39. The duration of illness 
was shorter for B. parapertussis with a maximum duration of 6 days compared to 
a maximum of 33 days for B. pertussis. A milder presentation is consistent with 
clinical knowledge of B. parapertussis infection39-41. B. parapertussis cases oc-
curred in a later season (September through February) than for B. pertussis 
(February through June). 
The low number of pertussis cases detected limited our ability to statisti-
cally test for differences between (1) respiratory episodes with confirmed pertus-
sis versus all respiratory episodes and between (2) pertussis and non-pertussis 
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cases. While the differences were not statistically significant pertussis episodes 
were more likely (>10% absolute difference) to include cough, wheeze, cough 
with vomit, and whoop compared to all respiratory episodes [Table 3]. The aver-
age pertussis episode was longer (13 days versus 5 days) than all respiratory 
episodes. For pertussis cases it was observed that pertussis infants were lower 
birthweight, younger gestational age, and had older age at first pertussis vaccina-
tion although the differences are not confirmed with statistical testing. Further, 
mothers of infants who experienced pertussis were more likely to be literate, pri-
miparous, and Pahadi ethnicity. 
Limitations 
There were several study design limitations. Pertussis is a cyclical dis-
ease, thought to peak every 2 to 4 years42. While we captured a full two years of 
surveillance data we may have captured the burden at a low period in its cycle. 
We assumed when B. pertussis and B. parapertussis were isolated they 
were the causative agent of the respiratory symptoms triggering the nasal swab. 
However, we cannot be certain whether pertussis caused the exhibited symp-
toms, another organism triggered the illness or if symptoms were related to two 
or more etiologic agents.  While co-infections with B. pertussis and B. paraper-
tussis have been widely documented33,43-48 there is mixed evidence for pertussis 
residing in the naspharynx of healthy individuals or long-term pertussis car-
riage29,49-51. Future analysis of the data (once available) will include an examina-
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tion of pertussis co-infection with influenza, RSV, and potentially other respiratory 
viruses. 
Our study was based within a randomized controlled trial of influenza vac-
cination in pregnancy for which sample size calculations and data collection 
methods were developed. Given the observed number of pertussis cases seen 
and the limit to our sample size we were unable to performed pre-specified statis-
tical testing for characteristics associated with pertussis disease and pertussis 
cases.  
Parents, rather than trained clinicians, reported the respiratory symptoms 
in their infants. Parents may have missed signs that otherwise would have been 
observed by a health care worker. However, the criteria for collection of the nasal 
swab were quite broad and largely did not require sophisticated clinical skills. 
Apnea and cyanosis however may have been difficult for parents to identify. In 
the first year of surveillance pertussis-specific symptoms were not included in the 
weekly morbidity assessment. To increased pertussis detection sensitivity addi-
tional pertussis-specific symptoms were added in year two, which included ap-
nea, cyanosis, cough with vomit, and whoop. While the addition of these symp-
toms expanded our clinical description of cases, these additions did not lead to 
any additional nasal swabs collected, over and above those triggered by the 
symptoms collected over the first year of the study. No infant experienced a per-
tussis-specific symptom in isolation without also having one of the originally 
specified respiratory symptoms. These data support our assumption that we 
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were unlikely to have missed pertussis cases in year one with our less sensitive 
respiratory symptom criteria. 
Nasal swabs were collected in the mid-nasal region for the primary pur-
pose of influenza virus detection. The mid-nasal area was selected as influenza 
is able to be isolated from this area and this procedure is less invasive and caus-
es less discomfort than nasopharyngeal area collection. In a field site (non-
clinical setting) the acceptability of multiple nasopharyngeal swabs in a home set-
ting would likely be limited and increase participant refusal rate. This would have 
decreased the generalizability of our results to the entire population. Currently, 
the mid-nasal region is not recommended as a specimen collection site for per-
tussis. Nasopharyngeal swabs or nasopharyngeal aspirates are the recommend-
ed specimen collection method52-54. However, the nasopharyngeal region was 
established as the collection area of choice when the sole diagnostic measure 
was culture, which has low sensitivity. No published studies to-date specifically 
examined the feasibility of mid-nasal swabs for pertussis using the highly sensi-
tive PCR diagnostic method17,55,56. One study tested nasal swabs for pertussis 
with 40% testing positive (no gold standard for comparison), demonstrating the 
possibility of detecting pertussis in the mid-nasal region57. A study by our collabo-
rators, currently under peer review, found that pertussis isolation from nasopha-
ryngeal swabs was comparable to that from the mid-nasal region at Seattle Chil-
dren’s hospital from 2011-201258. Our study was able to isolate pertussis DNA 
from the mid-nasal region. A limitation of our study is that the collection area may 
have lowered the sensitivity of pertussis detection. However, given the un-
 196 
published results from Washington we believe the isolation method is adequate 
for pertussis identification. 
Strengths 
Strengths of the study are that it was a population-based, prospective 
study, with very low refusal rates that identified risk factors and clinical symptoms 
without the potential bias that may occur when these data are collected retro-
spectively. The community-based design allows generalizability of these results 
to the entire population and not just those seeking care at a health facility or 
those in an outbreak situation. Sarlahi district, located in the terai region where 
the majority of Nepalese reside, has similar demographics to the entire popula-
tion. Sarlahi’s location near sea level and on the border with India supports the 
generalizability of these results to many populations living on the Indian subcon-
tinent59. The weekly active surveillance with sensitive criteria for pertussis testing 
was able to detect mild and atypical pertussis cases, which may have been 
missed by previous traditional surveillance. The multi-target PCR method allowed 
highly sensitive and specific detection of two additional Bordetella species be-




An epidemic level of pertussis seen in some countries was not observed in 
Nepalese infants. Whole cell vaccine appears to be protective of infants in this 
environment given the low incidence of pertussis during the study period. Pertus-
sis cases were generally milder than expected compared to traditional pertussis 
clinical definitions. These data support clinicians considering pertussis in their 
differential diagnosis of infants with mild respiratory symptoms. Policy-makers in 
Nepal will need to weigh the benefit of an additional prenatal pertussis vaccine or 
a switch to acellular primary pertussis vaccine with the low burden of pertussis in 
infants less than 6 months.  
Our study demonstrated that mid-nasal swabs are able to isolate pertussis 
for detection by multi-target PCR. Further research is needed comparing the mid-
nasal to nasopharyngeal isolation areas. The less invasive mid-nasal nasal swab 
is an attractive alternative for pertussis nasal swab collection. This method may 
in the future enhance population-based surveillance efforts, which are limited in 





































Table 4.1A-C Footnotes: 
A – Infant had 2 positive nasal swabs associated with this pertussis episode; all 
other infants had only 1 positive nasal swab 
B - Cyanosis, apnea, whoop, and cough with vomiting were asked in year 2 only 
so this infant does not have this data 























Table 4.2A-C Footnotes: 
A – SES - 4th = top income 
bracket 





















































































































































































































































































































































































































































































































Male Sex - no (%) 1,708 53% 3 43%
Gestational Age - weeks 39.5 ± 3.7 38.6 ± 2.1
Birthweight - (g) 2791 ± 496 2502 ± 408
Small-for-Gestational Age - no (%) 694 27% 2 40%
Age at 1st Pertussis Vaccine - days 83 ± 35 98 ± 36
6 Month Underweight - (z-score) -0.78 ± 3.66 -1.37 ± 1.38
6 Month Stunting - (z-score) -0.87 ± 1.39 -0.85 ± 0.83
6 Month Wasting - (z-score) -0.34 ± 2.76 -1.13 ± 1.45
Mom Age - years 23.5 ± 4.7 23.1 ± 7.2
Breastfeeding in 1st Hour - no (%) 1,106 35% 2 40%
Literate - no (%) 1,730 60% 6 86%
Primiparous  - no (%) 1,186 41% 5 71%
Pahadi Ethnicity - no (%) 1,697 58% 5 71%
Highest quaritile SES - no (%) 680 23% 1 14%
Household Number 8.6 ± 4.2 9.3 ± 5.9
Children under 15 years 2.5 ± 2.1 0.9 ± 1.1
Children under 5 years 1.2 ± 1.3 2.9 ± 3.1
* Plus–minus values are means ±SD. 
** Pertussis Cases are included in total population
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Appendix 4.1  
  
Primer Type and Name Sequence
Amplicon 
Length (bp) B. pertussis B. parapertussis B. bronchiseptica
IS481  (IS) 182 85-86°C - -
IS-F GATTCAATAGGTTGTATGCATGGTTC
IS-R TTCAGGCACACAAACTTGATGGGCG






 PCR primer targets and Melting Temperatures
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3,689 women vaccinated 
	




5 maternal deaths 
	
12 women have no MBAF 
	
3,571 live singleton births 
	
3,235 infants with at least one weekly morbidity visit during study period 
 






1 unknown birth status 
	
4 infants with no birth assessment 
	
332 infants with no follow-up between August 17, 2011 and August 16, 2013 
 
25 twin pregnancies 
	
3,605 episodes of ILI 
 
Infant Nasal Swabs 
 
424 episodes not matched to a nasal swab 
 
























6 nasal swabs 
	
323 nasal swabs missing PCR test results 
 
2,925 episodes of ILI matched to 1 or more nasal swabs with PCR test result 
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Background: Pertussis is estimated to cause 2% of childhood deaths globally 
and is a growing public health problem with infants at greatest risk of morbidity 
and mortality. Maternal vaccination during pregnancy may be effective to prevent 
pertussis in young infants but an understanding of pertussis antibody levels and 
the efficacy of maternal to infant antibody transfer in a low-income South Asian 
setting is lacking. 
Objective: To estimate the level of pertussis toxin antibody and the efficiency of 
its transfer from mothers to infant in Sarlahi District, Nepal.  
Design/Methods: Nested within a randomized controlled trial of influenza vac-
cination during pregnancy, a subset of paired mothers and infants’ blood samples 
were collected at delivery. Serum was tested for pertussis toxin (PT) antibodies 
using an ELISA. PT antibody levels and the maternal to infant transfer efficiency 
were estimated. 
Results: The PT infant to mother ratio was 1.1 (95% CI: 1.0 – 1.2) for 131 moth-
er-infant pairs. Mother and infant pairs with detectable PT antibody were corre-
lated but the majority of mothers and infants had antibody levels below the level 
of quantification 
Conclusions: Maternal and infant PT antibody levels were low in rural Nepal. 
While overall transport was active and there was an association between mother 
and infant PT antibody levels, a large proportion of infants had antibody levels 
below their mother’s level. Maternal immunization could be an important interven-
tion to support infant pertussis immunity before infants are fully vaccinated.  
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Introduction 
Epidemic levels of pertussis have been reported in several countries in re-
cent years1-8. Age groups particularly affected include infants and adoles-
cents9,10. The resurgence of infant pertussis is of greatest concern as infants are 
at highest risk for severe morbidity and mortality compared to other age 
groups3,11,12.  
Several strategies are available to protect infants in countries where 
booster acellular pertussis vaccines widely used. Adolescent vaccination pro-
vides immune boosting to reduce the number of susceptible persons who might 
transmit pertussis to infants although its effectiveness in protecting infants is un-
clear13. Parents and close caregivers are most likely to infect infants14; vaccinat-
ing these close contacts as a cocooning strategy has also been implemented. 
High vaccination costs, feasibility of vaccinating all contacts, and lack of demon-
strated efficacy continue to hamper efforts3. The most promising strategy to pro-
tect infants is vaccination of women during pregnancy so they are able to pas-
sively transmit pertussis antibodies through the placenta during gestation and 
breastmilk after birth15,16. Randomized control trials of pertussis vaccine in preg-
nancy were recently conducted in the United States17 and Canada18.  
While several studies have examined the level of pertussis antibodies in 
mothers and infants and the efficacy of transfer19-27, none of these has been 
conducted in a whole-cell vaccine using low-income country where malnutrition 
and prematurity are high. The goal of our study was to quantify maternal and in-
fant pertussis toxin (PT) antibody and the transfer efficacy in a south Asian set-
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ting. Maternal immunization may be a promising strategy to protect infants in this 
setting but a better understanding of population-level maternal antibody, the effi-
cacy of transfer to infants, and factors which modify these levels is needed to in-












Settings and population 
The setting of the study was Sarlahi District, located in the central terai 
(low lying plains) region of Nepal. The study was nested within a randomized 
controlled trial of maternal influenza vaccination during pregnancy. At the start of 
the trial, prevalent pregnancies were identified through a survey census of all 
households in the catchment area. The head of the household was read an in-
formed consent script and asked for consent to participate in the trial. For the du-
ration of the trial field workers visited all households in the community where 
married women (15 – 40 years) resided every 5 weeks for surveillance of incident 
pregnancies. Once a pregnancy was identified women were asked for their indi-
vidual consent to participate in the trial. Over a two-year period between April 25, 
2011 and April 24, 2013 women between 17-34 weeks gestation were enrolled 
and randomized to receive either an influenza vaccine or placebo. Due to ran-
domization of gestational age at vaccination, the last participant enrolled in the 
trial received their vaccine allocation September 9, 2013. All participants received 
ancillary benefits, which included a 90-day supply of iron-folic acid tablets, de-
worming medicine (single dose of albendazole), clean birthing kit, chlorhexidine 
ointment for umbilical cord care, a tetanus toxoid vaccine, if indicated, and health 
education messages, in addition to antenatal services according to the local 
standard of care. The study was a prospective cohort of mother-infants pairs. 
Approval for the study was obtained from the Johns Hopkins Bloomberg School 
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of Public Health Institutional Review Board and the local ethical review board (In-
stitute of Medicine at Tribhuvan University/Nepal Health Research Council). 
Data Collection 
At baseline, information was collected on household structure, socioeco-
nomic status, and demographics. At study enrollment, date of last menstrual pe-
riod and pregnancy history data were collected. A sterile plastic container was 
left with the mother prior to delivery. Mothers were requested to collect at least 2-
5cc of umbilical cord blood as soon as the placenta was delivered. The mothers 
then notified the local study team member of the birth so a trained worker could 
visit the house to collect the birth information, cord blood, and infant weight. For 
mothers who delivered in health facilities in the area, facility staff obtained cord 
blood, which was then collected by study staff for normal processing. The blood 
was transported on ice to the central field-processing laboratory where it was 
centrifuged after sufficient clotting. Sera was removed, aliquoted into cryovials 
and placed in liquid nitrogen. Maternal blood was collected from approximately 1 
week post-partum. Venous blood (~5cc) was collected from mothers’ arms and 
processed using the same technique as the infant cord blood. Serum samples 
were stored and shipped to the United States at -80° Celsius. 
Laboratory Assays 
The immunoglobulin G (IgG) anti-PT enzyme-linked immunosorbent assay 
(ELISA) was performed at Vanderbilt University School of Medicine according to 
previously described methods28. The reference standard was pertussis antiserum 
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(human), lot 3 (CBER3 [US Food and Drug Administration]). The lower level of 
quantification (LOQ) was 10 ELISA(EU)/mL.  
Analytic Dataset 
Mother-infants pairs were included in this analysis if they both had a deliv-
ery time point blood sample collected. See Appendix 5.1 – Population Selection 
for detailed sample selection procedures. Of 1,426 unique maternal and infant 
blood samples at delivery there were 908 maternal delivery and 518 infant cord 
blood samples. 637 mothers and 464 infant samples were matched to records of 
maternal vaccination and infant birth assessment. For 487 of these samples only 
the mother or infant were available (non-paired). The resulting 614 paired sam-
ples (307 pairs) had testing completed for 262 samples (131 pairs). Complete 
data from the trial including testing of the remaining 352 samples are pending. 
At baseline, data on household structure was gathered, including age and 
sex of all household members. Binary variables for household density were cre-
ated for all household members (>10 persons), those less than 15 years (>3 chil-
dren under 15 years), and those less than 5 years (>1 child under 5 years). At 
enrollment women reported their literacy status (binary) and pregnancy history. 
The field workers identified their ethnicity (Pahadi or Madeshi) from names and 
observation. For parity analysis women were categorized as nulliparous or mul-
tiparous. Responses to twenty-five questions were used to develop a construct to 
measure the socioeconomic status (SES) of households. The results were aver-
aged and divided into SES quartiles for analysis. 
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Gestational age was measured using a woman’s report of date of last 
menstrual period during pregnancy surveillance (an average of 3-4 weeks recall). 
Gestational ages <37 complete weeks were categorized as preterm. Birthweight 
was collected at the home as soon as possible after birth using a digital scale 
[Tanita model BD-585, precision to nearest 10g]. Birthweights collected >72 
hours after birth were excluded from the analysis of birthweight. Infants were cat-
egorized as low birthweight if weight was <2500 grams. Small for gestational age 
(SGA) was calculated using the sex-specific 10th percentile cut-off described by 
Alexander29.  
Statistical Analysis 
Individual Mother and Infant Antibody Titers 
PT Antibody levels below the LOQ were assigned one-half of the assay 
LOQ (5 EU/mL). Geometric mean concentrations (GMC) and bootstrapped-
derived 95% confidence intervals were constructed separately for mothers and 
infants. Reverse cumulative distribution curves were created to visualize and 
compare the distribution of log transformed antibody titers for mothers and in-
fants.30 To examine differences in PT levels by infant, maternal, and household 
characteristics, non-parametric testing was performed for binary (Wilcoxon rank 
sum test with continuity correction) and nominal (Kruskal-Wallis rank sum test) 
variables. For this testing, continuous predictors were transformed to dichoto-
mous and nominal factors. Bivariable and multivariable logistic regression mod-
els were used to assess the association of risk factors with the presence of PT 
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antibodies separately for mothers and infants. Antibody was modeled as a binary 
outcome as the distribution remained non-normal after log transformation. 
Infant to Mother Antibody Ratio 
The ratio of infant to maternal PT GMC was calculated both for all mother-
infant pairs and for the subset of mother infant pairs where at least one of the 
pair had an antibody level above the LOQ. This subset therefore excluded pairs 
where both mother and infant had antibody level below the LOQ. Additional anal-
ysis of the transfer ratio was restricted to the pairs in this subset. 
Spearman’s rank correlation rho was calculated for the correlation of 
mother and infant PT antibody. Unadjusted and adjusted linear regression mod-
els were developed for examining the association of log ratio of infant to maternal 
PT antibody levels with infant, maternal, and household characteristics. 
The cutoff for statistical significance in all testing was p<0.05. All statistical 




Maternal and Infant Antibodies 
Maternal post-partum and infant cord blood were collected from 131 
mother-infant pairs between May 12, 2012 and August 12, 2013. The range of 
maternal blood collection was 5-141 days post-partum; infant collection ranged 
from day of birth to 6 days post-birth. The majority (71%) of women delivered in a 
health facility. Infant PT GMC was 11.5 (95% CI: 9.8 – 13.5) EU/mL [Range 5 – 
258]. Maternal PT GMC was 10.6 (95% CI: 9.0 – 12.4) EU/mL [Range 5-145]. 
The majority of mothers and infants had PT antibody below the lower level of 
quantification (LOQ), 10 EU/mL. Forty-three percent of infants and 40% of moth-
ers had antibody above our LOQ [Figure 5.1]. Five mothers (3.8%) in our sample 
had PT IgG >100 EU/mL, indicative of recent pertussis infection. 
Mothers 
Mothers who were illiterate and of Madeshi ethnicity had statistically signif-
icantly higher PT antibody than mothers who were literate or Pahadi ethnicity 
[Table 5.1].   
Illiteracy and Madeshi ethnicity were the only two characteristics associat-
ed with presence of maternal PT antibody in bivariate logistic regression models 
[Table 5.2]. In a multivariate model adjusting for all potential predictors, literacy 
remained statistically significant with literate mothers having a 75% (95% CI: 32-
91%) decreased odds of having detectable PT antibody compared to mothers 
who were illiterate. Infant gestational age was also associated in the multivariate 
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model. For every week increased infant gestational age, mothers had 27% (95% 
CI: 2 – 62%) increased odds of having detectable PT antibody. 
Infants 
No statistically significant differences in infant PT antibody levels were 
found by infant, maternal, or household characteristics [Table 5.1]. 
In a bivariate logistic regression model for presence of PT antibody, gesta-
tional age was the only significant predictor of antibody presence in infants [Table 
5.3]. Infants born at one week greater gestational age had 23% (95% CI: 5-47%) 
increased odds of having detectable PT antibody compared to infants born a 
week prior. In an adjusted model, while the gestational age odds ratio estimate 
remained the same it was no longer statistically significant. 
Association of Maternal and Infant Antibodies 
The placental transfer estimate was 1.1 (95% CI: 1.0 – 1.2), indicating ac-
tive antibody transport from mothers to their infants [Table 5.4]. A total of 62 
mother-infant pairs had at least one of the pairing (mother or infant) with antibody 
above the LOQ. In this subset of 62 pairs, placental transfer was 1.2 (95% CI: 1.1 
– 1.4). Active transfer, equal transfer, and negative transfer were found for 62%, 
2%, and 35% of pairs respectively. Maternal and infant antibody levels were 
highly correlated (Spearman’s rank correlation, 0.82 (p<0.0001)), excluding pairs 
where both had non-detectable PT antibodies) [Figure 5.2]. 
Figure 3 shows the relationship between antibody transfer and maternal, infant, 
and household characteristics. In an unadjusted linear regression model of the 
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log-transformed transfer ratio, maternal literacy and higher gestational age were 
the only variables associated with statistically significantly higher antibody 
transport [Table 5.5]. For each week of increasing gestational age the ratio of in-
fant to maternal antibody had an absolute increase of 8% (95% CI: 0-16%). In 
the multivariable model literacy remained statistically significant with transfer for 
literate mothers 57% (95%: 2-139%) higher than for illiterate mothers. Similar to 
the multivariable logistic model for presence of PT antibody in mothers, gesta-
tional age had a similar estimate compared to the bivariate model but did not 




Antibody transfer was low with an infant to maternal PT IgG ratio of 110%.  
While the majority of pairs with detectable level of PT antibody had active 
transport from mother to infant, a sizeable minority of infants (35%) had lower PT 
antibody than their mothers. IgG is transferred from mother to fetus through the 
placenta beginning at approximately 16 weeks gestation, increasing until deliv-
ery20,31,32. Studies from the 1940s found low efficiency of maternal to infant PT 
IgG transport with only 2-12% of newborns having higher antibody levels than 
their mothers31. Mothers who previously contracted pertussis or were immunized 
with whole cell pertussis vaccine during pregnancy gave birth to infants with the 
highest pertussis antibody titers.  Recent studies have found a strong association 
between mothers and infants with active PT antibody transport; PT antibody 
transfer ranged from 107-169% (excludes preterm infants in studies where only 
separate transfer ratios reported)19-27. While we found high correlation between 
mothers and infants, the transfer in our study population was on the lower end of 
expected values. Studies rarely publish the proportion of pairs with negative 
transport so we are unable to compare whether the 35% we observed is compa-
rable to other populations. 
Older gestational age and maternal literacy were associated with higher 
transport compared to infants born at younger gestational age and to illiterate 
mothers. The association of preterm birth with lower transport is consistent with 
previous research in a variety of populations21,25,33. A biological explanation for 
lower transport in preterm infants is that IgG transfer increases during gestation 
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leaving infants born earlier with less opportunity for maternal transfer25. Maternal 
literacy was associated with increased transport and remained the only signifi-
cant predictor even when controlling for several infant, maternal, and household 
characteristics. Maternal literacy likely has no biological impact on PT IgG trans-
fer but serves as a proxy for an unmeasured variable(s) directly influencing pla-
cental transfer. Other factors which have been associated with transport are ma-
ternal ethnicity, pertussis vaccination, HIV and health status23,24,33,34. We found 
no difference in transport by sex, birthweight, parity, ethnicity, number of house-
hold members or socioeconomic status. 
Sixty percent of mothers had PT antibody level below our level of quantifi-
cation. While not directly comparable, pertussis antibodies were detected in 30-
50% of women in the pre-vaccine era35,36, while a lower percentage of contempo-
rary women harbor high levels of pertussis antibodies19,37-39. A recent study in the 
U.S. found comparable levels to ours with only a fifth of women at delivery with 
PT antibody levels >5 EU/mL27. In Nepal, maternal antibodies are either due to 
lingering immunity from the childhood vaccination series or a previous pertussis 
infection. As there are no adolescent or adult boosters in Nepal high PT antibod-
ies in mothers are likely due to recent infection. Approximately 4% of mothers 
had antibody levels, which suggest a recent pertussis infection. While there is no 
serological correlate of immunity, PT IgG antibody titers above 100 EU/mL are 
considered indicative of recent infection40,41.  
Women of Madeshi ethnicity or those who were illiterate were more likely 
to have detectable and higher levels of PT antibody than mothers who were Pa-
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hadi or literate. In our adjusted model literacy remained statistically significant 
and increased infant gestational age was associated with higher maternal anti-
bodies. One explanation could be that the Madehsi and illiterate population have 
lower health status and therefore are more susceptible to pertussis infection. By 
contracting pertussis themselves, these mothers have higher antibodies than 
mothers who remained pertussis uninfected. While infant gestational age cannot 
causally link to maternal PT levels we found an association of older gestational 
age with increased odds of maternal PT antibody. Potential unmeasured con-
founders might affect both gestational age and maternal antibody thus resulting 
in the association observed.  The literature on risk factors for maternal PT anti-
body levels is sparse. Mothers with a chronic disease(s) were found to have low-
er PT antibodies than mothers with no chronic health condition39. However, HIV 
infection was not shown to be associated with lower PT antibodies compared to 
those mothers who are HIV negative23. 
Over half of infants had PT antibody levels below our level of quantifica-
tion. Infant PT antibody at birth is the result of maternal placental transfer during 
gestation and is dependent on the maternal level. A recent study found only a 
quarter of infants at birth had PT antibody > 5 EU27. Passively derived PT anti-
bodies in infants can protect newborns from pertussis until they are able to be 
vaccinated themselves42.  The low level seen likely indicates that the majority in-
fants are susceptible to pertussis from birth. 
No characteristics were associated with the level of PT antibody in infants. 
In a model for the presence of PT antibodies gestational age was the only factor 
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associated with increased odds for detectable PT antibody. Factors previously 
shown to decrease infant PT antibody titers were lower maternal age, maternal 
HIV infection, and being born preterm21,23,25,27,33. Infants whose mothers have 
higher antibody levels due to recent infection or vaccination have higher antibody 
levels than infants of unexposed or unvaccinated mothers24,27,43. Pre-term infants 
have lower antibody concentrations compared to term infants21,25,33. Pregnancy 
history, occupation, education, ethnicity, marital status and number of household 
members have previously been found to have no association with infant PT anti-
body levels27. The effect of maternal age on infant antibody levels is mixed with 
some studies showing an association with increased maternal age and higher PT 
antibody23,27. Our results showing gestational age is the primary factor for the 
presence of PT antibodies are consistent with these prior studies.  
 One limitation of our study is that we only measured antibodies to PT and 
did not measure antibodies to other antigens thought to be important in pertussis 
infection including filamentous hemagglutinin (FHA), pertactin (Prn), fimbriae 
(FIM) type 2 and type 3. With limited resources, PT was chosen as the primary 
antigen of choice given its specificity to pertussis in comparison to other candi-
dates, which can be stimulated by other similar pathogens and its central im-
portance to pertussis pathogenesis44 Recently available funding will allow future 
analysis of these samples for FHA, Prn, and FIM. 
 Another limitation is that while our target population was population-based, 
the study is a convenience sample of those for which we collected paired mother 
and infant blood. Our results may not be representative of the entire community if 
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the samples are from a skewed distribution of the population, which was more 
likely to have blood collected.  
Our sample size was limited in this initial analysis. When complete trial da-
ta are available we will have more than twice the sample size presented here. 
The power of our study to detect associations with PT antibody and transfer will 
be increased. 
 A third limitation is that we cannot assess whether the antibody levels ob-
served are associated with protection from pertussis. While some classification 
levels have been described for PT IgG for protection and recent infection, there is 
no universal level for comparison of our results to those of other studies40 
 Strengths of this study are that it was a large study of paired infant and 
maternal pertussis antibody levels in a setting of whole cell pertussis vaccination. 
This was the first study, to our knowledge, to be conducted in a rural South Asian 
setting. Further it captured several infant, maternal and household factors not 




Low PT antibody levels were found in mothers and their newborn infants 
in Sarlahi District, Nepal. When PT antibodies were present, the majority of trans-
fer was active between mothers and their infants. Despite high correlation be-
tween mothers and infants a substantial proportion of infants had lower levels 
than their mothers. If the infant disease burden in Nepal justifies increased inter-
ventions, maternal immunization could be an important tool to boost maternal an-




























































No (%) GMC p-value* GMC p-value
Sex 0.29 0.85
Male 71 54% 12.53 11.34
Female 60 46% 10.44 9.71
Preterm 0.13 0.28
Term 117 89% 12.16 10.93
Preterm 14 11% 7.36 7.96
Low birthweight 0.56 0.39
Normal birthweight 105 81% 11.57 10.74
Low Birthweight 24 19% 10.11 9.36
Small for Gestational Age 0.83 0.76
AGA 70 54% 11.11 10.72
SGA <10% 59 46% 11.50 10.17
Literacy 0.09 <0.01
Literate 74 63% 10.03 8.54
Non-literate 44 37% 14.55 15.72
Parity 0.52 0.52
Primiparous 47 41% 12.39 11.29
Non-primiparous 68 59% 10.66 10.04
Ethnicity 0.06 0.01
Pahadi 74 63% 9.87 8.82
Madhesi 44 37% 14.95 14.88
SES **0.07 0.22
Lowest Quartile 25 21% 16.35 15.16
3rd Q. 28 24% 7.76 8.11
2nd Q. 33 28% 14.25 12.20
Highest Q. 32 27% 9.95 9.15
Crowding - All 0.41 0.31
Crowded 45 38% 12.53 11.96
Uncrowded 73 62% 10.94 10.03
Children <5 0.38 0.25
Crowded 30 25% 12.57 12.11
Uncrowded 88 75% 11.19 10.29
Children <15 0.85 0.41
Crowded 26 22% 11.85 12.26
Uncrowded 92 78% 11.43 10.32
**Kruskal-Wallis rank sum test
Differences in PT Antibody by Groups





















OR p-value OR p-value
Female Sex 0.53 0.26 - 1.08 0.09 0.69 0.28 - 1.68 0.42
Gestational Age (weeks) 1.15 0.99 - 1.36 0.09 1.27 1.02 - 1.62 0.04
Birthweight (Kg) 1.34 0.59 - 3.13 0.49 0.87 0.18 - 4.29 0.87
SGA <10% 0.89 0.44 - 1.82 0.75 0.58 0.14 - 2.27 0.43
Literate 0.29 0.13 - 0.63 <0.01 0.25 0.09 - 0.68 0.01
Non-Primiparous 0.78 0.37 - 1.68 0.53 0.65 0.26 - 1.59 0.35
Pahadi Ethnicity 0.34 0.16 - 0.74 <0.01 0.49 0.19 - 1.27 0.14
Household number 1.11 1.00 - 1.23 0.05 1.06 0.93 - 1.21 0.36
SES** 0.88 0.63 - 1.23 0.47 1.14 0.70 - 1.87 0.60
*Full model inclusive of all variables: sex, gestational age, birthweight, SGA status, literacy status, 
primiparous status, ethnicity, household number, and SES
** Higher versus lower quartile
Logistic Regression for Presence of PT Antibody in Mothers
Unadjusted Adjusted*













OR p-value OR p-value
Female Sex 0.68 0.33 - 1.36 0.27 1.03 0.45 - 2.37 0.94
Gestational Age (weeks) 1.23 1.05 - 1.47 0.02 1.23 1.00 - 1.55 0.06
Birthweight (Kg) 1.36 0.61 - 3.15 0.45 1.21 0.28 - 5.39 0.80
SGA <10% 1.11 0.55 - 2.25 0.76 1.14 0.33 - 4.01 0.84
Literate 0.59 0.27 - 1.25 0.17 0.59 0.23 - 1.52 0.27
Non-Primiparous 0.87 0.41 - 1.84 0.71 0.82 0.36 - 1.88 0.64
Pahadi Ethnicity 0.59 0.27 - 1.25 0.17 0.78 0.32 - 1.92 0.58
Household number 1.09 0.99 - 1.21 0.09 1.08 0.96 - 1.22 0.20
SES** 0.90 0.64 - 1.25 0.53 0.93 0.59 - 1.44 0.73
*Full model inclusive of all variables: sex, gestational age, birthweight, SGA status, literacy status, 
primiparous status, ethnicity, household number, and SES
** Higher versus lower quartile
Logistic Regression for Presence of PT Antibody in Infants
Unadjusted Adjusted*
95% CI 95% CI
GMC GMC
Infant 11.53 9.78 - 13.50 29.20 23.71 - 35.83
Mother 10.56 9.03 - 12.36 24.29 19.68 - 29.83
Transfer Ratio 1.09 1.02 - 1.16 1.20 1.05 - 1.39
Infant to Mother Antibody Ratio
*Pairs where either the mother, infant or both had PT antibody levels above the lower 
level of quantification; excludes pairs where mother and infant were both below the 
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The original impetus for this research stemmed from estimates that the 
burden of pertussis disease in children was the highest in South Asia coupled 
with the existence of a pertussis vaccine that would theoretically be safe and ef-
fective in pregnancy for protecting infants from pertussis1,2. However, key pieces 
of information were missing. First, there were no population-based estimates of 
pertussis disease burden in South Asia. Second, only one Senegal-based study 
had followed infants from birth to actively monitor pertussis disease in early in-
fancy3. Third, the sensitivity of surveillance in prior studies was not high, poten-
tially resulting in unawareness of milder pertussis disease. Lastly, while serologi-
cal studies had been conducted in mothers and infants, most of these were con-
ducted in high and middle-income countries, whose environments are vastly dif-
ferent from much of South Asia where prevalence of prematurity and malnutrition 
are high. The purpose of the research was to understand the epidemiology of 
pertussis in early infancy in Nepal to inform whether the disease burden warrant-
ed increased interventions, namely maternal pertussis vaccination. 
The pertussis study harnessed the extensive resources of a maternal in-
fluenza vaccination trial and combined this infrastructure with a grant for pertus-
sis-specific research4. The innovative design allowed us to add to pertussis 
knowledge in several ways. First, this study applied one of the most sensitive, if 
not the most sensitive, surveillance published for capturing infant pertussis. 
Study workers, who lived in the local communities, visited each household in the 
study every week and collected a nasal swab if any respiratory symptoms were 
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observed in the infant in the past week. This is in contrast to previous studies, 
which have generally relied on phone follow-up or parental report, had a longer 
duration between follow-ups, and whose criteria for testing required a minimum 
duration of cough (exception is the Senegal study). The greater length from 
commencement of symptoms to testing decreases the sensitivity of laboratory 
testing5,6. The high frequency of visits coupled with the sensitive definition al-
lowed us to detect pertussis cases that would have been missed using traditional 
pertussis surveillance. Second, this is the only study of PCR-confirmed pertussis 
to our knowledge conducted in South Asia that is population-based. All popula-
tion-based data of PCR-confirmed pertussis to-date are from clinical trials con-
ducted primarily in high-income countries with the exception of Senegal. Lastly, 
all population-based PCR-confirmed pertussis studies published to-date (exclud-
ing the Senegal clinical trial) monitored infants after receipt of the first or most 
commonly the third pertussis vaccination. These studies therefore missed the pe-
riod in early infancy when infants are at highest risk for morbidity and mortality7-
11. Our study followed infants from birth through 6 months providing a more com-
plete dataset of pertussis incidence in infancy. 
We hypothesized we would find a higher incidence of infant pertussis than 
found in other settings where population-based active surveillance was used as 
the burden of childhood pertussis disease is estimated to be highest in South 
Asia1. Further, Nepal provides no pertussis booster doses in adolescents or 
adults as are routinely given in other settings. Moreover, we expected high delay 
in receipt of the primary pertussis vaccination series.  
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Contrary to expectations, our prospective, population-based cohort of in-
fants in Sarlahi, Nepal found a relatively low incidence of pertussis. The finding of 
low incidence was unexpected based on our original assumptions. However, 
since our research began, the published literature on pertussis epidemiology and 
vaccine research has increased dramatically. Reasons for this acceleration of 
pertussis research include increasing pertussis incidence combined with a move 
towards maternal pertussis immunization12. These recent data supports our find-
ings and provide a potential rationale for the low pertussis incidence observed. 
While pertussis incidence has gradually increased in the last two decades, 
the most recent four years have seen a dramatic jump in cases13. Infants and 
adolescent have experienced the most pronounced pertussis resurgence com-
pared to other age groups. Outbreaks have been reported in multiple high-
income countries14-21. Several factors have contributed to this increase including 
the switch from a whole-cell pertussis (wP) vaccine in high resource settings to 
an acellular pertussis (aP) vaccine3,22-27. Data from animal models and humans 
support the hypothesis of lower efficacy and shorter duration of protection for 
those partially or exclusively immunized with aP vaccines. The outbreaks have 
primarily occurred in aP vaccine settings. Our data are consistent as we found 
low incidence in Nepal’s wP vaccine setting. Moreover, low infant pertussis bur-
den was observed despite substantial delays in receipt of the primary pertussis 
vaccine series and overall low levels of maternal PT antibody levels. Over half of 
infants who contracted pertussis had received no pertussis vaccinations even 
though they all were eligible for at least one vaccination by the time of disease 
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onset. If vaccination delays were minimized and maternal pertussis antibody lev-
els were boosted, we would expect an even lower pertussis incidence in infants. 
The symptoms of infants with pertussis were generally milder than that 
expected by traditional pertussis case definitions. Detection of less severe cases 
was expected as the study used testing criteria that were more sensitive than 
previously used. This supports our understanding of pertussis as an underreport-
ed disease. However, the public health significance of this under reporting is un-
clear given the unreported cases are likely to be mild and cause limited morbidity 
compared to reported cases. These mild cases may play a role in disease trans-
mission to susceptible persons such as vulnerable infants. 
Over half of the mothers had PT antibody levels below the lower level of 
quantification. While PT antibodies were passively transferred to infants, infants 
often had a lower level of PT antibodies than their mothers. The low prevalence 
of PT antibodies would support a strategy to increase maternal pertussis antibod-
ies to protect mothers and their infants before they can be vaccinated them-
selves. An original goal of our study was to support a maternal pertussis vaccina-
tion strategy since there were no data or recommendation to vaccinate women 
during pregnancy. Since our study began there have been at least two random-
ized trials of aP vaccine in pregnancy of which the results are starting to become 
available12,28,29. In addition, in the U.S. and England, pertussis vaccination was 
recently recommended in pregnancy30,31. The support for these recommenda-
tions came not from the ongoing clinical trials but from the high risk infants faced 
during the pertussis resurgence in these countries. The Advisory Committee on 
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Immunization Practices (ACIP) advised that the risk of infant pertussis disease 
outweighed the theoretical risk of vaccine adverse events and should be recom-
mended in all pregnancies32. While data are being generated for aP vaccines in 
pregnancy in high-income countries, data are still lacking to support this strategy 
in other settings, such as Nepal, that have limited resources and need to invest in 
strategies for which evidence of cost effectiveness is compelling. 
Limitations 
 While our study had several limitations outlined in the individual studies, 
some key limitations should be highlighted. First, our infant follow-up ended at 6 
months. For comparability of our vaccination timing data to World Health Organi-
zation (WHO) reported coverage it would have been ideal to follow infants until at 
least 12 months of age. While we saw vaccination delay in the first 6 months, ex-
tending the surveillance would allow greater understanding of when the vaccines 
were actually received, given that high coverage is reported nationally at this 
age. 
 Second, one of our original aims was to conduct a case-control study 
identifying pertussis cases and controls and estimating the difference in their and 
their mother’s PT antibody levels at birth. When this idea was originally proposed 
no published study had examined the association between antibody level at birth 
and protection from clinical disease. Unfortunately, we were not able to collect 
blood specimens at birth from any of the infants who contracted pertussis and 
thus unable to complete this aim. In the interim however, there have been data 
published demonstrating clinical protection of disease associated with higher in-
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fant pertussis antibodies33. More data are needed on the efficacy of maternal 
vaccination in reducing infant pertussis. 
 A third limitation of our study was that mid-nasal swabs were collected in-
stead of the deeper nasopharyngeal swabs. Our method was non-standard (and 
based on the needs of the influenza study for the least invasive sampling meth-
od) but is supported by preliminary evidence in one study under review34. Guide-
lines for specimen collection were developed for testing by culture, which is sig-
nificantly less sensitive than PCR. Combined, the theoretical plausibility with the 
initial data support that we were able to capture all pertussis cases for which we 
took nasal swabs. However, until further data are collected we cannot be certain 
that we did not miss cases due to our specimen collection method. 
 Another important limitation was that our surveillance period for pertussis 
was limited to a two-year period. Pertussis is a cyclical disease, even in the vac-
cine era35. There is a potential that our surveillance captured pertussis burden 
during years of lower incidence. A longer surveillance period spanning several 
years would have been optimal to ensure we captured the peak and nadir of per-
tussis circulation. 
Future Research 
 While pertussis research has expanded in recent years there is still a need 
for additional data given pertussis’ changing epidemiology and new prevention 
strategies. Our initial findings lead to several research questions for further study. 
We have secured additional funding from the Bill and Melinda Gates Foundation 
 251 
to address some of our limitations and expand our pertussis research questions 
where indicated.  
 Future research should include comparing the sensitivity and specificity of 
PCR using mid-nasal specimens versus nasopharyngeal specimens. With ad-
vancements leading to PCR as the assay of choice to diagnosis pertussis there 
also should be commensurate work into the appropriate sampling region for the 
more sensitive PCR assay. Currently, health care workers must use the invasive 
and uncomfortable nasopharyngeal swab or aspirate, which may limit the ease 
and acceptance of testing in a community-based setting. If comparability studies 
confirm the initial finding of the acceptability of mid-nasal swabs this could ex-
pand the populations for which persons with suspected pertussis are tested thus 
reducing under diagnosis and under reporting. 
 Data on the safety, immunogenicity, and efficacy of aP vaccines in preg-
nancy are needed in a variety of settings. While we expect these data to be 
available in the near future for Canada and the U.S. there are no known planned 
studies in South Asia or other low-income settings. If the results from the current 
trials are in support of pertussis vaccine in pregnancy, efforts should be made to 
accelerate testing to expand access to this vaccine to low and middle-income 
countries.  The current trials are being conducted in settings where aP vaccines 
are used exclusively. Further research will be needed on whether an aP vaccine 
in pregnancy can be coupled with a wP childhood vaccination series. The WHO 
already recommends tetanus toxoid vaccine in pregnancy so adding an addition-
al target (acellular pertussis) to this vaccine would not add an additional immun-
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ization in pregnancy, or at least would not add another antenatal care visit for 
vaccination. 
 With emerging evidence showing that the aP vaccine has low efficacy and 
limited duration of immunity, researchers in vaccine development should work 
towards a vaccine that has a similar safety profile to the aP paired with the effec-
tiveness of the wP vaccine. A proliferation of studies in the past two years 
demonstrates the acceleration of pertussis vaccine development36-46.  
 Vaccine delay for pertussis vaccination was common in our study popula-
tion.  Groups at higher risk for non-vaccination in Nepal were children born SGA, 
mothers who delay initiation of breastfeeding, and mothers of Madeshi ethnicity. 
Further research is needed on which policies or interventions are effective in im-
proving timely vaccination uptake.  
 Our study contributes to the growing knowledge that the WHO metric of 
vaccination coverage does not adequately measure delays in time to pertussis 
vaccination nor do reported pertussis cases capture the true burden of disease. 
Research into methods to improve surveillance of pertussis disease and vaccine 
coverage should be pursued. A limitation of our study was that we only captured 
two years of surveillance. Additional funding will now allow us to test all of the 
nasal swabs collected during the larger trial, expanding our observation period to 
approximately 3 years. Data from a third year will decrease the possibility that 
our surveillance period was during a time of low pertussis incidence.  
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 Our original funding covered testing of antibodies to only one pertussis an-
tigen, pertussis toxin (PT). Funding from the Bill and Melinda Gates Foundation 
will allow us to conduct ELISA testing on three additional pertussis antigens – fil-
amentous hemagglutinin (FHA), pertactin (Prn), and fibriae (FIM). Since no one 
antigen can be correlated to pertussis immunity, having antibody levels to the 
four antigens most commonly used in acellular pertussis vaccines will provide a 
more comprehensive set of data on maternal and infant pertussis-related anti-
bodies. 
 In addition to passive transfer of antibodies through the placenta during 
gestation infants are also able to receive maternal antibodies during breastfeed-
ing in infancy. There are limited data on the level of PT breastmilk IgA and its role 
in infant protection47-51. Supplemental funding will allow us to test previously col-
lected breastmilk samples from the same women who we have already tested at 
the delivery time-point blood for pertussis antibodies in breastmilk. While we will 
not be able to correlate breastmilk antibody levels with infant pertussis disease 
we will be able to look at the association of breastmilk antibody with maternal se-
rum antibody levels. 
Policy Implications 
 Several recommendations to policy makers in Nepal follow from this re-
search. First, increased emphasis is needed on vaccination timeliness in the first 
year of life as a complement to high vaccination coverage at 12-23 months. Our 
data show there is substantial delay for pertussis containing vaccines that likely 
extends to other childhood immunizations. While children are unimmunized they 
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are at unnecessary increased risk for contracting vaccine-preventable diseases. 
Our research indicates specific groups could be targeted for vaccine outreach to 
improve vaccine uptake and understand in greater detail Nepal-specific barriers 
to vaccination. Concurrently, while there are logistical challenges to monitoring 
for pertussis such as the availability of trained clinicians with the ability to test for 
pertussis and equipped laboratories for performing the assays, investments 
should be made in disease surveillance infrastructure.  
 We found a low burden of pertussis in infants less than 6 months of age in 
Nepal. One conclusion from this could be that the current vaccine is effective in 
preventing pertussis through herd immunity, despite delays in receiving the vac-
cines. In the recent past some countries were considering a switch from whole 
cell pertussis vaccines to acellular pertussis vaccines. Nepal should follow re-
cently released WHO recommendations to continue using the whole cell pertus-
sis vaccine in light of data showing its superior efficacy compared to acellular 
pertussis vaccines 52. Another consideration for switching to the acellular vaccine 
would be an increased cost compared to the whole cell vaccine. 
 An original aim of this research was to provide foundational data for future 
studies on maternal pertussis vaccination in low-income settings. Given our find-
ings of low pertussis incidence and low levels of maternal pertussis antibody the 
decision to introduce pertussis vaccination in pregnancy is not clear. First, the 
results from studies in the U.S. and Canada have not been fully published so we 
lack a complete understanding of their safety and immunogenicity in pregnancy. 
If the final results from these two trials are supportive of this strategy it would be 
 255 
important to gather local data in Nepal or a similar country to understand if the 
vaccine would continue to have positive outcomes in a different population. If the 
vaccine was found effective in the Nepalese population, policy-makers would 
have to consider whether the disease burden warrants introduction of a new vac-
cine in pregnancy, especially given it would be a permanent increased cost to the 
government or external funding agency53. Logistically, Nepal has an existing 
framework for vaccination during pregnancy with the tetanus toxoid vaccination 
program. Combination vaccines exist, which include both of these antigens, so 
an additional vaccination would not be necessary. The pertussis study was nest-
ed within a trial of influenza vaccination during pregnancy. The government of 
Nepal will likely use the pending results from this trial to inform a decision of 
whether to include influenza vaccination in its maternal vaccination program. The 
Nepal government’s decision-making with influenza vaccine will likely influence 
its future desire to support and recommend new vaccines. 
Conclusion 
Substantial delays in pertussis vaccination were found in the first 6 months 
of life that are not captured by WHO vaccination coverage estimates. Over half of 
mothers and their infants had PT antibody levels too low to be quantified. Some 
infants had antibody levels lower than their mothers indicating not all gestational 
transfer was active. Despite vaccine delay and low antibody seroprevalence we 
found low risk for pertussis among infants in rural Nepal. The duration and se-
verity of pertussis disease was generally milder than expected based on tradi-
tional clinical findings. Even with delays the whole cell pertussis vaccine appears 
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to be effective in protecting infants from pertussis. The epidemiology of pertussis 
should be monitored for increasing incidence with maternal pertussis vaccination 
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